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Background:    Polycystic kidney disease (PKD) is a leading cause of kidney failure, 
and one of the most prominent rare hereditary diseases in New Zealand, as well as globally. 
The autosomal dominant form of this disease (ADPKD) has a country dependant prevalence 
rate of between one in 400 and one in 1000, and a 50% inheritance rate of the causal polycystin 
gene mutation in the offspring of an affected individual. The polycystin proteins act as a cell 
signalling complex in many cell types including the cilia of kidney tubule cells. Polycystin-1 
makes contact with the extracellular matrix while polycystin-2 promotes the flow of calcium 
into the cell to regulate a cellular response during environmental change. A malfunction in the 
polycystin complex caused by genetic mutation results in the dysregulation of cellular 
processes due to a change in cyclic-AMP mediated activity and release of the cells from the 
highly moderated cell cycle, leading to uncontrolled proliferation and cyst formation. Once the 
kidney cells become cystic they lose the ability to exchange material with surrounding 
capillaries which ultimately reduces the kidney’s ability to filter the blood. Tolvaptan treatment 
is the only current means of slowing the process of cyst formation, by targeting the vasopressin 
pathway and inhibiting the conversion of ATP to cyclic AMP, thus reducing fluid uptake into 
the cells. Alongside Tolvaptan, a number of other drug targets have proven promising in PKD 
models, yet these therapies often fail to proceed past clinical trials due to drug toxicity and off 
target side effects which cause the continuation of treatment to be intolerable for patients. 
Therefore, investigation of a long-term solution for cyst reduction to treat PKD is imperative. 
Objectives: This project investigated the efficacy of novel compounds to reduce cyst growth 
by targeting pathways modified in ADPKD, as well as the use of a kidney specific peptide as 
a compound chaperone. Ultimately this study aimed to identify the impact of novel compounds 
on cyst growth, compound associated pathway alterations, and kidney specific peptide uptake. 
 ii 
Methods: The novel compounds (SAHA, EG1, Gymnodimine and Portimine) were 
optimised for treatment of the ADPKD cyst growth cell line models MDCK and LLC-PK1. 
These cell lines were used to measure the effect compound treatment had on cystic area and 
changes in the activity of the compound’s target. The actions of the compounds were 
determined via HDAC activity assay, western blotting or Annexin V flow cytometry assays. 
Uptake of the G3-C12 peptide into cells of the kidney tubules was achieved through flow 
cytometry detection of a fluorescently labelled peptide in vitro, as well as immunofluorescent 
staining of kidney derived cells and peptide injected mouse kidneys.  
Results:  Treating the cyst growth assays with EG1 and Portimine caused significant 
decreases in cystic growth. The EG1 treated cultures had 2 to 7-fold less area growth than the 
controls, and the Portimine treated cultures had 2 to 9-fold less area growth than the controls. 
Gymnodimine treatment produced a significant reduction in the LLC-PK1 spheroid growth 
area, with these cultures having 22-fold less area growth than the controls. Additionally, the 
therapeutic compound SAHA caused the MDCK spheroids to have reduced cystic area growth 
but was unable to reach statistical significance, yet when attached to the peptide there was a 
significant 2 to 3-fold decrease in the cyst growth area of the MDCK cultures. 
Discussion: The cyst growth assays suggested that novel therapeutic compound treatment 
of EG1 and Portimine consistently had the greatest impact on cyst growth area change in vitro, 
however the attachment of the kidney specific peptide to SAHA also enabled this compound 
to slow cystic growth. Additionally, kidney targeted peptide uptake in vivo and in vitro 
identified peptide accumulation within the proximal tubular cells of mice kidneys, and in vitro 






ACE    Angiotensin converting enzyme  
ADPKD    Autosomal dominant polycystic kidney disease 
ARPKD   Autosomal recessive polycystic kidney disease 
ATP    Adenosine triphosphate 
BSA    Bovine serum albumin 
cAMP     Cyclic AMP 
CDK    Cyclin dependant kinases 
Co-A     Coenzyme A 
Cy/+    Heterozygous SamCystin (rat model) 
DAPI    4′,6-diamidino-2-phenylindole 
DMEM   Dulbecco’s Modified Eagle Media 
DNMT   DNA methyltransferase 
DNMTi   DNA methyltransferase inhibitor 
ESKD     End stage kidney disease 
EGF     Epidermal growth factor 
EMT     Epithelial-to-mesenchyme transition 
EndMT   Endothelial-to-mesenchyme transition 
ERK     Extracellular signal-regulated kinase 
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FCS     Fetal calf serum 
FDA    Food and drug administration  
H2A/H2B/H3/H4  Histone 2A/2B/3/4 
HAT     Histone acetyltransferase 
HDAC    Histone deacetylase 
HDACi   Histone deacetylase inhibitor 
HMT     Histone methyltransferase 
LLC-PK1   Lilly laboratories cell porcine kidney 1 
MAPK    Mitogen-activated protein kinase 
MDCK   Madin-Darby canine kidney 
mRNA    messenger RNA 
mTOR    mammalian target of rapamycin 
nAChR    Nicotinic acetylcholine receptor 
NGS     Normal Goat Serum 
PAX2    Paired box gene 2 
penstrep    Penicillin/streptomycin 
PBS     Phosphate buffered saline 
PKD     Polycystic kidney disease 
PC1    Polycystin 1 
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PC2    Polycystin 2 
PKA     Protein kinase A 
SAHA    Suberanilohydroxamic acid 
siRNA    Small inhibitory RNA  
TBS     Tris buffered saline 
TBS-T    Tris buffered saline with 0.1% Tween-20 
VR2    Vasopressin receptor II 
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C H A P T E R  1  :  B A C K G R O U N D  
1.1 Autosomal Dominant Polycystic Kidney Disease 
 
Autosomal dominant polycystic kidney disease (ADPKD) is a ciliopathy that disrupts 
cell cilia function and affects kidney health in individuals who predominantly carry mutations 
in the genes PKD1 and PKD2 (Halvorson et al., 2010). This section will discuss the genetics 
of ADPKD, including the known causes of cyst development in the kidneys of patients, as well 
as in vitro and in vivo models of PKD, and the clinical characteristics of this disease. Identifying 
the clinical characteristics of ADPKD has been important in previous drug discovery research 
and within this study. These include cystogenesis, dysregulation of apoptosis and proliferation, 
changes in transcription factor expression, epigenetic modification, hypertension and end stage 
kidney disease. 
 
1.1.1 Causative Genes  
ADPKD has one of the highest prevalence rates of all hereditary diseases, with a 
proposed 1 in 400 to 1 in 1000 individuals diagnosed worldwide (Iglesias et al., 1983; Stayner 
et al., 2018; Willey et al., 2017). The high prevalence of this disease may in part be associated 
with its dominant inheritance pattern, with 50% of all offspring acquiring the causative 
mutation if either parent presents with the disease. The two genes most closely linked to 
ADPKD and cyst growth in the kidney tubules, are PKD1 and PKD2, which encode the 
proteins polycystin 1 (PC1) and polycystin 2 (PC2) respectively (Bergmann, 2018; Hateboer 
et al., 1999; Lee & Somlo, 2014). The polycystin proteins can act independently of one another, 
or can assemble to form the polycystin complex (Giamarchi et al., 2010), thereby functioning 
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as a signal transductor and calcium channel to activate a G-protein, among other functions, for 
the conversion of ATP to cyclic AMP (cAMP), a process which is crucial in a number of 
intracellular signalling pathways involved in cellular regulation (Kuo et al., 2007). The 
polycystin complex is often located on the apically situated ciliated membrane of kidney 
tubules, where movement of the cilia is postulated to cause a mechanosensory activation of 
PC1, followed by the uptake of calcium through PC2 (Lee & Somlo, 2014). Cilia are important 
in the sensing of environmental factors for pathways which rely on chemo- and mechano- 
sensory initiation, so the disruption of cilial function caused by a loss of the polycystin complex 
in PKD is classified as a ciliopathy (Lee & Somlo, 2014). 
Two additional genes, GANAB and DNAJB11, have recently been identified as 
candidates for the onset of milder forms of ADPKD (Cornec-Le Gall et al., 2018; Porath et al., 
2016). The GANAB gene, encoding the catalytic subunit of glucosidase II α (GIIα), is a 
necessary component in the maturation and membrane delivery of PC1 and PC2, with GANAB 
negative renal cortical tubular epithelial cells having partial formation of PC1 proteins and a 
loss of PC2 expression at the cilia (Porath et al., 2016). Mutations identified in GANAB are 
often truncating in families with recurring incidents of ADPKD and autosomal dominant 
polycystic liver disease (Porath et al., 2016). Furthermore, seven families and 102 unrelated 
individuals also presented with monoallelic mutation in the DNAJB11 gene. Similar to the 
GANAB gene, DNAJB11 encodes the binding immunoglobulin protein (BiP), a glycoprotein 
which acts as a cofactor of the heat shock protein chaperone, responsible for the proper folding 
and assembly of membrane proteins, including PC1 (Cornec-Le Gall et al., 2018). Therefore, 
loss of DNAJB11 results in decreased amounts of mature PC1, and thus decreased membrane 
expression, as observed by Cornec-Le Gall et al. (2018) in DNAJB11-/- primary cortical tubule 
cells. 
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Autosomal recessive polycystic kidney disease (ARPKD), is an early onset cystic 
kidney disease, developing in utero and causing death in 30-50% of affected neonates. This 
disease has a prevalence rate of between 1 in 8,000 and 1 in 20,000 individuals (Bergmann, 
2018; Kaariainen, 2008), with siblings of affected children having a 67% chance of being 
carriers of a causal mutation (Bergmann, 2018). The ARPKD phenotype is caused by a variety 
of recessive genetic mutations, most commonly occurring in PKHD1 (Sweeney & Avner, 
2001), which encodes the transmembrane receptor fibrocystin, and is important for 
environmental response, cellular proliferation, and the adhesion of neighbouring cells in the 
kidney tubules. Fibrocystin, like the polycystin proteins, is located on the primary cilia and 
therefore a disruption of this protein has the potential to cause the ciliopathy, ARPKD 
(Bergmann, 2018). However, due to the length and alternative splice sites along the PKHD1 
gene, there is a complex range of causal mutations in this gene, making detection difficult, and 
so diagnosis is often focused on the impact the mutation has on the gene product rather than 
the mutation itself. 
 
Figure 1.1-1 PKD1, PKD2 and PKHD1 gene loci and the major role of each protein 
product.  
The locations of the most commonly mutated genes in ADPKD (PKD1 and PKD2), and 
ARPKD (PKHD1) on karyotypic chromosomes 16, 4 and 6. 
 
1.1.1.1 Mechanisms of Cystogenesis 
A means by which polycystic kidney disease arises in an autosomal dominant manner 
has been proposed in the literature as the two-hit hypothesis (Pei, 2001), where a germline 
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mutation causing loss of function in either PKD1 or PKD2 is inherited by an individual, yet 
will have minimal impact due to redundancy in the second gene copy. This initial mutation can 
heighten an individual’s risk of gaining a second, somatic, mutation in the remaining gene 
copy, resulting in complete dysfunction of the PKD gene product, a loss of heterozygosity in 
the cell, and consequently an imbalance between the polycystin proteins (PC1 and PC2) (Pei, 
2001). This protein imbalance will eliminate the formation of the PC1-PC2 polycystin 
complex, which then modifies the downstream signalling of pathways involved in maintaining 
healthy cell growth and proliferation, and ultimately initiating the cystic phenotype (Torres et 
al., 2007). This two-hit process of functional genetic loss is a term adopted from the Knudson 
two-hit hypothesis describing the loss of both tumor suppressor gene copies in cancer 
tumorigenesis. The Knudson two-hit hypothesis proposes that hereditary cancers carry a 
germline mutation in one gene copy and acquire a later somatic mutation on the second gene 
copy (Knudson, 1996; Knudson, 2002), which could explain why initiation of the cystic 
phenotype varies between kidney tubules cells carrying identical germline mutations (Eccles 
& Stayner, 2014). For example, some individuals that carry the PKD mutation will never 
receive a second mutation and are unaffected or will receive the second mutation late in life 
and do not acquire a severe disease phenotype. Contrastingly, individuals who do receive the 
second mutation early to mid-way through life are more likely to reach end stage kidney disease 
(ESKD), where their kidneys shut down due to exponential nature of cyst expansion throughout 
the nephron (Lee & Somlo, 2014). A number of studies revealed that this process may be dose 
dependant, where a complete loss of the gene function is not necessary (Cordido et al., 2017; 
Leonhard et al., 2016; Stayner et al., 2006), but instead a protein imbalance is sufficient for the 
loss of cellular regulation and therefore cyst formation (Lee & Somlo, 2014; Piontek et al., 
2007). Furthermore, this change in gene or protein dosage is often an outcome of disrupted cell 
signalling and changes to the expression of genes such as Dicer1, PRKCSH, SEC63 and HNF-
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1β, which interact with either the PKD genes or polycystin proteins (Eccles & Stayner, 2014; 
Fedeles et al., 2011; Ferreira et al., 2011; Igarashi et al., 2012). Therefore, modifying the 
function of these genes has a downstream effect on the regulation of the polycystin complex 
formation, and cellular signalling. 
 
1.1.2 Models Of PKD 
The use of in vitro and in vivo disease models benefit disease research by imitating 
pathologies and acting as potential identifiers of disease status, or indicators of human response 
to treatment. PKD models were used in this study of therapeutic compound treatments and 
peptide drug delivery.  
1.1.2.1 Cell Culture Models 
 Previously established normal and PKD kidney cell lines include a normal proximal 
tubule epithelial cell line (HK-2) (Ryan et al., 1994), immortalised epithelial cell lines derived 
from cyst walls (Loghman-Adham et al., 2015), induced pluripotent stem cells from patient 
nephrons (Freedman, 2015, Huang et al., 2017), a canine kidney cyst model (MDCK), a 
proximal tubule porcine kidney cell line (LLC-PK1) (Neilsen et al., 1998) and cyst-derived 
epithelia of non-kidney origin (Perrone et al., 1995). The extensive range of kidney cell lines 
allows for highly specialised investigations into different areas of disease, and regarding our 
research, has promoted confidence in novel compound therapy and kidney specific peptide 
uptake. Furthermore, two of the cell lines adopted in this study were the MDCK and LLC-PK1 
cell lines, both of which have the ability to form cyst-like structures in culture. The ADPKD 
9-7 cell line was also used in this study as a cell line isolated from single cyst epithelia of 
proximal tubule origin, to include a human disease model (Loghman-Adham et al., 2015).  
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1.1.2.2 Animal Models 
A number of animal models have been developed to provide further complexity to 
disease models, providing more realistic outcomes of research by often mirroring what is 
observed in humans. The most common small animal models used are mice and rats, due to 
the larger phenotypic variability that can be produced via Pkd knockout, hypomorphic 
mutation, or protein over expression (Happé and Peters, 2014, Upadhya, 2003). Zebrafish 
models have also proven to be valuable, as these animals develop only two nephrons 
(Drummond, 2003) making them simpler to study. The zebrafish model is developed by 
mutation in pkd, ift or hnf1ba genes (Cao et.al, 2009, Cirio et al., 2015), which are targeted due 
to their association with modifications that arise in human PKD. The pkd and hnf1ba gene 
mutations have been identified in cystic kidney diseases, and ift genes are essential in cilia 
formation (Cirio et al,. 2015). A large animal model of PKD has been developed in lambs, 
where a previous study found cystic structures throughout the renal, pancreatic and bile duct 
tissue of these animals, as well as some cases of considerable liver fibrosis. The disease 
prevalence and phenotype which arose in these lambs was more closely associated with 
autosomal recessive PKD in humans (Johnstone et al., 2005). Our lab has also identified a flock 
of sheep carrying a TMEM67 mutation that caused a ciliopathy in these animals, which 
presented with renal cyst growth and liver fibrosis (Stayner et al., 2017). These symptoms are 






1.1.3 Clinical Characteristics 
 The initial diagnosis of ADPKD relies heavily on the identification of characteristic 
ADPKD symptoms, such as hypertension, urinary tract infections, kidney pain, haematuria and 
excessive urination (Halvorson et al., 2010). These symptoms are often recognised prior to a 
confirmed diagnosis by MRI (magnetic resonance imaging), glomerular filtration rate and 
genetic testing (Torres et al., 2007). During the onset of these symptoms the kidneys are 
undergoing pathological changes which often disrupt normal cellular function, including 
changes in gene expression, apoptosis, necrosis and proliferation. These changes result in the 
formation of cysts throughout the kidney nephron, blocking the kidney tubules and eventually 
leading to end stage kidney disease (Li, 2015; Torres et al., 2007). 
1.1.3.1 End Stage Kidney Disease 
ESKD is the shutdown of the kidneys associated with organ failure due to the loss of 
nephron function, determined by a glomerular filtration rate lower than 15mL/min. ADPKD 
patients are predisposed to ESKD as a result of cyst formation throughout the tubules, and the 
inability to filter toxic material. At this stage of the disease, the individuals are placed on 
dialysis for manual filtration of their blood. Few are given the potential lifesaving option of a 
kidney transplant, as the waiting list for this procedure is extensive, with no assurance of 
success.  
1.1.3.2 Hypertension 
Normally, when blood pressure is too low (hypotension) the macula densa cells of the 
distal tubule will detect a change in filtered sodium chloride levels, or baroreceptors in the 
carotid sinus will detect a drop in blood flow. These signal to the juxtaglomerular cells of the 
kidney glomerulus which convert the hormone prorenin into renin which is then released into 
the blood stream. Renin travels through the circulatory system to convert angiotensinogen from 
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the liver to angiotensin I. Angiotensin I moves into the lungs where angiotensin-converting 
enzyme (ACE) converts angiotensin I into angiotensin II. Once angiotensin II is formed it 
initiates vasoconstriction of blood vessels and the release of aldosterone from the adrenal 
cortex. Aldosterone signals back to the kidneys, causing the reabsorption of sodium and water 
into the blood and the uptake of potassium into the tubules, which increases extracellular fluid 
and therefore increases blood pressure. Once blood pressure has returned to normal vasopressin 
signalling from the hypothalamus signals for the reabsorption of fluid into the cells. When 
blood pressure is too high (hypertension) the kidneys attempt to maintain high intracellular 
concentrations of sodium and water while excreting potassium.  
In ADPKD the kidney’s ability to filter blood is reduced due to excessive fluid uptake 
and cystic growth which disrupts kidney homeostatic feedback . The retention of water and 
sodium in the ADPKD kidneys can mimic hypertensive signals and contribute to increased 
blood pressure (Chapman et al., 2010). High blood pressure then leads to the conversion of 
angiotensin I into angiotensin II through ACE activity in the lungs (Chapman et al., 2010; Helal 
et al., 2017). To relieve hypertension, patients are prescribed ACE inhibitors to help reduce 
fluid volume in the blood stream, or angiotensin-II-receptor blockers to dilate blood vessels. 
More recently, patients are given antagonists of the vasopressin receptor II, such as Tolvaptan, 
which binds to vasopressin receptors, stopping the binding of vasopressin and inhibiting the 
ability of cells to release fluid into the blood, or undergo fluid uptake into the cysts. 
1.1.3.3Cystogenesis 
In ADPKD cyst growth often arises first in the glomerulus and proximal tubules, with 
growth occurring in the distal tubules and collecting ducts of the kidney nephrons as the disease 
progresses (Ahrabi et al., 2010).  Early cystic dilation occurs in utero, however in the autosomal 
dominant form of PKD, cyst growth usually becomes detrimental in the 5th to 6th decade of life 
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(Piontek et al., 2007). Therefore, the extent of disease progression is often dependent on the 
timing of functional protein loss in the individual (Lee & Somlo, 2014), and so an earlier age 
of onset could result in more rapid cystic growth. 
In ciliated cells of the kidney tubules the polycystin proteins dimerize to form a 
complex which is embedded in the cellular/cillial membrane, and is responsible for 
communication between the extracellular matrix and the intracellular space. Multiple 
signalling pathways are activated in ADPKD including, Wnt, MAPK and ERK, with the latter 
two being regulated by cyclic AMP (cAMP) activity (Lee, 2016). The decrease in calcium 
uptake into the cells through the polycystin complex causes an increase of cAMP activity which 
initiates protein kinase A (PKA) activity, an enzyme which in PKD activates MAPKs and 
upregulates ERK activity, therefore increasing proliferation, and enabling cyst formation 
(Hanaoka & Guggino, 2000; Lee & Somlo, 2014).  
 In combination with cyst development, the kidneys of ADPKD patients are often highly 
fibrotic, leading to issues with kidney function and the potential to result in renal failure (Thiery 
et al., 2009). Fibrosis of the kidneys due to apoptosis, inflammation and other mechanisms has 
also been linked to the occurrence of epithelial-to-mesenchyme transition (EMT) and 
endothelial-to-mesenchyme transition (EndMT)(Portilla, 2014; Thiery et al., 2009). Cells 
typically undergo EMT during development, or as they gain invasive properties. EMT and 
EndMT have previously been suggested as a possible mechanism of cyst formation due to the 
involvement of TGFβ, MAPK and other proteins affected in ADPKD (Liu, 2004; Thiery et al., 
2009). However, this theory has come into contention due to the limited evidence of these 
processes in the diseased kidneys (Chea & Lee, 2009). Regardless, fibrosis has been repeatedly 
identified in the ADPKD kidney, due to the proliferation of fibroblasts and extensive collagen 
deposition (Chea & Lee, 2009; Liu, 2004; Norman, 2011). 
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1.1.3.4 Apoptosis and Proliferation 
 Healthy tissue undergoes normal cellular growth that is maintained by a controlled 
balance between apoptosis and proliferation. In polycystic kidneys this balance is disrupted 
due to certain cell populations in the kidney being prone to excessive apoptosis or proliferation 
(Lee, 2016).  Improper regulation in these mechanisms causes kidney dysfunction due to a loss 
of tissue integrity or increased cellular density. 
Increased apoptosis in certain areas of the kidneys causes irreparable damage, and 
therefore presents a risk to the kidney health of individuals with ADPKD. This damage is due 
to a loss of tubule structure, as observed in patient epithelial tissue derived from renal tubules 
devoid of cysts (Lee, 2016). Apoptosis occurs in the absence of inhibitors of apoptosis (IAPs), 
allowing caspases, the mediators of apoptosis, to undergo cleavage into their functional forms 
and signal programmed cell death (Goilav, 2011). During the intrinsic pathway of apoptosis, 
cytochrome c and the protease activating factor-1 will recruit caspases for their transition into 
active isoforms, whereas in the extrinsic pathway apoptosis is initiated through extracellular 
factors such as the death ligands, FAS-FAS receptor or TNF and TNF receptor. These factors 
recruit caspases for their cleavage into active forms, commonly caspase-8 for the activation 
other caspases (Lee, 2016; Portilla, 2014). Differential apoptosis in PKD has been described in 
a variety of animal models which develop renal cysts (Goligorsky & Upadhya, 2003; Tao et 
al., 2005; Zhou & Li, 2015), of which a Cy/+ PKD rat litter has been shown to have increased 
levels of apoptosis inducing factors, such as activated caspases, compared to the healthy 
controls (Tao et al., 2005). 
Proliferation occurs through cell cycling, a process made up of four main phases, the 
DNA synthesis (S) phase, two growth (G) phases, and the mitotic (M) phase, with entry into 
each of these phases being tightly regulated by cyclin dependant kinases (CDKs) (Lee, 2016). 
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However, the actions of other protein kinases are also able to moderate signalling pathways 
which regulate cellular growth, specifically Ras/Raf mitogen-activated protein kinase 
(MAPK) factors, such as the extracellular signal-regulated kinase (ERK) (Yamaguchi et al., 
2003) (figure 1.2-1). The signalling pathways that these kinases are involved in, such as the 
mTOR pathway, are regulated through cyclic AMP (cAMP) activity which either activates or 
deactivates different protein kinases, enabling the cell control over proliferation (Mendoza et 
al., 2011). Regulation by the mTOR pathway has proven to be crucial in cellular proliferation 
and survival, by enhancing synthesis of nucleotides, proteins and other cellular components, 
and can be activated or inhibited by the ERK pathway and visa-versa (Mendoza et al., 2011). 
Notably, the mTOR pathway has previously been a target for ADPKD therapies in clinical 
trials, with the discovery of the mTOR inhibitor Rapamycin. Rapamycin is often used as an 
immunosuppressant in kidney transplant, and despite promising pre-clinical studies has shown 
to have no impact on disease progression during human clinical trials (Cadnapaphornchai, 
2017). Additionally, the ERK pathway is important for determining cell fate and initiating 
proliferation by regulating gene expression and cellular metabolism (Dumaz & Marais, 2005). 
Contradictory to this, ERK can also be involved in the inhibition of proliferation, which occurs 
when small GTP-binding protein kinases (Ras/Raf), which normally activate ERK, are instead 
inhibited by a cAMP activated protein kinase A (PKA), resulting in the loss of ERK activity. 
The action of ERK has also been shown to correlate with the activity of the epidermal growth 
factor (EGF) (Yamaguchi et al., 2003)(figure 1.2-1), an important component of cellular 
proliferation which signals entry into the M phase of the cell cycle, and has previously been 
identified in patient cyst fluid at levels that stimulate proliferation (Lai et al., 2008; Munemura 
et al., 1994). Similar to ERK, EGF can also be inactivated by an increase in cAMP (Dumaz & 
Marais, 2005), which indicates that the role cAMP plays in regulating these pathways is 
important for understanding cellular dysfunction in ADPKD.  
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In normal kidney tissue, increasing cAMP activity results in reduced proliferation. In 
ADPKD however, MAPK’s become atypically activated by PKA, as the Raf-1 kinase is 
replaced by B-Raf for the initiation of ERK activity. The increase in B-Raf activity is due to 
this kinase having fewer phosphorylation sites than Raf-1, making it unsusceptible to cAMP 
inhibition and easily phosphorylated by PKA, causing ERK to be constitutively activated 
(Wallace, 2011). As a result the kidney tissue undergoes excessive proliferation leading to cyst 
formation in the affected cells. 
1.1.3.5 Transcription Factor Expression 
Transcription factors are required to guide RNA polymerases to the promotor regions 
of genes during transcription. Therefore the ability of these factors to be recruited by the cell 
is important in the maintenance of gene expression. In ADPKD there is a dysregulation of 
transcription factor expression, which can potentially be modified by the expression of proteins 
required for cell sustainability, including the PC1 and PC2 proteins. An example of this occurs 
in kidney cystic tissue with elevated levels of activating protein 1 (AP-1), and a subsequently 
heightened expression of the PC1 protein (Le et al., 2004; Le et al., 2005). AP-1 is a 
transcription factor complex comprised of multiple domains, such as Jun, Fos and the 
activating transcription factor (ATF), each of which are regulated by the kinases MAPK, ERK, 
p38 and JNK. The action of AP-1 is able to regulate genes involved in cellular proliferation, 
differentiation and survival (Le et al., 2005). Furthermore, cellular Myc (MYC) has recently 
been shown to be associated with the PKD1 promotor during transcription, and upregulates the 
expression of PC1 during cystogenesis in an SBM transgenic mouse model of ADPKD (Parrot 
et al., 2019). Expression of the MYC gene is associated with cell cycle transitioning from the 
G0 phase to the G1 phase, and therefore impacts cellular proliferation (Shichiri et al., 1993). 
The expression of proto-oncogenes like MYC can be repressed by the Wilms’ tumor repressor 
1 (WT1) protein, which is expressed in the kidney nephron, usually during nephrogenesis 
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(Hewitt et al., 1995) WT1 itself is up-regulated in ADPKD renal cysts, alongside other 
transcription factors associated with kidney development. Additionally, WT1 normally 
supresses paired box gene 2 (PAX2) encoding a transcription factor implicated in kidney 
development and proliferation, and has been demonstrated to be overexpressed in ADPKD 
(Ostrom et al., 2000; Stayner et al., 2006). The PAX2 protein is activated by PKA (X Li, 2015), 
causing changes in the expression of target genes such as N-cadherin and TGF-β, resulting in 
the expansion of cysts throughout the nephron. PAX2 overexpression has also been shown in 
other related chronic kidney diseases, and influences the epithelial-to-mesenchyme transition, 
a potential mechanism of cyst initiation (Murer et al., 2002; Wang et al., 2019). 
1.1.3.6 Epigenetic Modification 
Epigenetics describes the change of cellular factors which directly or indirectly impact 
DNA transcription or translation without changing the DNA sequence. For instance, epigenetic 
changes can occur through the enzyme mediated placement of acetyl and methyl marks on 
histones or DNA, enabling cellular control over gene transcription. 
Table 1.1-1. The regulation of acetylation, methylation, and phosphorylation on gene 
transcription.  
This table incorporates histone acetylation and phosphorylation, as well as methylation of 
both histones and DNA. Modified from Zhang and Reinburg (2001) and Strahl and Alice 
(2000). 
Modification Activating transcription Repressing transcription 
Acetylation H3: K9, K14, K18, K56 
H4: K5, K8, K12, K16 
H2B: K6, K7, K16, K17 
 
Methylation H3: K4me2, K4me3, K36me3, 
K79me3, R2, R17, R26 
H4: R3 
H3: K9me3, K27me3 
H4: K20me3 
DNA: CpG islands 




1.1.3.6.1 Histone acetylation 
Histone acetylation is the placement of acetyl marks on the lysine residues of histone 
H2A, H2B, H3 and H4 tails by histone acetyl transferases (HATs). These acetyl marks are 
donated by coenzyme A (CoA), which becomes acetyl-CoA after the addition of an acetyl 
group via the enzymatic action of acetyl-CoA synthetase during the breakdown of pyruvate in 
glycolysis (Galdieri & Vancura, 2012). When these negatively charged acetyl marks are placed 
on histone tails they remove the positive charge of the lysine residue on which they are bound, 
reducing the affinity of the histones to the negatively charged phosphate group of DNA. 
Acetylation will either cause the histones to dissociate from the DNA for the binding of 
transcription factors (Verdone et al., 2006), or will allow the binding of transcriptional 
activators to remodel the chromatin, depending on the histone code (Gregory et al., 2001). 
Following transcription, the acetyl marks may be removed by a histone deacetylase (HDAC) 
enzyme and the section of DNA is able to, once again, associate itself with a histone. HDACs 
are classified using a numbered class system based on sequence homology, in which class I 
includes four types of HDACs: HDAC1, 2, 3 and 8, class IIA includes: HDAC4, 5, 7 and 9, 
class IIB includes: HDAC6 and 10, and finally, class IV consists only of HDAC11 (Kuo & 
Allis, 1998). Each of these HDAC classes have specific roles in cellular regulation and respond 
differently to environmental cues or other cellular regulatory factors. In the kidneys, the class 
I HDACs are most often expressed in the cortex during development, as well as continual 
expression in renal fibroblasts, while class IIA and IIB HDACs appear to be most active in the 
renal tubules (Liu & Zhuang, 2015; Pang & Zhuang, 2010). However, little evidence has been 
shown of class IV HDAC activity in the kidneys. In ADPKD mouse models, histone acetylation 
has been shown to increase on histone H3 at lysine 9, and decrease on histone H3 at lysine 23 
(Fontecha-Barriuso et al., 2018; Sayyed et al., 2010). Thus, by altering the activity of HDACs 
using therapeutic compound targeting by Trichostatin A, Vorinostat, Valproic acid or other 
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HDAC inhibitors (Cao et al., 2009; Liu & Zhuang, 2015), histone acetylation is modified, 
which is likely to alter gene transcription and restore protein expression modified in ADPKD.  
1.1.3.6.2 Histone and DNA methylation 
 Methylation is a process involving the covalent addition of methyl groups to the 
cytosine residues of DNA or lysine and arginine residues of histones, catalysed by DNA 
methyltransferases (DNMTs) or histone methyltransferases (HMTs)(Zhang & Reinberg, 
2001). The methyl groups arrive in the nucleus as a side chain of S-Adenosyl methionine 
(SAM). SAM is formed in the coordinated breakdown of Adenosine triphosphate (ATP) and 
the attachment of Methionine through the action of Methionine Adenosyl transferase (Födinger 
et al., 2000). During histone methylation the number of methyl marks placed on an amino acid 
residue of a histone tail varies between residues and has the ability to determine the action of 
transcription. Lysine residues on histones are more commonly methylated by HMT which can 
place either one (mono-), two (bi-) or three (tri-) methyl marks on the lysine’s of histones H2A, 
H2B, H3 and H4 (table1.1-1)(Zhang & Reinberg, 2001). In addition to lysine methylation, 
histones H3 and H4 can also be methylated on arginine by either protein arginine 
methyltransferase (PRMT) I, placing a monomethyl mark, or a PRMT II, placing a second 
methyl mark on a monomethylated arginine to produce a dimethyl mark (Zhang & Reinberg, 
2001). DNA methylation typically involves a transferral of the methyl group from SAM to the 
C5 position of cytosines (5mC) by DNMT (Moore et al., 2013) within CpG islands, and is 
associated with the regulation of gene transcription (table 1.1-1). The removal of these methyl 
marks occurs via the conversion of 5mC to 5-hydroxymethylcytosine (5hmC) by Tet protein 
activity (Li & Zhang, 2014). Methylation has also been identified on other dinucleotides as 
having functional importance within the nucleus (Wei & Moss, 1977; Yue et al., 2015). 
Previous research identified changes in DNA methylation patterns between healthy and 
ADPKD kidney tissue (Bowden et al., 2018; Woo et al., 2014), which encourages the use of 
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therapies that target methylation by modifying DNMT activity. DNMT inhibitors, such as 
Decitabine, have been tested in animal models of ADPKD (Bechtel et al., 2010; Fontecha-
Barriuso et al., 2018), but are yet to progress into clinical trial.  
 
1.2 Current Treatment 
Currently, for ADPKD, there is a lack of effective treatments to delay cystic growth, 
and those which have been investigated in clinical trials are often toxic to patients when 
delivered over the extended period of time necessary to treat this disease.  
The most common form of treatment for ADPKD, and other kidney diseases, is dialysis. 
Dialysis is a tool used to extend an individual’s life by acting to filter (i.e dialyse) blood in 
place of their kidneys. However, dialysis doesn’t delay cyst formation and so the individual’s 
life remains shortened due to symptoms associated with the growth of cysts throughout 
multiple organs, predominantly the kidneys and liver. Additionally, peritoneal dialysis can 
cause peritoneal fibrosis due to the conversion of mesothelial cells to mesenchymal cells 
(Thiery et al., 2009). Another common treatment is kidney transplant, which is a highly 
invasive procedure for both the donor and recipient, in which the polycystic kidney function is 
replaced by the matched donor kidney. If successful, kidney transplant is a cure for ADPKD, 
but it is possible for the kidney to be rejected by the individuals immune system. Other 
treatments for this disease involve drugs which act to either repress symptoms or reduce cyst 
growth. The drug treatments currently given to ease the main symptom of hypertension include 
Angiotensin-I converting enzyme (ACE) inhibitors, angiotensin-II-receptor blockers, and 
Tolvaptan. Furthermore, multiple treatments aimed at reducing cyst growth have entered into 
clinical trials, including inhibitors of cAMP accumulation (e.g. somatostatin), mTOR inhibitors 
(E.g. Rapamycin) as well as vasopressin receptor II (VR2) inhibitors (e.g. Tolvaptan) (Harris 
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and Torres, 2009). Most of these clinical trials were unsuccessful due to their limited impact 
on cyst growth, or as a result of toxicity and non-compliance. A treatment which has shown 
promise is Tolvaptan, which was able to slow disease progression in the TEMPO and REPRISE 
trials (Harris and Torres, 2009). Tolvaptan acts as a competitive inhibitor of VR2, which causes 
aberrant cAMP activity when activated in PKD tissue, and thus lowers the accumulation of 
cyst fluid (figure 1.2-1). It is also likely that inhibition of VR2 by Tolvaptan reduces the 
conversion of ATP to cAMP by reducing the intracellular vasopressin concentration, delaying 
protein kinase A activation and overall cellular proliferation, resulting in slowed cystic growth. 
However, lifelong treatment is required in ADPKD, and regardless of Tolvaptan’s ability to 
quickly limit cyst expansion it can cause severe side effects with extended treatment length, 
especially concerning the liver (Watkins et al., 2015). 
 
Figure 1.2-1 A diagram of select pathways commonly dysregulated in polycystic kidney 
disease cells. 
These pathways are targets in clinical trials for therapeutic compounds such as statins 





1.3 Novel Therapeutic Compounds 
A range of therapeutic compounds have been trialled in ADPKD patients, targeting 
cellular mechanisms such as apoptosis (Rapamycin), proliferation (Somatostatin), cell growth 
and developmental pathways (tyrosine kinase inhibitors), and epigenetic expression 
(Nicotinamide)(Belibi & Edelstein, 2010; Cadnapaphornchai, 2017; Stayner et al., 2018). 
These processes are often disrupted in ADPKD making them suitable targets of therapy, 
although further investigation of therapeutic compounds is required due to limited success of 
clinical trials to date. This study has focused on four novel compounds which act on 
components of aberrant cellular processes with the potential to delay cyst growth.  
 
1.3.1 Suberoylanilide Hydroxamic Acid 
The inhibition of histone deacetylases (HDACs) by Suberoylanilide Hydroxamic acid 
(SAHA) lengthens the period of time in which histones are acetylated, extending gene 
transcription and increasing protein product. SAHA acts as a rapidly binding competitive 
inhibitor of the class I HDAC enzyme family (Lauffer et al., 2013) and has been approved as 
a treatment of small cell lymphoma under the clinical name Vorinostat (Lauffer et al., 2013; 
Richon, 2006). Additionally, this compound has been tested as an ADPKD treatment in animal 
models, alongside other HDAC inhibitors such as Trichostatin A. The use of these compounds 
in ADPKD models has caused a significant reduction in the kidney cystogenesis of mice (Cao 
et al., 2009; Xiaogang Li, 2011) and zebrafish (Cao et al., 2009). However, the use of HDAC 
inhibiting compounds as a treatment method in patients may encounter toxicity related 




 EG1 is a small benzoic acid compound with a carboxylic acid side chain that selectively 
binds to the active site of the paired box 2 (PAX2) protein. PAX2 has a role as a transcription 
factor during kidney development, specifically in lineage differentiation (Grimley et al., 2017), 
by binding to the promotor region of genes and facilitating polymerase recruitment in gene 
transcription (section 1.1.3.5). Although PAX2 is primarily active in development, this protein 
has been found to be reactivated in a number of human cancers, including renal cell carcinoma, 
and in polycystic kidney disease (Grimley & Dressler, 2018; Stayner et al., 2006). A previous 
study in our laboratory discovered that the pkd1del34/del34 mouse model of polycystic kidney 
disease had increased expression of Pax2, mainly in cysts originating from Pax2 positive 
epithelia, when compared to the wild type healthy mouse model (Stayner et al., 2006). 
Additionally, reducing the expression of Pax2 in Pkd-/- mice by heterozygous knockout also 
reduced the number of cysts in a mouse model of ADPKD, and therefore a PAX2 inhibitor has 
the potential to be used as a therapeutic target (table 1.3-1). Previous work in our lab has 
identified that knocking out PAX2 in cancer cell lines causes a decrease in the expression of a 
number of genes, most notably N-cadherin, indicating that PAX2-DNA binding plays a role in 
N-cadherin transcription (figure 1.3-1). The N-cadherin protein is a component of adherens 
junctions and is important for developing organ symmetry during development.  
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Figure 1.3-1 qPCR expression analysis of Pax2 and N-cadherin in siRNA control (grey) 
and siRNA-PAX2 knockout (striped) cancer cell lines. 
A) the expression of PAX2 mRNA was depleted in the PAX2 knockout cells compared to the 
controls. B) The loss N-cadherin mRNA expression in the PAX2 knockout cells indicates that 
the PAX2 transcription factor has a role in N-cadherin gene transcription. Work by a previous 
student, Dr Grace Li (Li, 2010) 
 
 
1.3.3 Marine Toxins 
A number of marine organisms produce toxic compounds which cause apoptosis at low 
concentrations in mice and mammalian cell lines. The ability of these toxins to induce 
apoptosis can be utilised as a treatment, having the potential to combat the excessive 
proliferation occurring in ADPKD cysts (Hanaoka & Guggino, 2000; Lee, 2016). Two marine 
toxins were made available to us through a collaboration with researchers at the Cawthron 
Institute in Nelson. 
1.3.3.1 Portimine 
Portimine is a marine cytotoxin isolated from the marine dinoflagellate Vulcanodinium 
rugosum (Selwood et al., 2013) (table1.3-1). This compound is a cyclic imine that when 
exposed to mammalian cells at concentrations below ten nanomoles, can induce apoptosis by 
causing global modifications to DNA, proteins and lipids (Cuddihy et al., 2016). A study into 
Portimine treatment of sea squirts found an association between this compound and the nuclear 
activation of phosphorylated ERK, a key regulator of cellular growth and maintenance which 
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enhances cytochrome c release and caspase activity for the initiation of apoptosis (Chambon et 
al., 2002). Another study also found that the use of Portimine at very low concentrations is able 
to activate the apoptosis pathway, while at higher concentrations the cells become necrotic, as 
increasing the dosage alters the cells metabolism and causes a loss of membrane integrity, 
therefore blocking apoptosis (Cuddihy et al., 2016). 
1.3.3.2 Gymnodimine 
Gymnodimine is a phycotoxin belonging to the cyclic imine class of marine compounds 
isolated from shellfish and plankton (Vilariño et al., 2009) (table1.3-1). This compound has 
previously been tested in mice at doses ranging from 80-96ug/kg (Kharrat et al., 2008; Munday 
et al., 2004), indicating its potential to modify muscular contraction and induce apoptosis by 
binding to nicotinic acetylcholine receptors (nAchR), inhibiting the binding of 
neurotransmitters and other ligands (Vilariño et al., 2009). The nAchR has been found to be 
activated by protein kinase A mediated phosphorylation, and modifies the action of 
downstream kinases such as ERK, which induces apoptosis via caspase activity (Pitchford et 









Table 1.3-1 Therapeutic compounds used in this study. 
These compounds include Tolvaptan, Portimine, Gymnodimine, EG1, SAHA, and Decitabine 
Compound Action Structure 
Suberoylanilide 
Hydroxamic acid (SAHA) 
Clinically rereferred to as 
Vorinostat. This compound 
inhibits histone deacetylase 
enzymes, and has been FDA 





A compound which inhibits 
the binding of the transcription 
factor PAX2 to DNA. 
  
Gymnodimine 
An apoptosis inducing 
compound which inhibits 




An apoptosis inducing 
compound which modifies 
cellular building blocks. 
 
 
1.4 Peptide Drug Delivery 
A prominent issue with current ADPKD drug development is the off target effects 
caused by non-specific global actions, resulting in toxicity at distant organs. As a consequence 
of this toxicity, many of these treatments are not well tolerated by patients, with several failing 
to complete the duration of clinical trials. An example of this is the ALADIN trial of 
somatostatin, which caused eventual formation of gall stones or gall bladder inflammation in 
patients, and failed to reach statistical significance in the total kidney reduction of the treated 
compared to the placebo controls after three years (Cadnapaphornchai, 2017). Additionally, 
patients treated with Rapamycin in a clinical trial often suffered from edema and had trouble 
urinating, as well as an overall decline in glomerular filtration rate and a statistically 
 36 
insignificant change in total kidney volume (Walz et al., 2010). However, a potential solution 
to reducing this toxicity is to target drugs directly to the organ of interest, for instance the 
kidney, using techniques such as liposomes, nanoparticles or macromolecules (Otvos & Wade, 
2014; Stayner et al., 2018). This study has chosen to use a macromolecule for drug delivery, 
and more specifically the Galectin-3 (G3-C12) binding peptide, which has the potential to 
direct drug compounds to the kidneys through its recognition and uptake by the megalin 
receptor (Geng et al., 2012). The megalin receptor is a membrane bound protein expressed on 
kidney tubular cells, which when activated induces endocytosis on site, engulfing what is 
bound to the cell surface, therefore allowing the G3-C12 peptide to gain entry into the cell. The 
G3-C12 peptide can act as a drug carrier due to its ability to be conjugated to free side chains 
of therapeutic compounds through a polypeptide linker (Geng et al., 2012)(figure 1.4-1). To 
release the compound into the cell, the linker is cleaved intracellularly, allowing the therapeutic 
compound to remain structurally unaffected. 
 
Figure 1.4-1 The conjugation of the G3-C12 peptide to therapeutic compounds. 
This diagram represents the configuration between the G3-C12 peptide and therapeutic 
compound when conjugated through a polypeptide linker which acts as the site of 
intracellular cleavage. The spacer was included to reduce steric hindrance occurring with the 









This study hypothesised that the targeting of previously identified cyst inducing 
pathways via therapeutic compound treatment will delay the growth of cystic kidney cell lines 
in 2.5D and 3D culture, and that G3-C12 kidney specific peptide uptake into in vitro PKD cell 
culture models, and an in vivo mouse model, will support its use in targeted drug delivery. 
 
1.6 Aims 
1. To identify changes in the cystic growth of therapeutic compound treated in vitro PKD 
models, and determine the impact these compounds have on intracellular factors often 
modified in PKD. 
2. Detect kidney specific uptake in vitro and in vivo, and locate peptide accumulation 











C H A P T E R  2  :  M E T H O D S  
All centrifugation steps were performed at 20°C unless specified otherwise. 
 
2.1 Buffers and Solutions 
1x PBS 
8g Sodium chloride 
0.2g Potassium chloride 
1.15g Di-sodium hydrogen phosphate 
0.2g Potassium dihydrogen phosphate 





4g Sodium  chloride 








RIPA lysis buffer 
1% NP-40 
1% sodium deoxycholate 
0.15M sodium chloride 
0.01M sodium phosphate (pH 7.2) 
2mM EDTA 
50mM sodium fluoride 
0.2mM sodium orthovanadate 
100U/mL protease inhibitor  
Made up to 50mL by distilled water 
 
Histone extraction hypotonic lysis buffer 
1.2g Tris in 10mL distilled water, pH 7 (1mol/L Tris-Cl) 
0.75g Potassium chloride in 10mL distilled water (1mol/L KCl) 
3.05g Magnesium chloride in 10mL distilled water (1.5mol/L MgCl2) 
0.31g Dithiothreitol in 2mL distilled water (1mol/L DTT) 
0.17g phenylmethylsulphonyl fluoride in 1mL distilled water (1mol/L PMSF) 
 
The lysis buffer was made by adding 100μL of 1mol/L Tris-Cl, 10μL of 1M KCl, 10μL 
of 1mol/L MgCl2, and 10μL of 1mol/L DTT to 9.87mL distilled water. Prior to cell lysis the 
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1mmol/L DTT and PMSF solutions were diluted to 10mmol/L, and 4μL of each was added to 
40μL (per sample) of 25x complete protease inhibitor cocktail (Sigma, 1167498001). For each 
sample the protease inhibitor cocktail (48μL) was combined with 952μL of the lysis buffer to 

























2.2 Cell Culturing 
 Cell culturing is the process of removing cells from an organism, and growing them in 
a vessel under the conditions of their preference. 
 
Table 2.2-1 A table of the cell lines utilised throughout this study. 
These cell lines include ADPKD 9-7, two huADPKD primary cell lines, MDCK and LLC-
PK1. This table also includes where the cell line has been used in the study, the tissue type 
they were derived from and where they were sourced. 
ADPKD cyst derived cell lines 
Cell line Study use Origin Source 
ADPKD 9-7 Peptide uptake Proximal tubule cyst ATCC CRL-2830 
huADPKD - M Novel compound optimisation 
peptide uptake 
Cystic ADPKD tissue Generated in this 
study 
huADPKD - W Peptide uptake Cystic ADPKD tissue Generated in this 
study 
MDCK Cyst growth assays 
peptide uptake 
Canine distal tubule 
and collecting duct 
ATCC CCL-34 






2.2.1 Growth Conditions 
 The immortalised cell lines used in this study were ADPKD9-7, MDCK and LLC-PK1 
(ATCC), with the addition of the huADPKD primary cell cultures, each with different optimal 
growth conditions. The ADPKD9-7 cell lines were grown on type I collagen (Sigma C9791), 
in high glucose Dulbecco’s Modified Eagle Medium (DMEM)(Life Technologies 11995-065) 
supplemented with 10% Fetal bovine serum (FBS)(Moregate, BBP5) and 1% penicillin and 
streptomycin (penstrep)(Life Technologies 15140-122). The MDCK and LLC-PK1 cell lines 
formed multi-dimensional cultures so required more complex environments. The MDCK cells 
were grown in the absence of collagen when being maintained as a 2D culture, on type I 
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collagen (Sigma C9791) coated surfaces to form 2.5D cyst-like dome structures, and in ultra-
low attachment surface Corning spheroid microplates (Sigma CLS4520) when grown as a 3D 
spheroid culture. These MDCK cultures were grown in DMEM supplemented with 10% FCS, 
1% penstrep and additional 1% L-Glutamine. To maintain the LLC-PK1 cell line the 2D 
cultures were grown on uncoated plastic, and to produce 3D spheroid cultures the cells were 
grown in ultra-low attachment surface Corning spheroid microplates (Sigma CLS4520). The 
LLC-PK1 2D cultures were grown in DMEM supplemented with 3% FCS and 1% penstrep, 
and the 3D cultures were grown in DMEM supplemented with 3% FCS, 1% penstrep, 100nM 
Hydrocortisone (Sigma HO888-5G), 0.75x insulin-transferrin-selenium, 6ng/μL 
triiodothyronine and 10ng.mL human EGF (Sigma, SRP6253). Additionally, huADPKD 
primary cells retrieved from human ADPKD kidney tissue were used as a patient model for 
therapeutic compound optimisation and peptide uptake. These cells required growth on type I 
collagen (Sigma C9791) coated surfaces and were sustained using DMEM/F12 media (Life 
Technologies 11320) supplemented with 5% FCS, 1% penstrep, 0.75x insulin-transferrin-
selenium (Invitrogen 41400-045), 100ng/mL dexamethasone (Sigma D8893), 6ng.uL 
triiodothyronine (Sigma T5516) and 10ng.mL murine EGF (Sigma E4127), these growth 
factors were added to favour epithelial growth.  
2.2.1.1 Human ADPKD Primary Kidney Cell Culture Development 
Kidney tissue received from two ADPKD patients who had their kidneys removed 
during kidney transplant were made into the primary cell cultures huADPKD-M and 
huADPKD-W (by informed consent and approved by the University of Otago humans ethics 
committee: H15/110). Highly cystic regions of the fresh kidneys were dissected into four 
approximately 2cm2 sections, which were further reduced to a weight of 0.5g and placed in 
sterile petri dishes with 1mL of cold DMEM/F12 (ThermoFisher 11320) media. The kidney 
sections were fractionated using CRL single edge razor blades until they reached a liquidised 
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state, to be transferred from the petri dish via pipette into a 15mL Falcon tube. Excess tissue in 
the petri dish was collected by washing with cold DMEM/F12 media. For 0.5g of tissue, the 
necessary amount of media was added to make up a total volume of 15mL, and then 1.5mL of 
a 10mg/mL collagenase type I (Sigma C9891) solution was added to give a final concentration 
of 1mg/mL (30mg/g of tissue). Following this, the tissues were incubated for 30 minutes at 
37°C on an orbital shaker at 350rpm. After incubation the tissue was pelleted by centrifugation 
for five minutes at 350rpm to remove most of the supernatant, and washed with cold 
DMEM/F12 (ThermoFisher 11320). This wash step was then repeated two more times to 
remove the collagenase solution. After the last wash step the cells were resuspended in warm 
working media (section 2.2.1) and placed in small culture flasks (T25) coated with type I 
collagen (Sigma C9791). After 45 minutes the non-adherent (epithelial rich) cells were re-
plated in a secondary collagen coated flask to minimise the fibroblast population (which adhere 
more rapidly) in the final cultures. The first cell populations appeared after 72 hours (figure 
2.2-1), and growth of the cells to full confluency occurred after one week (appendix A), with 
media changes every two or three days. 
 
Figure 2.2-1 Early growth stages of the huADPKD-M1 cell culture during primary cell 
line development. 
Immediately after the isolation of cells from kidney tissue we observed large non-adherent 
fragments in the cultures, and after 24 hours we saw less debris and more cells settled on the 
base of the flask. After 72 hours the cells had been washed with PBS and small cell 




2.2.1.2 LLC-PK1 Transformation 
Spheroid growth of LLC-PK1 was enhanced through transformation of the porcine 
proximal tubule cell line as demonstrated in a paper by Kuo et al. (2014), which knocked down 
inositol triphosphate receptor 1 (ITPR1) expression using custom Sigma siRNAs with dT 
overhangs, recognising the ITPR1 sequence (5’GCUGACGGAAGAUAAGAA 3’) and a 
scrambled sequence (5'AGAGGACGAAGCGGUACUU 3'). To enable entry of siRNA into 
the LLC-PK1 cells, an siRNA and Lipofectamine RNAiMAX (Invitrogen 13778-150) complex 
was formed during their incubation together in OptiMEM media (Invitrogen 31985-070) at 
room temperature for 20 minutes. To determine the 15nmol/L siRNA working concentration 
used for the spheroid assays, optimisation of the siRNA concentration was performed, and a 
no siRNA control was included by adding lipofectamine only to the OptiMEM media. Initiating 
the knockdown process required collection and resuspension of the LLC-PK1 cells in working 
media devoid of antibiotics, for counting. A volume of 3,000 cells multiplied by the number of 
wells to be plated, was placed into a 15mL Falcon tube and centrifuged. The supernatant was 
then removed from the cells and they were resuspended in a volume of antibiotic free working 
media, made up to 500μL per well. After 20 minutes of siRNA incubation with Lipofectamine 
RNAiMAX in OptiMEM, 500μL was added to a 6 well plate, along with 500μL of cell 
suspension. The plates were then carefully tipped to spread the media over the bottom of the 
wells and incubated at 37°C for 24 or 48 hours. 
 
2.2.1.3 Spheroid Growth 
To develop spheroids from MDCK and transformed LLC-PK1 cultures, the cells were 
grown in ultra-low attachment surface Corning spheroid microplates (Sigma CLS4520). The 
MDCK cells were split 1 in 10, 24 hours prior to plating to ensure that the cells remained in 
the growth phase during spheroid development over seven days. The LLC-PK1 cells were 
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treated with 15nM siRNA for 24 hours, to knock-down the inositol triphosphate receptor 
(ITPR1) and then harvested and resuspended in 1mL of spheroid growth media (section 2.2.1) 
to be plated for growth over two weeks. The MDCK and LLC-PK1 cells were plated at a 
density of 3,000 cells, with the MDCK spheroid media being changed every four days, and the 
LLC-PK1 24 hour knockdown occurring every fifth day, followed by the replacement of 
working media. 
 
2.3 Cyst Assays 
The use of a cyst assay assisted in identifying changes in cyst growth over time with 
the administration of therapeutic compounds or a conjugated drug. 
2.3.1 Source of Novel Compounds 
The histone deacetylase inhibitor SAHA was modified for G3-C12 peptide linkage by 
Professor Margaret Brimble and Erin Wilks at the University of Auckland. Optimisation of 
SAHA through HDAC activity assays and cyst growth assays found that the optimal SAHA 
dosage was 15μmol/L over three consecutive days. The PAX2 transcription factor EG1 
(BMK3_27_1st) was generously provided by Professor David Larson and synthesized by Jake 
Ward  at the University of Otago. Optimisation of EG1 treatments identified that exposure of 
the cyst assays to EG1 at a concentration of 25 μmol/L over three consecutive days was 
appropriate. The apoptosis inducing compounds Gymnodimine and Portimine were provided 
by Dr Darby Brooke at the Cawthron Institute. Optimisation of Portimine and Gymnodimine 
via flow cytometry using an Annexin V assay identified that 6 nmol/L Portimine and 120 
nmol/L Gymnodimine successfully induces apoptosis in cyst assays. The 3D MDCK and LLC-
PK1 spheroid assays were used to determine the impact these novel compounds have on 
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complex cyst growth structures. To identify changes in cyst growth the cultures were imaged 
using an Olympus IX71 inverted light microscope. 
 
2.3.2 Cyst Assay Analysis 
To measure the cyst growth area, images of the cultures were taken prior to and post 
treatment using an Olympus IX71 inverted microscope, and then loaded into the ImageJ 
software. Once in ImageJ a global scale was set according to the image scale bar, and the cysts 
were outlined using the selections tool to give an area measurement in millimetres. Once all of 
the data was collected for each time point, the change in growth area was calculated for the 3D 
spheroids by removing the pre-treatment measurement from the post-treatment measurement, 
and then averaging these, or in the 2.5D cyst assay the pre and post measurements for each 
image were initially averaged and then the change in growth measured, due to the inability to 
track individual cysts in these cultures. To determine the P-value for statistical significance an 
unpaired student T-test was performed on the data prior to averaging, which encapsulated the 
range of measurements for each condition. This data was also used to calculate the standard 
deviation and standard error in Rstudio, to produce the error bars. 
 
2.4 HDAC Activity Assay 
The histone deacetylase activity assay kit (abcam ab156064) is a fluorometric measure 
of HDAC activity in cell lysates after SAHA treatment.  
2.4.1 HDAC Activity Assay Procedure 
Cell lysates were extracted from MDCK and LLC-PK1 cell cultures at each time point 
during the cyst assays. Lysis of the cells was performed using the activity assay kit protocol, 
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via a 15 minute lysis buffer incubation at 4°C and a 10 minute 1300xg centrifugation through 
a sucrose cushion. This was followed by the extraction of the nuclei during a 30 second 
sonification of the pellet in extraction buffer, a 4°C incubation for 30 minutes and a subsequent 
10 minute centrifugation at 20,000xg, to retrieve the HDAC lysate in the supernatant. The 
retrieval of a nuclear extract via this method can be determined using a Pierce BCA protein 
assay kit (ThermoFisher 23227). The HDAC lysate was used as the enzyme sample added to 
the assay buffer, fluorescent HDAC substrate, inhibitor or solvent, and the developer for the 
one-step method of HDAC inhibitor screening (table 2.4-1). The reagents correlating to each 
assay type were added in parallel to a 96 well black walled plate for fluorometric reading 
(Ex/Em = 355/460nm), performed on a plate reader at two minute intervals for one hour, 
producing 30 data points given in relative fluorescent units (RFU) for each assay. During 
fluorescent reading the HDAC substrate will fluoresce if deacetylated, or if acetylated will 
remain undetected. If SAHA is inhibiting the HDACs there will be a loss of activity in these 
enzymes and consequently a lower fluorescent reading. To account for non-enzymatic activity, 
a number of reagent control reactions were run alongside the test assays, as well as a positive 
enzyme inhibitor assay (table 2.4-1C), and an untreated test reaction (table2.4-1A) which acted 








Table 2.4-1 HDAC activity assay reaction compositions. 
The HDAC activity assay consisted of four controls and the treated samples. The controls 
were used as moderators of the fluctuation that occurred with fluorometric reading. The No 
enzyme and Solvent controls were also used to measure the normal HDAC activity, which 
was set as baseline and used as a reference point of HDAC activity with HDAC inhibitor 
treatment.  





























Inhibitor Solvent only SAHA Trichostatin A Solvent only SAHA  
Extracted 
HDACs ✘ ✘ ✓ ✓ ✓ 
 
 
2.4.2 HDAC Activity Assay Analysis 
To measure normal HDAC activity, the final 30-minute time points of two fluorometric 
assays were used to remove the background level of fluorescence (table 2.4-1A) from the non-
inhibited HDAC activity (table 2.4-1D). The inhibition of HDACs in the HDAC inhibitor 
(SAHA) treated and solvent control cultures were then measured by calculating the difference 
between the activity of the treated assays and the normal HDAC activity, thereby producing a 
normalised HDAC activity value of the control and SAHA treated samples which was plotted 
on a graph (figure 2.4-1). To calculate the percent of change in fluorescent HDAC activity 
between two conditions, the larger of the two values was divided by the smaller value to give 
the fold change between the values, then the total percentage of the larger value (100%) was 
divided by the fold change to determine the percentage difference between the two conditions, 
for example 750/300 = 2.5 fold, 100/2.5 = 40%.  
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Figure 2.4-1 A diagram of the HDAC activity setup and aspects of the plotted activity. 
A) The assay types are loaded in separate wells of a 96 well plate for their fluorometric 
reading on a plate reader. B) The treated HDAC activity values are plotted in comparison to 
the normal HDAC activity, or baseline. 
 
 
2.5 Western Blotting 
Western blotting was performed as a quantification method of detecting protein 
expression in novel compound treated cell cultures. 
2.5.1 Western Blot Procedure 
Western blotting was performed on the protein extracts of cyst growth cultures,  which 
were retrieved using RIPA buffer or hypotonic lysis buffer (section 2.1). The cells were 
harvested and a pellet was produced though centrifugation prior to protein extraction. To 
retrieve the total protein lysate, the cell pellet was resuspended in 50μL of RIPA buffer and 
incubated at 4°C on an orbital shaker for 30 minutes. During this incubation the RIPA buffer 
lysed the cell membranes to release cytoplasmic and some membrane bound proteins. After 
incubation the cell suspensions were centrifuged for 20 minutes at 12,000rpm, maintaining a 
temperature of 4°C, which gave the protein lysate in the form of the supernatant, which was 
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stored at -20°C. Nuclear extraction of histones was also performed on cell pellets by 
resuspension in hypotonic lysis buffer and histone acid extraction. To initiate the release of 
histones, lysis via swelling and rupture of the nucleus occurred with the incubation of the 
nuclear suspension in 1mL of complete lysis buffer for 30 minutes at 4°C on a rotator, and then 
centrifuged at 10,000xg for 10 minutes maintaining 4°C. After centrifugation, acid extraction 
of the histones commenced by removing the supernatant and resuspending the nuclei in 400μL 
of 0.4N (0.2M) sulfuric acid until no clumps were visible, vortexing where necessary, followed 
by an overnight incubation on a rotator at 4°C. After incubation the suspension was centrifuged 
at 16,000xg for 10 minutes maintaining 4°C to pellet the histones and remove the supernatant, 
the histones were then washed twice with cold acetone and centrifuged at 16,000xg for five 
minutes at 4°C to remove any residual acid without dissolving the pellet. After washing the 
histones the acetone was removed and the pellet was left to air dry at room temperature for 20 
to 25 minutes, and then resuspended in ~100μL of 1mmol/L sodium butyrate, depending on 
the initial cell density. Sodium butyrate encourages the preservation of acetyl marks on histone 
tails, so was important in this study for the discovery of changes to histone acetylation with 
SAHA treatment. 
Protein concentration was determined via the Peirce BCA protein assay kit 
(ThermoFisher 23227) and the formation of bovine serum albumin standard curve as suggested 
by the Thermo Scientific user guide. The standard curve was used to calculate the volume of 
the protein lysate required to load 10μg of sample into the wells. Once this volume was 
calculated the sample was diluted in Laemmli buffer to make up a volume of 20μl, or to the 
largest sample volume if over 20μL, and the total protein lysates were heated at 100°C for 5 
minutes to denature the proteins. The histone lysates were not heated as this is damaging, and 
not required for their antibody detection. The entire volume of the samples were then loaded 
into the wells of the western blot Bolt 4-12% Bis-Tris plus gel (Invitrogen NW0412) in loading 
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buffer (Invitrogen, B0002), and run at 100V for two to three hours, or until the Laemmli buffer 
dye had run off the gel. The gel was then transferred onto an iBlot nitrocellulose membrane 
(Invitrogen IB3010) using the ThermoFisher iBlot machine. Once transferred the membrane 
was cut depending on the target protein size and incubated in the respective blocking buffers, 
5% skim milk in TBS-T for rabbit primary antibody or 3% BSA in TBS-T for mouse primary 
antibody, for two hours on a shaker at room temperature. After incubation the blocking buffer 
was removed and replaced with 15mL of new blocking buffer which contained the diluted 
primary antibody, and incubated overnight at 4°C  (in a stationary position). Following the 
incubation, the membrane was washed three times in 0.001% TBS-T for five minutes on a 
shaker. TBS-T was then replaced with 10mL of blocking buffer which contained the diluted 
secondary antibody, and the membrane was incubated for an hour on a shaker at room 
temperature in the dark.  After the secondary antibody incubation the membrane was again 
washed three times with TBST-T, and then dried at room temperature in the dark. Once dry 
the membrane was scanned using the Millennium science Odyssey CLx scanner for fluorescent 
detection of protein expression. 
Table 2.5-1 A description of the antibodies used in western blotting 
Antibodies used in western blotting 
Antibody Host species,  clonality Source 
Anti-β-actin Mouse, monoclonal Sigma A1978 
Anti- H2A/H3-Ac Rabbit, polyclonal Merck 07-355 
Anti-H4 Rabbit, monoclonal abcam ab177840 





2.5.2 Western Blot Analysis 
To quantify protein expression via western blotting, the membranes were initially 
imaged using the Millennium science Odyssey CLx scanner to analyse the intensity of band 
fluorescence compared to background fluorescence, measured in relative fluorescent units 
(RFU), for both the protein of interest and the housekeeping protein (β-actin). These 
measurements were then used to determine the amount of protein expression in the treated and 
control cultures by protein normalisation to the housekeeper. Firstly, to achieve normalisation 
an arbitrary number, larger than the housekeeping value, was divided by the fluorescent 
intensity of the housekeeper to adjust for any differences in this protein between the samples. 
Following this, the fluorescent intensity of the protein of interest was multiplied by the 
equalised housekeeper value to produce the final normalised value, which was then plotted on 
a graph. To further calculate the percent of change in protein fluorescence between two 
conditions, the larger of the two values was divided by the smaller value to give a fold change 
between them, and then the total percentage of the larger value (100%) was divided by the fold 
change to determine the percentage difference between the two conditions, for example 
750/300 = 2.5 fold, 100/2.5 = 40% (figure 2.5-1).  
 
Figure 2.5-1 Calculating the percent of fluorescent change between two conditions to 
determine the difference in expression. 
The relative fluorescent values (RFU) of two conditions were used to measure the percentage 
change 
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2.6 Fluorescence-Activated Cell Sorting 
Fluorescence-activated cell sorting (FACS) is a technique used to separate 
fluorescently stained cells into populations according to the detection of distinct light emissions 
via flow cytometry. 
2.6.1 Apoptosis Assay 
An Annexin V assay was performed by flow cytometry to determine the amount of 
apoptosis occurring in cell cultures treated with apoptosis-inducing therapeutic compounds for 
48 hours. This was achieved via dual staining of the harvested control and treated cells with 
zombie yellow (BioLegend BIO423103) diluted 1:200 and Annexin V-APC (Invitrogen 
BA23204) diluted 2:100 in annexin binding buffer for 15 minutes at room temperature. The 
Zombie viability dye stains dead cells by entering the cytosol of cells that have lost membrane 
integrity to stain intracellular proteins, while Annexin V will bind to phosphatidylserine, an 
outer membrane marker of apoptosis. Once stained, the cells were collected and sorted using 
the Beckman Coulter Gallios flow cytometer, and the apoptotic cells were measured by 
isolating the living cells with no zombie staining, and then identifying the sub-population 
stained positive for Annexin V. This procedure identified cells at the beginning of the apoptosis 
process before they lost membrane integrity, and eliminated cells which had undergone normal 
cell death, or apoptosis, outside the 48-hour time point. The FACS controls included an 
unstained culture, a zombie yellow only heat treated dead culture, a zombie yellow only living 
culture, an Annexin V only untreated culture, a zombie plus Annexin V stained untreated 
culture, a zombie only stained positive control doxorubicin treated apoptotic culture, and an 
Annexin V only stained positive control doxorubicin treated apoptotic culture. These control 
cultures were used to set the living, dying, dead and apoptosing gates during collection of the 
cells. 
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2.6.2 Peptide Uptake 
 Uptake of a fluorescently tagged G3-C12 peptide into kidney derived cell lines after 
their exposure to either 15μM fluorescent peptide (treated) or solvent (control) for six hours, 
was determined by viability staining of zombie yellow (BioLegend BIO423103) diluted 1:200 
in PBS for 15 minutes at room temperature, and 0.005% trypan blue (Sigma T6146) in BSA 
(bovine serum albumin)(Sigma A9647) for five minutes at 37°C to reduce membrane auto 
fluorescence. These cells were then washed once with PBS, centrifuged and re-suspended in 
FACS buffer prior to flow cytometry collection and population separation. The FACS controls 
also included unstained, peptide only, zombie yellow only, trypan blue only, and zombie 
yellow plus trypan blue stained cultures, to set the gating parameters during the flow cytometry 
cell collection process.  
 
2.6.3 Flow Cytometry Analysis 
Flow cytometry was used in this study as a method of identifying the proportion of 
apoptosis in therapeutic compound treated cultures, and as a determiner of peptide uptake in 
vitro. Therefore, analysis has been tailored to each of these experiments to produce different 
outputs.  
2.6.3.1 Apoptosis Assay Analysis 
During cell collection by flow cytometry for the apoptosis assay, the cell populations 
were gated on zombie stained viability, separating the living, dying and dead cells (appendix 
K), to analyse the living and dying populations. The cells were also gated for Annexin V 
staining, as an indicator of the sub-population exhibiting apoptotic features. During therapeutic 
compound optimisation the cells were introduced into a dot plot of cell viability versus 
apoptosis, split into quadrants determined by the apoptosis and viability gating, of which the 
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bottom left quadrant included living apoptotic cells, negative for the zombie stain and positive 
for Annexin V stain, and therefore were the population that was beginning the apoptosis 
process (appendix I). To analyse apoptosis in the therapeutic compound treated cyst assays, 
histograms and dot plots were formed from the FACS data by selecting the living unstained 
zombie and Annexin V positively stained populations, for the analysis of apoptosis occurring 
in the living population of each culture. The plots of the solvent control and compound treated 
populations were overlayed, and due to their strict parameters, were used as the final percentage 
of apoptosis induced in the treated cultures. 
2.6.3.2 Peptide Uptake Analysis 
When collecting the cells of the peptide uptake assay by flow cytometry, gating was set 
to include only the zombie negative population of live cells, limiting any false positive 
fluorescence from dying cells. Using the isolated living cells another gate was set to measure 
the number of peptide inclusive cells in the population. To analyse peptide uptake in vitro, the 
living populations of the solvent control and peptide exposed cultures were overlayed in 
histograms, and a peptide positive gate was applied to calculate change in population 
percentage between the two conditions, adjusting for false positive detection in the peptide 
exposed. Additionally, an overlayed dot plot gave a more accurate visualisation of the shift in 






2.7 Immunofluorescence and Lectin Staining 
Immunofluorescence and lectin staining has been used to show tubule specific peptide 
uptake in vivo and cellular uptake in vitro. 
 
2.7.1 Immunofluorescence 
Immunofluorescence is a technique which involves fluorescently labelled antibody 
detection of a protein of interest. Binding of antibodies indicates protein expression, and 
fluorescence allows for their identification. 
2.7.1.1 Cell line immunofluorescence 
The cell lines were plated on coverslips in 24 well plates, in an identical manner to the 
normal culturing procedure for each cell line (section 2.2.1), during which time the cells were 
treated where necessary. Once the cells had grown to an appropriate density, and the treatment 
was complete, the media was removed and the coverslips were washed with 1x PBS. After 
washing the coverslips, 300μL of (1:1) methanol:acetone was gently pipetted over the 
coverslips, making sure that they were completely submerged, and then incubated at 4°C for 
10 minutes. The methanol:acetone solution was then removed, and the coverslips were washed 
twice with 1x PBS. Permeabilization was performed by incubating the coverslips at room 
temperature in 300μL of a 0.1% Triton-x solution in 1x PBS for 15 minutes and then washed 
with 1x PBS. The cultures were permeabilized to enable antibodies to detect intracellular 
proteins by piercing small holes in the cellular membrane. The coverslips were further blocked 
using 500μL of 2%  BSA (Sigma A9647) in 1x PBS, at room temperature for one hour prior 
to incubation of the primary antibody diluted in 0.1% BSA overnight at 4°C, sealing the edges 
of plate to minimise evaporation. After primary antibody staining, the cultures were washed 
three times with 1x PBS, and incubated for one hour in the dark at room temperature with the 
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fluorescent secondary antibody diluted 1:500 in 0.1% BSA. After secondary antibody staining, 
the coverslips were washed once with 1x PBS and then all liquid was removed and the 
coverslips were air dried until excess liquid had evaporated. Once dry, the coverslips were 
mounted onto slides using a 75% Prolong and DAPI solution in 1x PBS. The slides were then 
visualised using an Olympus BX53 epi-fluorescence light microscope. 
2.7.1.2 Antibody staining of mouse tissue 
The paraffinated mouse kidneys collected by a previous student, Michael Bates, were 
cut into 3μm thick sections and rehydrated through three, five-minute xylene incubations, 
followed by five minute incubations in 100%, 90% and 75% ethanol. Antigen retrieval was 
then performed by placing the slides in 0.01% citrate buffer and heating to 70°C for 10 minutes, 
and then cooling to room temperature for 30 minutes. After three, five minute TBS washes the 
sections were blocked with 5% normal goat serum (NGS)(abcam ab7481) for 30 minutes at 
room temperature and again washed three times with TBS. The primary antibody diluted 1:500 
in 1% NGS was added to the sections outlined with a hydrophobic marker. After a 24-hour 
incubation of the primary antibody at 4°C in a humidity chamber, the sections were washed 
once with TBS-T and twice with TBS. Following this the sections were incubated for 30 
minutes with secondary Anti-rabbit488 (abcam ab150077) diluted 1:1000 in 1% NGS, and then 
washed once with TBS-T and twice with TBS. Finally, 5μl of Prolong gold with DAPI 
mounting media (Life Technologies P36934) was added to the sections for coverslip mounting 






Table 2.7-1 A description of the antibodies used in immunofluorescence 
Antibodies used in immunofluorescence  
Antibody Host species, clonality Source 
Anti-IP3 Rabbit (IgG), polyclonal Merck 07-1210 
Anti-LRP2 (Megalin) Rabbit, polyclonal abcam ab76969 
 
2.7.2 Lectin Staining 
Lectin staining shares many similarities with immunofluorescence, by using 
fluorescently labelled lectins as a direct detection method of specific mono- and 
oligosaccharides on cell membranes. The staining protocol differs from immunofluorescence 
only by the blocking of 1x immunocoat for 30 minutes at room temperature, in place of BSA 
or NGS, followed by a 60-minute incubation of the lectin at room temperature. These 
parameters apply to both cell culture and tissue staining for wheat germ agglutinin (nephron), 
Soy bean agglutinin (distal tubule), Lotus Tetragonolobus lectin (proximal tubule) and 
Dolichos Biflorus Agglutinin (collecting duct). 
Table 2.7-2 A description of the lectins used in lectin staining 
Lectins used in the detection of kidney nephron compartments 
Lectin Cell specificity Source 
Dolichos Diflorus agglutinin 
(DBA) 
Collecting ducts Abacus FL-1031 
Lotus Tetragonolobus lectin 
(LTL) 
Proximal tubule Abacus FL-1321 
Soy Bean Agglutinin 
(SBA) 
Distal tubule ThermoFisher L11272 
Wheat Germ Agglutinin (WGA) Whole nephron, 





2.7.3 Immunofluorescence and Lectin Analysis 
The immunofluorescence and lectin stained cultures were imaged using the Olympus 
BX53 epi-fluorescence light microscope and then loaded into ImageJ as tif files. The tif files 
were pseudo-coloured using colour compensation, and then initialised for cell counting. During 
the cell counting, different patterns of fluorescent staining in the cells or tubules were separated 
into ‘types’ using the cell counter add-on, which allowed for differentiation of staining co-
localisation. Once all data was collected, the proportion of staining in each counter type was 
determined using the negative control images as a comparison. Additionally, the amount of co-
localisation between stains was calculated by subtracting the degree of staining in the negative 
control images from the degree of staining in the stained sections (stained cell or tubule/(All 
stained cells/tubules)), and multiplying this value by 100 to give a percentage (i.e ((200/600)-











C H A P T E R  3  :  R E S U L T S  
This study aimed to investigate novel therapeutic compounds as possible treatments for 
ADPKD cystogenesis. These compounds target pathways previously been linked to the 
initiation or expansion of cyst growth (Goilav, 2011; Liu & Zhuang, 2015; Stayner et al., 2006). 
Additionally, this study aimed to determine the potential of a kidney specific peptide (G3-C12) 
for its conjugation and delivery of therapeutic compounds to kidney tubular cells.  
3.1 Novel Therapeutic Compounds 
The novel compounds tested in this study required optimisation of their dosage and 
treatment duration. Optimisation was required due to an absence of research into the actions of 
these compounds in cultured cell models of polycystic kidney disease. Three in vitro cyst 
assays were developed to quantify how these therapeutic compounds impacted PKD cyst 
growth and aberrant PKD associated cellular signalling. To firstly identify the appropriate 
dosage of the novel therapeutic compounds SAHA, EG1, Portimine and Gymnodimine, the 
growth of 2.5D cyst-like structures was established using the Madin-Darby canine kidney 
(MDCK) cell line. The MDCK cells have the ability to form de-differentiated 2.5D clusters 
when grown on type I collagen for seven days (Zegers et al., 2003)(section 2.2.1), and so are 
commonly used as a cystic model for ADPKD. The use of MDCK as a disease model is due to 
the growth of cellular clusters above the monolayer as a result of epithelial to mesenchyme 
transition (EMT)(Thiery et al., 2009). The process of EMT has been suggested as a possible 
mode of cyst formation in PKD (Togawa et al., 2010), and so the MDCK model acts as an in 
vitro representation of the maturing cysts observed in ADPKD. Another model used for the 
optimisation of the therapeutic compounds was human ADPKD kidney-derived primary cell 
cultures. These cultures enabled us to determine the potential impacts these compounds have 
in human tissue. Additionally, spheroids from the MDCK cell line, and a porcine proximal 
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tubular cell line (LLC-PK1), were investigated for their use in cyst assay mediated therapeutic 
compound testing. Spheroids are three dimensional cultures derived from a single cell type and 
suspended within a cell culture vessel, with some spheroids requiring additional supplementary 
factors in order to form spherical cultures. An advantage of spheroid culturing is the 
physiological relevance absent in two dimensional cell culturing, including surface area for 
drug development, realistic changes in growth, and a better representation of cellular function 
(Achilli et al., 2012). Spheroids were used in this study to model ADPKD cyst growth and to 
determine the effects of the novel therapeutic compounds.  
 
3.1.1 Human PKD Primary Culture Optimisation 
This study included primary human ADPKD cultures as examples of non-immortalised 
diseased tissue developed from ADPKD human kidneys. The kidney tissue retrieved for this 
study was generously donated by two individuals undergoing kidney transplant (following 
informed consent, section 2.2.1.1). The kidneys were sectioned for the development of cell 
lines which proved to be an important component of novel therapeutic compound optimisation 
and kidney specific peptide uptake. Areas of these kidneys were also formalin fixed for lectin 
and immunofluorescent staining (section 3.2.1). 
The donated kidneys were used to develop primary cell cultures that represent a 
subpopulation of the diseased human kidney, and therefore were useful as a human ADPKD 
reference. These allowed us to monitor the results obtained using non-human cell lines, and 
identify how ADPKD tissue may respond to treatment. To assess the cell types present the 
primary cell cultures were characterised after one week of growth using lectin staining of 
proximal tubule (LTL), distal tubule (DBA), and collecting duct (SBA) derived cells (section 
2.7.2). In addition to these three cell types, a fourth category of uncharacterised cells was 
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included to potentially encompass glomerular, muscle, endothelial or other tissue of the kidney 
for which we had no specific markers. However the tubular epithelial cell types were of most 
interest to this study, as they are more likely to undergo cystogenesis in ADPKD patients (Li, 
2015). To calculate the percent of tubule derived cells in each culture, we counted the number 
of stained cells and compared that to the total number of cells within five fields of view for 
each lectin stain, and then normalised these values using the percent of non-specific 
fluorescence in the negative control.  
 
Figure 3.1-1 Representation of lectin stained huADPKD-W cells for culture composition 
analysis. 
The percent of proximal tubular (LTL), distal tubular (SBA) and collecting duct (DBA) cells 
of the huADPKD-W1 cell line was calculated by lectin staining (green) of associated nuclei 
(blue). The control DAPI stained was used to adjust for background staining. Scale bar = 
200μm. 
 
The first patient kidney will be referred to as huADPKD-M. Four cultures were initiated 
from separate locations throughout this kidney in areas of high cyst density (appendix P). Three 
of these four cultures grew successfully and therefore had their cellular composition 
characterised (figure 3.1-2A). The cell culture huADPKD-M1 and huADPKD-M3 had similar 
compositions, with equal amounts of proximal tubule, distal tubule and collecting duct, as well 
as minimal uncharacterised cells (figure 3.1-2B). In contrast, the final cell culture, huADPKD-
M4, was comprised mostly of distal tubule and collecting duct, with only 10% of the cells being 
of proximal tubule origin (figure 3.1-2C). Additionally, all three of these huADPKD-M 
cultures had near identical compositions of uncharacterised cells in the culture. 
 63 
 
Figure 3.1-2 Lectin staining identification of kidney tubule composition of the 
huADPKD-M primary cell cultures. 
A) The huADPKD-M1 cell cultures had equal amounts of distal tubule and collecting duct 
derived cells. The largest population of cells in this culture were of proximal tubule origin. 
n = 3 cultures, six fields of view. B) The huADPKD-M3 cell cultures had similar amounts of 
collecting duct and distal tubule derived cells. The largest population of cells in this culture 
were of proximal tubule origin. n = 2 cultures, four fields of view. C) The huADPKD-M4 
cell cultures had the least amount of proximal tubule derived cells. This culture had large 
proportions of cells that were of collecting duct and distal tubule origin. n = 2 cultures, four 
fields of view.  
 
The second patient kidney donated will be referred to as huADPKD-W, and again, this 
kidney produced three successful cultures from areas of the kidney with high cyst density. 
From these areas the huADPKD-W1 and huADPKD-W2 cultures contained distinct 
populations of cells from the proximal tubule, distal tubule and collecting duct (figure 3.1-3A). 
However, the huADPKD-W3 culture was comprised mostly of distal tubule cells, with some 
proximal tubule cells and an almost undetectable number of collecting duct cells (figure 3.1-
3B). All three of the huADPKD-W cell cultures were predominantly made up of 
uncharacterised cells (figure 3.1-3C, appendix A).  
 
Figure 3.1-3 Lectin staining identification of kidney tubule composition of the 
huADPKD-W primary cell cultures. 
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A) the huADPKD-W1 cell cultures had similar amounts of distal tubule and collecting duct 
derived cells. The largest population of characterised cells in this culture were of proximal 
tubule origin. n = 3 cultures, six fields of view. B) the huadpkd-m3 cell cultures had low 
proportions of collecting duct derived cells and a small percent of distal tubule derived cells. 
The largest population of cells in this culture were of proximal tubule origin. n = 3 cultures, 
six fields of view. C) the huadpkd-m4 cell cultures had very few collecting duct derived cells 
and low numbers of distal tubule derived cells. This largest population of cells in this culture 
were of proximal tubule origin. n = 3 cultures, six fields of view. 
 
 
The huADPKD-M cell cultures were further utilised in section 3.1.3 for novel 
therapeutic compound optimisation and section 3.2.1 for G3-C12 peptide uptake, as these 
cultures gave higher percentages of characterised cell types than the huADPKD-W cultures. 
Kidney tissue sections from these patients, and an additional patient, have also been used for 
the localisation of the G3-C12 peptide receptor in human tissue (section 3.2.2.2). 
 
3.1.2 Cyst Growth Optimisation 
The cell lines MDCK and LLC-PK1 were optimised for 2.5D and 3D growth prior to 
their use in the cyst growth assays. It was necessary for these cultures to reliably produce cyst-
like structures, and maintain consistency in their growth area measurements during therapeutic 
compound treatment. The 2.5D cultures were used as an indication of the impact novel 
compounds had on the developing cysts, however the 3D cultures provided a more robust 
observation of the potential that these compounds had on slowing cyst growth. Previous 
research has identified that the growth of cell lines as 3D spheroids differs from their growth 
in 2D, not only structurally but within regulatory pathways, gene expression and molecular 
gradients, showing more similarity to in vivo models (Ravi et al., 2015). These changes are 
important for drug discovery, an example of which is the more realistic cell-cell and cell-ECM 
communication in spheroids, which produces a microenvironment that modulates the effect 




Figure 3.1-4 Cystic growth of the 2.5D MDCK, 3D MDCK and 3D LLC-PK1cell cultures. 
A) The 2.5D MDCK cultures consist of cyst-like structures protruding from the cellular 
monolayer after seven days of growth, the area of the cysts were highly variable. Scale bar = 
5μm. B) The 3D MDCK spheroids grow as spherical 3D cell culture suspensions over seven 
days, reaching an area of 1-2mm2. Scale bar = 2mm. C) The LLC-PK1 3D spheroids grow as 
spherical 3D cell culture suspension over two weeks, reaching an area of 1-3mm2. Scale bar 
= 1mm. (appendix C) 
3.1.2.1 MDCK cyst growth 
The MDCK cell line was optimised previously in our lab for its use in the 2.5D cyst 
assay, by plating 50,000 cells on type I collagen coated six well plates (9.62cm2 in area) for 
growth over seven days. After seven days a subset of cells formed populations of 2.5D cyst-
like structures within the cellular monolayer, averaging areas of 0.5mm2 (figure 3.1-4A). Once 
the density of cyst-like structures resembled cystic tissue the cyst growth assays were initiated 
by treatment with therapeutic compounds. Additionally, the MDCK cell culture has been 
optimised for 3D spheroid growth. The MDCK cells are self-sufficient in spheroid 
development when plated in a collagen-Matrigel scaffold, or in Corning spheroid microplates 
at a density of 3,000 cells, and growing to an appropriate size after seven days, with divisions 
every 12 hours (appendix H). The ability of the MDCK cell line to form hollow spheres in 
three dimensional culture (Hall et al., 1982; McAteer et al., 1987), widely known as spheroids, 
is due to their de-differentiation under certain conditions, thereby forming acini or cell clusters. 
The MDCK spheroids were used in this study as a cyst assay model for therapeutic compound 
treatment. 
 66 
3.1.2.2 LLC-PK1 cyst growth 
The LLC-PK1 cell line was included in this study as a proximal tubule derived cyst 
model, due to the receptor of the G3-C12 kidney specific peptide being expressed on this tubule 
type (Sun et al., 2017). This study set out to develop 2.5D cultures of the porcine proximal 
tubule cell line LLC-PK1, but had difficulties in consistently producing the cyst-like clusters 
(Appendix B). However LLC-PK1 adequately produced cystic 3D spheroids, based on the 
method by Kuo et al (2014), who assisted spheroid development by knockdown of the inositol 
triphosphate receptor 1 (ITPR1) with small interfering RNA (siRNA). The LLC-PK1 cell line 
in this study underwent immediate knockdown after being plated at a density of 3,000 cells in 
Corning spheroid microplates, and then was re-transformed every five days following. The 
custom designed siRNA fragments, developed by Sigma (section 2.2.1.2), targeted ITPR1 
which acts as a calcium channel in the cell, similar to that of the polycystin complex. ITPR1 
was selected as a target based on the findings by Kuo et al. (2014), who identified three proteins 
which when knocked down have the potential to amplify the cystic phenotype. These proteins 
included polycystin 2 (PC2), inositol triphosphate receptor 1 (ITPR1) and inositol phosphate 
receptor 3 (ITPR3), all three of which interact on the endoplasmic reticulum (ER). PC2 
stimulates the release of calcium through the ITPR proteins into the cytoplasm from the ER, 
regulating the levels of intracellular calcium (Lee, 2016; Li et al., 2005; Li et al., 2009). Kuo 
et al. (2014) found that the knockdown of PC2 had no obvious effect on spheroid growth, and 
knockdown of ITPR3 had far slower spheroid expansion compared to that of the ITPR1 
knockdown, which had the most prominent cyst development over eight weeks. Therefore, this 
study used an identical ITPR1 siRNA sequence at similar concentrations over a shorter period 
of time in order to identify the optimal conditions for spheroid development. 
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3.1.2.2.1 Optimising ITPR1 knockdown in LLC-PK1 cells 
A range of siRNA concentrations between 5nmol/L and 30nmol/L were suggested by 
the authors of the Kuo et al. (2014) paper to be within the optimal range for knock down, and 
therefore were maintained for the three conditions, lipofectamine only (no siRNA), a targetless 
scrambled siRNA sequence (scr siRNA) and a siRNA sequence targeting ITPR1 mRNA 
(ITPR1 siRNA). The LLC-PK1 cells were exposed to each of these conditions for either 24 or                                                                                                                                                                 
48-hours, to determine the most effective siRNA knockdown concentration and length. 
Initially, both qPCR and western blotting were pursued for the quantification of knockdown 
efficiency in LLC-PK1, however both of these approaches were unsuccessful, and so semi-
quantitative detection of ITPR1 via immunofluorescence was used to determine the optimal 
knockdown conditions (Toki et al., 2017). To measure ITPR1 expression, the average ITPR1 
area of staining per cell was calculated following immunofluorescence using an antibody 
against ITPR1 and DAPI nuclear staining (figure 3.1-5). From these calculations we identified 
that half of the ITPR1 siRNA concentrations, not including 5nmol/L, 15nmol/L and 20nmol/L, 
had increased ITPR1 expression after 24 and 48 hours compared to their scr siRNA 
counterparts, and therefore were excluded (table 3.1-1). Of the concentrations which had 
decreased ITPR1 expression, the 5nmol/L siRNA knockdown had the least change and so was 
also removed from the study (table 3.1-1), and the remaining 15nmol/L and 20nmol/L siRNA 
concentrations were further optimised in a spheroid assay to determine their impact on the 






Table 3.1-1 The average ITPR1 protein expression per cell for each optimising condition. 
These were grouped according to siRNA concentration, which incorporates both the 
scrambled and ITPR1 targeting sequence. They were further separated into the knockdown 
period for each of these conditions (24 or 48 hours). The average area per cell has been 
calculated from immunofluorescent staining of ITPR1 and nuclear DAPI staining, and the p 
value calculated by unpaired student T-test. n=2 assays,  six fields of view. 




Condition Length of 
knockdown 
(hrs) 
Average area per cell 
expressing ITPR1 
(μm2) 
 p value  and 
expression (↑or ↓) 
0 No siR 24 846  
  48 441  
5 scr siRNA 24 626  
  48 366  
5 ITPR1 siRNA 24 722 0.44 ↑ 
  48 353 0.92 ↓ 
10 scr siRNA 24 704  
  48 0  
10 ITPR1 siRNA 24 812 0.21↑ 
  48 711 - 
15 scr siRNA 24 825  
  48 666  
15 ITPR1 siRNA 24 713 0.14 ↓ 
  48 849 < 0.01↑ 
20 scr siRNA 24 818  
  48 643  
20 ITPR1 siRNA 24 721 0.30 ↓ 
  48 845 0.01↑ 
25 scr siRNA 24 638  
  48 505  
25 ITPR1 siRNA 24 784 0.02↑ 
  24 810 < 0.01↑ 
30 scr siRNA 24 558  
  48 596  
30 ITPR1 siRNA 24 726 0.17 ↑ 








Figure 3.1-5 Immunofluorescent detection of ITPR1 protein expression in LLC-PK1 
after a 24-hour knock down. 
The knock down efficiency was measured from the average area of peak ITPR1 fluorescence 
(red) per nuclei (blue). A) The no siRNA control cultures had more ITPR1 expression per 
cell than the 15nmol/L or 20nmol/L siRNA knock downs. B) The 15nmo/L scrambled siRNA 
treated cultures had slightly less ITPR1 expression per cell than the no siRNA control. C) 
The 20nmol/L scrambled siRNA treated cultures also had less ITPR1 expression per cell than 
the siRNA control. D) The 15nmol/L ITPR1 siRNA treated cultures had the least ITPR1 
expression per cell of all conditions. E) The 20nmol/L ITPR1 siRNA treated cultures had 
less ITPR1 expression per cell than the no siRNA control and the 20nmol/L scrambled siRNA 
cultures. F) Expression of ITPR1 in these cultures was measured by calculating the total area 
of peak fluorescence divided by the number of nuclei, to give the average area of expression 
per cell. Scale bar = 50μm, n = 2 assays, six fields of view. 
 
To measure spheroid growth of LLC-PK1 after a single ITPR1 knockdown with 
15nmol/L or 20nmol/L siRNA for 24 and 48 hours, the cells were plated in Corning spheroid 
microplates and grown for 14 days, with imaging on days 3, 5, 7 10, 12 and 14. The LLC-PK1 
cultures exposed to 15nmol/L and 20nmol/L ITPR1 siRNA both showed significantly 
increased spheroid growth on day five post treatment compared to the scr siRNA treated 
cultures. By day five the 15nmol/L ITPR1 cells had grown to an average area of 379μm2, 1.4-
fold larger than the 15nmol/L scr siRNA treated cells (figure 3.1-6A), and the 20nmol/L ITPR1 
siRNA had grown to an average area of 792μm2, 2.4-fold larger than the 20nmol/L scr siRNA 
treated cells (figure 3.1-6B). Additionally, on day seven the 15nmol/L and 20nmol/L ITPR1 
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siRNA treated cultures had grown significantly larger spheroids than the scr siRNA treated 
cultures, with the 15nmol/L ITPR1 siRNA treated cultures averaging an area of 561μm2, 3.2-
fold larger than the 15nmol/L scr siRNA treated cultures (figure 3.1-6A), and the 20nmol/L 
ITPR1 treated cultures averaging an area of 733μm2, 2.7-fold larger than the 20nmol/L scr 
siRNA treated cultures (figure 3.1-6B). However, after day seven the growth of the 20nmol/L 
ITPR1 siRNA declined, while the 15nmol/L ITPR1 siRNA treated cultures exhibited continual 
growth until day 14, with the increase in average cellular area reaching statistical significance 
on days 10 and 14 (p<0.05), when compared to the 15nmol/L scr siRNA cultures. A slowing 
of spheroid growth occurred between day seven and 12 in these ITPR1 siRNA cultures, and so 
to maintain steady growth in future spheroid assays the LLC-PK1 cells were knocked down 
after every fifth day (section 2.2.1.3).  
 
Figure 3.1-6 Cystic growth optimisation of LLC-PK1 spheroids over 14 days post 
15nmol/L and 20nmol/L siRNA knockdown. 
A) Spheroid area of no siRNA and 15nmol/L siRNA knockdown of LLC-PK1 cells over two 
weeks. The LLC-PK1 cultures knocked down with 15nmol/L ITPR1 siRNA has a significant 
increase in area on days five (p = 0.01), seven (p = 0.02), ten (p = 0.004) and fourteen (p = 
0.007) compared to the no siRNA cultures, while also nearing statistical significance on day 
twelve (p = 0.07). B) Spheroid area of no siRNA and 20nmol/L siRNA knockdown of LLC-
PK1 cells over two weeks. The LLC-PK1 cultures knocked down with 20nmol/L ITPR1 also 
reached statistical significance on days five (p = 0.04) and seven (p = 0.05), however past 
day ten they showed a loss in area. Statistical values calculated by unpaired student T-test. * 
= p < 0.05, n = 2 assays, six fields of view. 
 
In summary, the 15nmol/L ITPR1 siRNA knockdown over 24 hours was chosen for the 
therapeutic compound treatment of 3D cyst assays.  This knockdown gave the most promising 
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decrease in ITPR1 expression in LLC-PK1 cultures, and produced a statistically significant 
increase in spheroid growth area over two weeks. Measurements of the no siRNA spheroid 
cultures showed a slight increase in spheroid size, indicating that the LLC-PK1 cells have a 
natural inclination towards spheroid expansion which is exaggerated with ITPR1 knockdown.  
 
3.1.3 Investigating Novel Therapeutic Compounds 
Four novel therapeutic compounds were investigated in this study for their ability to 
slow cyst growth in the kidney derived 2.5D and 3D culture models of cystogenesis. These 
compounds are SAHA, EG1, Gymnodimine and Portimine, which each target a cellular 
mechanism often modified during cyst growth (Liu & Zhuang, 2015; Stayner et al., 2006; Zhou 
& Li, 2015).  
3.1.3.1 Modified SAHA 
Suberoylanilide Hydroxamic acid (SAHA), also known by its trade name Vorinostat, 
is a tight-binding competitive inhibitor of histone deacetylases (HDACs)(Lauffer et al., 2013).  
The SAHA compound used in this study has been conjugated to a small polypeptide fragment 
by collaborators at the University of Auckland, as a partial construct of future peptide 
conjugation. SAHA has previously been FDA approved for the treatment of small-cell 
lymphoma, and based on animal models has the potential to slow cystic growth in polycystic 
kidney disease (Cao et al., 2009; Li, 2011). Therefore, a form of SAHA modified for its ability 
to be conjugated to a kidney specific peptide was used to identify the effect of its treatment in 




3.1.3.1.1 Optimisation of SAHA 
HDAC inhibitors have previously been used as a treatment in small animal models of 
polycystic kidney disease (Cao et al., 2009; Liu & Zhuang, 2015; Yanda et al., 2017). A 
modified version of the HDAC inhibitor SAHA was developed by collaborators at the 
University of Auckland and optimised in cyst growth and HDAC activity assays. MDCK 2.5D 
cyst cultures were treated with five SAHA concentrations ranging from 0μmol/L to 
100μmol/L, and the cystic area was measured after three days. The data from these cyst assays 
suggested that the cultures treated with SAHA at 20μmol/L and 50μmol/L had the lowest 
average cyst growth areas (figure 3.1-7A), as well as the lowest numbers of large cysts (greater 
than 100μm2) (figure 3.1-7B). We focused on the large cysts as a better indication of SAHAs 
ability to slow the growth of established cysts, although due to the broad variation of cyst areas 
in each culture the small cysts were included in measuring the average area to avoid skewing 
in the results. 
 
Figure 3.1-7 Cyst growth optimisation of modified SAHA in 2.5D MDCK cultures. 
A) The average area of the MDCK cysts in the untreated, 20μmol/L, 50μmol/L, 80μmol/L 
and 100μmol/L SAHA treated cultures. The 20μmol/L (p = 0.02) and 50μmol/L (p = 0.01) 
SAHA treated cultures grew significantly smaller cysts on average. B) Isolation of the cysts 
larger than 100μm depicts the number and size of the largest cysts in each SAHA treated 
culture. The 20μmol/L, 80 μmol/L and 100μmol/L SAHA treated cultures had the smallest 
median cyst area in this population, while the 20μmol/L, 80 μmol/L and 50μmol/L SAHA 
treated cultures had the fewest cysts larger than 100μm. The blue lines represent the median 
cyst size of each condition. * = p < 0.05, n= 1 assay, five fields of view. 
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In addition to the cyst growth assay, an HDAC activity assay was used to ensure that 
SAHA was able to inhibit HDACs at concentrations ranging from 0μmol/L to 100μmol/L. To 
do so, assays were set up to measure the activity of MDCK lysates exposed to each SAHA 
concentration, in parallel with two control assays, one devoid of HDACs and the other in which 
SAHA was replaced by its solvent (section 2.4). The activity of the assays was measured 
fluorometrically, with the controls used to measure background fluorescence and the activity 
of non-inhibited HDAC lysates. By using the controls to measure normal HDAC inhibition, 
accounting for background fluorescence, we determined the inhibition effect of SAHA on 
HDAC. The 20μmol/L and 50μmol/L SAHA concentrations had considerably more inhibition 
than the 0μmol/L control, with a plateau in inhibition after 50μmol/L indicating saturation of 
SAHA binding to the HDAC enzymes (figure 3.1-8A). Therefore, the combination of cyst 
growth and HDAC activity assay results suggested that 20μmol/L SAHA is sufficient for 
inhibiting HDAC activity. However, to ensure that the lowest inhibitory concentration was 
identified by HDAC activity assay, the untreated MDCK HDAC lysates were further exposed 
to a range of SAHA concentrations between 0μmol/L and 20μmol/L. From these 
concentrations, 15μmol/L SAHA caused the most inhibition (figure 3.1-8B), and so 15μmol/L 





Figure 3.1-8 HDAC activity assay measurement of a range of SAHA concentrations for 
the optimisation dose dependant HDAC inhibition. 
A) The 20μmol/L, 40μmol/L, 50μmol/L, 60μmol/L, 80μmol/L and 100μmol/L SAHA 
concentrations were tested for HDAC inhibition ability in MDCK cell lysates. HDAC activity 
was reduced from the control at all concentrations, with the least inhibition occurring at 
40μmol/L SAHA. n = 1 example of three independent assays. B) The SAHA concentrations 
2.5μmol/L, 5μmol/L, 7.5μmol/L, 10μmol/L, 12.5μmol/L, 15μmol/L, 17.5μmol/L and 
20μmol/L were tested for HDAC inhibition ability in MDCK lysates. The most inhibition 
occurred with 15μmol/L SAHA exposure. n = 1 example of two independent assays.  
 
To identify the length of time taken for SAHA to reach its inhibitory potential, a number 
of 2.5D MDCK cultures had a single exposure to SAHA after seven days of growth, and then 
underwent HDAC extraction every three hours over a 12 hour period, as well as at 24 and 48 
hours. Following HDAC extraction, inhibition was measured using the HDAC activity assay 
kit (ab156064) one-step method. At each of these time points across all assays, inhibition of 
the HDACs occurred at an equal or greater rate than the Trichostatin HDAC inhibitor control 
(appendix D). This inhibition indicates that the action of SAHA is both immediate and long 
lasting, as has been previously demonstrated by Lauffer et al. (2013), with the greatest effect 
occurring nine hours post SAHA treatment in all cell cultures (figure 3.1-9). Lauffer et al. 
(2013) also found that SAHA treatment at 24 and 48 hours corresponded with hyperacetylation 
which began dropping at 96 hours.  Therefore, based on these results, the HDAC inhibition of 
SAHA treated cysts was measured nine hours after treatment each day over three days. 
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Figure 3.1-9 A time-point assay of multiple cell lines to determine the length after 
15μmol/L SAHA treatment of greatest HDAC inhibition. 
A) The assay controls included a developer control, no enzyme control, inhibitor control and 
solvent control (table 2.4-1) B) The time-point assay of huADPKD HDAC inhibition. The 
huADPKD culture had the least HDAC activity after nine hours, and the most activity after 
24 hours. C) The time-point assay of MDCK HDAC inhibition. The MDCK culture had the 
least HDAC activity after nine hours, and the most activity after 48 hours. The MDCK culture 
also gave the expected enzyme activity curve. D) The time-point assay of LLC-PK1 HDAC 
inhibition. the LLC-PK1 culture had the least HDAC activity after nine hours, and the most 
activity after 24 hours. All cultures showed the same downward trend in HDAC activity 
during the first nine hours, followed by an increasing trend until the assay was terminated at 
48 hours. n = 2 assays. 
 
3.1.3.1.2 SAHA treated 2.5D cyst assay 
The SAHA treated MDCK 2.5D cultures were exposed to 15μmol/L SAHA each day 
over three consecutive days, during which time measurements of mean cystic area were made 
by taking images of the cultures under a light microscope and analysing them using ImageJ 
analysis software (section 2.3.2). HDAC inhibition (determined by HDAC activity assays) was 
measured to determine if SAHA treatment caused a change in HDAC activity in the MDCK 
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cysts. From these measurements, we observed that over all three days the average area of the 
cysts in the SAHA treated cultures was larger on average than those in the control treated 
samples. On day one the SAHA treated cysts reached an average 1.3mm2, 1.4-fold larger in 
area than the controls (figure 3.1-10A). On day two the SAHA treated cysts reached an average 
1.7mm2, 1.2-fold larger in area than the controls (figure 3.1-10A). Finally, on day three the 
SAHA treated cysts reached an average 2.7mm2, 2-fold larger in area than the controls (figure 
3.1-10A). However, during the three days the SAHA treated cultures grew fewer cysts than the 
controls on each day (appendix E), most noticeably on day one with an average of five fewer 






Figure 3.1-10 Average cyst growth area and HDAC activity of 15μmol/L SAHA and 
solvent control treated 2.5D MDCK cultures. 
A) Area change of solvent control and SAHA treated MDCK cyst assays. The SAHA treated 
cultures grew larger cysts than the solvent controls on average, over all three days, n = 8 
assays, 32 fields of view. B) The HDAC activity of the SAHA treated cultures was lower 
than that of the solvent controls on day one and two, but higher on day three whereas the 
controls HDAC activity decreased, n = 1 example of four independent assays. * = p<0.05 
 
From these SAHA treated MDCK cyst cultures, HDAC enzymes were extracted to 
determine SAHA’s inhibitory potential by performing HDAC activity assays. Each of the 
HDAC activity assays were performed nine hours after SAHA or solvent treatment of the 2.5D 
cultures every day. To measure HDAC inhibition of each condition the normal untreated 
control HDAC activity was substracted from the HDAC activity of the SAHA or solvent 
control treated samples (section 2.4.2). On day one of SAHA treatment we observed 1.3-fold 
(26%) less HDAC activity in the treated than the controls, and no change between the two 
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conditions on day two (figure 3.1-10B). Between the second and third day of SAHA treatment 
HDAC activity had increased 1.6-fold (38%), during which time the cysts had grown to twice 
the average area of the controls (figure 3.1-10B). In addition, on the third day of treatment the 
HDAC activity of the controls had a 3-fold (49%) reduction from the previous day (figure 3.1-
10B). In the controls there was an overall downward trend towards a loss of HDAC activity, 
while the SAHA treated cultures showed a trend towards a gain of HDAC activity over the 
three treatment days . 
In summary, SAHA treatment was expected to reduce cyst growth and inhibit HDAC 
activity. However, the opposite result was observed and so continued testing of SAHA in 
spheroid cultures was performed to strengthen this finding or identify potential differences. 
3.1.3.1.3 SAHA treated 3D spheroid assay 
The MDCK and LLC-PK1 spheroids were treated with SAHA at a concentration of 
15μmol/L each day over three consecutive days, with imaging, HDAC extractions and histone 
extractions being executed nine hours after treatment commenced. The measurement of cystic 
area from the images was performed using ImageJ software to determine the pre-treated and 
post-treated spheroid areas, calculating the difference between spheroid area each day and the 
pre-treatment area allowed for the measurement of overall change in cystic area when treated 
by SAHA (section 2.3). These results identified a trend towards decreasing cystic area over the 
three treatment days in the MDCK spheroids, but no change in the LLC-PK1 spheroids (figure  
3.1-11). 
The SAHA and control treated MDCK spheroids were similar in area prior to treatment 
(appendix C.1), however the controls exhibited a consistent increase in area over three days, 
during which time the SAHA treated spheroids trended towards having slowed cystic area 
growth. On day three the SAHA treated spheroids had reduced in area by 0.18mm2,  1.4-fold 
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(0.37mm2) smaller than the controls. Unfortunately, due to the variability in the area change of 
these spheroids, statistical significance was unable to be reached by unpaired student T-test 
between the solvent control and SAHA treated spheroids after the final day of treatment (p = 
0.4), nor was it in the area change between days one and three in the treated spheroids (p = 0.3) 
(figure 3.1-11A). Contrastingly, the LLC-PK1 spheroid assay treated with SAHA had similar 
average area changes as the solvent controls on all three days, and by day three the SAHA 
treated spheroids were 1.3-fold (0.13mm2) larger than the controls (p = 0.6)(figure 3.1-11B). 
Therefore, SAHA had seemingly no significant effect on cyst growth in both of these spheroid 





Figure 3.1-11 The change in cyst growth area of spheroids treated with 15μmol/L SAHA.  
A) Area change of solvent control and SAHA treated MDCK spheroids. The SAHA treated 
MDCK spheroids had an average reduction in cyst growth area compared to the controls on 
days two (p = 0.5) and three (p = 0.4). The standard error of the mean was too large to produce 
significance in these spheroids. n = 2 assays, 12 spheroids per day. B) Area change of solvent 
control and SAHA treated LLC-PK1 spheroids. The SAHA treated and control LLC-PK1 
spheroids had no significant difference in area change over the treatment duration, with a 
slight reduction in the average area change of the controls on day three (p = 0.6). n = 2 assays, 
16 spheroids per day. 
 
To identify the impact the HDAC inhibitor SAHA was having on enzymatic activity, 
HDAC activity assays were performed on each day of treatment (figure 3.1-12) where the 
normal untreated HDAC activity (measured by fluorescence at 460nm) was subtracted from 
the HDAC activity of the SAHA and solvent control treated samples, to identify the inhibition 
effect of SAHA in the spheroids (section 2.4.2). From these measurements, the MDCK SAHA 
treated spheroids showed a 3% decrease in HDAC activity after three days of SAHA treatment, 
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while initially having higher activity than the controls on days one and two. By day three the 
SAHA treated spheroids had 2% less activity than the controls (figure3.1-12A). During the 
three days of treatment the controls had increasing HDAC activity, resulting in these spheroids 
exhibiting 4% more activity on day three than they did on day one (figure 3.1-12A). The HDAC 
activity of the LLC-PK1 spheroids showed the same trend as the MDCK spheroids, although 
the SAHA treated and solvent control LLC-PK1 spheroids had similar HDAC activity on day 
one, so on day two the activity of the SAHA treated culture was less than that of the controls, 
and even more so on day three (figure 3.1-12B). However, very little change occurred between 
time points (less than 6%). Between days one and three the range of the LLC-PK1 SAHA 
treated HDAC activity (43RFU) is smaller than that of the MDCK SAHA treated spheroids 
(80RFU), indicating that the MDCK spheroids may have been more sensitive to the SAHA 
treatment. 
 
Figure 3.1-12 HDAC activity assays of 15μmol/L SAHA treated and control spheroids. 
A) HDAC activity of solvent control and SAHA treated MDCK spheroids. The SAHA treated 
MDCK spheroids had increased HDAC activity compared to the controls on days one and 
two, and then reduced activity on day three. n = 1 example of two independent assays due to 
variance in range. B) HDAC activity of solvent control and SAHA treated LLC-PK1 
spheroids. The SAHA treated and control LLC-PK1 spheroids had similar HDAC activities 
on day one, however on days two and three the HDAC activity in the controls increased while 
the activity in the SAHA treated spheroids decreased. n = 1 example of two independent 
assays due to variance in range. 
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To investigate if SAHA treatment of the MDCK and LLC-PK1 spheroids correlated 
with increased histone acetylation, western blotting of histone extractions was conducted for 
the detection of acetylated lysine 23 on histones H2A and H3. The SAHA treated and control 
MDCK spheroids both had a loss of acetylation on days two and three, with 99% less than day 
one (appendix F). Therefore, SAHA has had no impact on acetylation in these cultures. The 
LLC-PK1 spheroids showed a 1.2-fold increase in acetylation from the controls on day two 
(13%) and a 1.5-fold increase on day three (32%) (appendix F). The most evident increase in 
acetylation, of 98%, happened between days one and two of SAHA treatment in the LLC-PK1 
spheroids.  
It was concluded from these results that the modified SAHA treatment has no effect on 
cyst area or the activity of HDACs in the MDCK or LLC-PK1 cultures. 
 
3.1.3.2 EG1 
EG1 is a compound that interacts with the DNA binding site of the transcription factor 
PAX2, therefore inhibiting the ability of PAX2 to recruit polymerases to the promotor regions 
of target genes, such as N-cadherin. Previous studies identified PAX2 overexpression in the 
cystic kidneys of ADPKD animal models (Ostrom et al., 2000; Stayner et al., 2006) and patients 
(Heuvel, 2014), and so the inhibition of PAX2 activity has the potential to be used as a therapy 
to delay cystic growth. The EG1 compound used in this study was developed by Professor 
David Larson, a collaborator at the University of Otago. 
3.1.3.2.1 EG1 concentration 
The concentration at which EG1 successfully inhibits the binding of PAX2 to DNA has 
been previously investigated in the paper by Grimley et al. (2017), which treated a cultured 
kidney model with EG1 at either a 12.5μmol/L, 25μmol/L or 50μmol/L concentration once 
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over a 48-hour time period. Grimley et al (2017) observed stunted nephrogenesis and decreased 
cell culture viability in the cultures treated with 25μmol/L EG1, therefore this concentration 
was adopted for our study. However, the length and regularity of EG1 treatment was adjusted, 
to treatment every 24 hours over three consecutive days showing a noticeable effect on cyst 
growth in MDCK 2.5D cultures. 
3.1.3.2.2 EG1 treated 2.5D cyst assay 
The previously published conditions of EG1 treatment were used in the MDCK 2.5D 
cyst assay to determine the effect EG1 had on cyst growth over three days (figure 3.1-13A). 
By quantification of cystic area in the cyst assays using ImageJ software, we observed an 
overall slowed cystic growth in the EG1 treated 2.5D MDCK cultures after three days, when 
compared to the solvent control (figure 3.1-13B). On day one of treatment there appeared to 
be no difference in the cyst growth between the EG1 treated and control cultures, while on day 
two and the EG1 treated cultures had an average 1.1-fold (0.04mm2) increase in cystic area 
from the controls. On day three a 2-fold (0.53mm2) increase in the cystic area of the controls 
from the EG1 treated was observed (figure 3.1-13B), however no statistical significance was 
found between these cultures (p = 0.09).  
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Figure 3.1-13 Cyst growth change of 2.5D MDCK control and 25μmol/L EG1 treated 
cultures. 
A) The control MDCK cultures had steady cyst growth over three days, while the EG1 treated 
cultures showed slowed cystic growth compared to the controls which becomes noticeable by 
day three. B) Area change of solvent control and EG1 treated MDCK cyst assays. The EG1 
treated MDCK cultures had increasing cyst growth in the controls and EG1 treated cultures 
over three days, however the cystic growth in the EG1 treated cultures was slower than that 
of the controls. On the third day of treatment the control culture cysts were 0.53mm2 larger 
than the EG1 treated culture cysts on average (p = 0.09). n = 4 assays, 20 fields of view. 
Scale bar = 200μm 
 
3.1.3.2.3 EG1 treated 3D spheroid assay 
Spheroid assays of MDCK and LLC-PK1 were solvent control and EG1 treated to  
identify the impact that EG1 treatment has on cyst growth in a 3D structure (figure 3.1-14). To 
show a change in spheroid growth, the growth areas pre and post treatment were measured in 
the individual spheroids. On day one the MDCK spheroids had a 4.8-fold (0.14mm2) reduction 
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in the growth of the controls compared to the EG1 treated, although by day two the area of the 
EG1 treated spheroids had decreased 2-fold (0.26mm2) compared to the controls (figure 3.1-
15A). By day three the MDCK spheroids had a significant 7.2-fold (0.47mm2) reduction 
compared to the controls (p = 0.05)(figure 3.1-15A). The MDCK spheroid controls had 
increased in area by 0.19mm2 between days two and three, which exaggerated the growth 
change between the control and EG1 treated spheroids on day three (figure 3.1-15A). Similarly, 
EG1 treated LLC-PK1 spheroids on day one showed no change in area growth compared to 
the solvent controls, yet showed a significant 5.4-fold (0.2mm2) reduction in average area 
growth on day two and a 7-fold reduction on day three (p<0.01) in the EG1 treated compared 





Figure 3.1-14 A representation of the 3D MDCK and LLC-PK1 control and 25μmol/L 
EG1 treated cultures. 
A) The control MDCK spheroids had a loss and subsequent gain in area over three days of 
growth, while the EG1 treated spheroids had reduced in area by day three. B) The control 
LLC-PK1 spheroids maintained similar growth area over all three days while the EG1 treated 




Figure 3.1-15 The change in growth area of control and 25μmol/L EG1 treated MDCK 
and LLC-PK1 spheroids. 
A) Area change of solvent control and EG1 treated MDCK spheroids. The EG1 treated MDCK 
spheroids had reduced average area growth on days two and three (p = 0.05), compared to 
the controls n = 2 assays, 12 spheroids per day. B) Area change of solvent control and EG1 
treated LLC-PK1 spheroids. The EG1 treated LLC-PK1 spheroids had reduced average area 
growth on days two (p < 0.01) and three (p < 0.01), compared to the controls. At t0 the EG1 
treatment population area was significantly larger (p = 0.02)(appendix C). * = p £ 0.05, ** = 
p < 0.01, n = 2 assays, 16 spheroids per day. 
 
Total protein extraction and western blotting of the control and EG1 treated MDCK 
and LLC-PK1 spheroids was conducted to investigate the effect EG1 had on a PAX2 target, 
N-cadherin. The EG1 compound is an inhibitor of the transcription factor PAX2 and therefore 
likely to modify protein expression from a target gene (Grimley et al., 2017). In the MDCK 
spheroids we observed a 3.5-fold reduction of N-cadherin expression in the EG1 exposed 
cultures over treatment duration, resulting in an almost complete loss of N-cadherin by day 
three (291RFU) (figure 3.1-16B). During the three days of treatment, the solvent control 
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MDCK spheroids had a small increase in N-cadherin expression (205RFU), indicating that 
without treatment these spheroids may have produced more N-cadherin over time. Expression 
of N-cadherin in LLC-PK1 spheroids on day one of EG1 treatment was similar to that of the 
solvent controls. On day two of treatment the treated spheroids had a 2-fold (51%) reduction 
in N-cadherin expression, which then increased 3.2-fold (70%) on day three, when compared 
to the controls (figure 3.1-15B). 
 
Figure 3.1-16 Western blotting of solvent control and 25μmol/L EG1 treated spheroids. 
A) Western blotting of total protein extracted from MDCK spheroids for the detection of N-
cadherin with EG1 treatment, normalised to β-actin. B) The fluorescent intensity of N-
cadherin in EG1 treated and control MDCK spheroids. The EG1 treated MDCK spheroids 
had a decrease in N-cadherin protein expression over three days of treatment, with increasing 
expression in the controls. C) Western blotting of total protein extracted from LLC-PK1 
spheroids for the detection of N-cadherin with EG1 treatment, normalised to β-actin. D) The 
fluorescent intensity of N-cadherin in EG1 treated and control LLC-PK1 spheroids. The EG1 
treated LLC-PK1 spheroids had a reduction in N-cadherin protein expression from day one 
to day three, however there was an increase in N-cadherin between day two and three. The 
controls exhibited a steady decrease in N-cadherin over all three days. n = 1 example of two 
independent assays. 
 
3.1.3.3 Portimine and Gymnodimine 
A confirmed mode of cyst expansion in ADPKD is excessive cellular proliferation 
which increases cell number and density (Lee, 2016). Therefore, inducing apoptosis by 
targeting growth and developmental pathways with Gymnodimine and Portimine treatment has 
the potential to balance cellular, and simultaneously, cyst growth. Gymnodimine is a cyclic 
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imine which induces apoptosis by inhibiting intracellular pathways through its binding to 
nicotinic acetylcholine receptors (nAChRs) (Kharrat et al., 2008). The nAChRs are expressed 
in many cell types, and when activated by nicotine will function as a signal transducer in anti-
apoptotic pathways involving kinases such as MEK, PI3K and ERK (Resende & Adhikari, 
2009; Yu et al., 2011). These kinase pathways are important in proliferation and cell growth, 
and are often dysregulated in ADPKD (Cowley, 2008; Saigusa & Bell, 2015). Additionally, 
inhibition of nAChR by Gymnodimine has been shown in mice to cause apoptosis related 
toxicity at concentrations between 450ug/kg and 755ug/kg (Munday et al., 2004). However, 
this compound is yet to be used for therapeutic purposes. Portimine is a cyclic imine that 
induces apoptosis through modifications of DNA, proteins, and lipids via changes in signalling 
pathways (Cuddihy et al., 2016), specifically the ERK pathway. ERK has been shown to be 
activated prior to apoptosis with Portimine treatment, likely due to the initiation of cytochrome 
c release which upregulates caspases, the key mediators of apoptosis (section 1.1.3.4) (Brooke 
et al., 2018; Chambon et al., 2002). Portimine treatment in the Jurkat cancer cell line has also 
proven that this compound can induce apoptosis at concentrations below 100nmol/L after 48-
hours (Cuddihy et al., 2016). Gymnodimine and Portimine were supplied to us by a 
collaborator at the Cawthron Institute Dr Darby Brooke to determine if these apoptosis 
inducing compounds are able to slow cyst growth.  
3.1.3.3.1 Optimisation of Gymnodimine and Portimine 
Previously a study by Vilariño et al. (2009) measured the response time of ligand 
binding to nAChRs in T. marmorata membranes exposed to Gymnodimine at concentrations 
of 12.5, 25, 125, 250 and 500nmol/L. The addition of Gymnodimine steadily reduced ligand 
binding as concentration increased. Therefore the concentrations chosen for optimisation in 
this study were similar to those identified by Vilariño et al. (2009). To optimise Gymnodimine 
dosage, cultured huADPKD primary cells and MDCK cells were exposed to a range of 
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concentrations diluted in ethanol, as indicated by Vilariño et al. (2009), for 48 hours. The 48 
hour exposure was chosen to determine the percent of cellular viability and apoptosis, as a 24 
hour incubation was insufficient in promoting apoptosis in excess of the solvent control 
(appendix J). The Gymnodimine concentrations used were 12nmol/L, 24nmol/L, 120nmol/L 
and 240nmol/L, and the apoptosis induced by each was measured via flow cytometry of 
Annexin V stained phosphatidylserine (PI), an apoptotic cell clearance signaller, as well as 
zombie yellow, a cell viability marker (section 2.6.1). The Gymnodimine concentration that 
induced the most apoptosis and least cell death was identified by measuring the Annexin V 
positive cells in the live population. Of the huADPKD cells, up to 3.4% underwent  apoptosis 
following Gymnodimine treatment, as well as up to 1% of the MDCK cultures (figure 3.1-17, 
appendix I). The most promising apoptosis inducing concentrations of Gymnodimine in the 
huADPKD cultures were 24nmol/L and 120nmol/L, and in the MDCK cultures were 
12nmol/L, 24nmol/L and 120nmol/L. The huADPKD cultures treated with 120nmol/L 
Gymnodimine had 3.3% apoptosis and 17.5% cell death in the population, the lowest of all 
four concentrations, indicating that Gymnodimine at 120nmol/L promotes apoptosis while 
causing the least cytotoxicity (figure 3.1-17A). The 240nmol/L Gymnodimine treatment in the 
huADPKD cultures caused less apoptosis (3.1%) and more cellular death (18.4%). The MDCK 
cultures treated with 120nmol/L Gymnodimine underwent apoptosis in  0.6% of the population, 
similar to what was found in the 12nmol/L treated cultures and 0.3% less than the 24nmol/L 
treated cultures. However, 120nmol/L Gymnodimine caused only 0.4% more cell death than 
the solvent control, as well as 5% less cell death than the 12nmol/L concentration (figure 3.1-
17B). Therefore, the parameters chosen to induce measurable apoptosis while limiting cell 




Figure 3.1-17 Optimisation of Gymnodimine dosage by Annexin V apoptosis assay. 
 A) Apoptosis in a range of Gymnodimine treated (blue) and solvent control (grey) 
concentrations in huADPKD cell cultures. The most apoptosis occurred within the 24nmol/L 
and 120nmol/L Gymnodimine treated live cells after 48 hours. The percent of apoptosed dead 
cells in each population after 48 hours of Gymnodimine treatment was similar at all 
concentrations, each of which was greater than the solvent control. B) Apoptosis in a range 
of Gymnodimine treated (blue) and solvent control (grey) MDCK cell cultures. The most 
apoptosis occurred within the 12nmol/L, 24nmol/L and 120nmol/L Gymnodimine treated 
cultures after 48 hours. The largest percent of apoptosed dead cells after 48 hours occurred 
in the 24nmol/L Gymnodimine treated culture. n = 2 assays per cell line. 
 
Portimine, diluted in DMSO, has previously been reported as inducing apoptosis at low 
concentrations, between 2nmol/L and 100nmol/L, in a Jurkat Bcl2-overepressing cell line 
(Cuddihy et al., 2016). Cuddihy et al. (2016) found no cytotoxicity after exposing the cells to 
a range of Portimine concentrations for six or 24 hours, and therefore measured viability after 
48 hours. This study also found more substantial apoptosis occurring after 48 hours than at six 
hours in huADPKD Portimine treated cell cultures than the solvent controls (appendix J). 
Cuddihy et al. (2016) discovered that after 48 hours of exposure Portimine had cytotoxic 
properties and a median lethal concentration (LC50) of 6nmol/L in Jurkat cells, measured via 
PI staining and flow cytometry. We observed similar results in the MDCK, and huADPKD cell 
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lines using a live-dead zombie viability stain and Annexin V staining for dose optimisation of 
the Portimine concentrations, 2nmol/L, 4nmol/L, 6nmol/L, 8nmol/L and 10nmol/L. After 48 
hours of treatment the 2nmol/L, 4nmol/L and 6nmol/L Portimine exposed huADPKD cultures 
showed the largest increases in apoptosis from the solvent controls, as well as in the 6nmol/L 
and 8nmol/L Portimine exposed MDCK cultures. Notably, the huADPKD cultures treated with 
2nmol/L and 4nmol/L Portimine were found to have 0.2% and 0.6% more apoptosis as well as 
6% and 38% less cell death respectively than the cultures treated with 6nmol/L Portimine. Yet, 
the MDCK cultures treated with 2nmol/L and 4nmol/L Portimine had less apoptosis than the 
solvent control (1.3% and 0.5%) and less apoptosis than 6nmol/L Portimine treated cultures 
(1.6% and 1%)(figure 3.1-18, appendix I). Therefore, these Portimine concentrations were 
excluded. Furthermore, 8nmol/L Portimine treatment caused 0.1% less apoptosis than the 
6nmol/L treatment in the MDCK cultures, while the cultures treated with 6nmol/L Portimine 
also had 31.5% less cell death than the 8nmol/L treated cultures (figure 3.1-18B). From these 
findings, 6nmol/L Portimine exposure over 48 hours was chosen as the most appropriate 
treatment for the cyst growth assays. A comprise was made in deciding upon 6nmol/L, as this 
concentration gave high cellular death in the huADPKD culture but was able to induce more 




Figure 3.1-18 Optimisation of Portimine dosage by Annexin V apoptosis assay. 
A) Apoptosis in a range of Portimine treated (blue) and solvent control (grey) concentrations 
in huADPKD treated cell cultures. The most apoptosis occurred in the 2nmol/L, 4nmol/L and 
6nmol/L Portimine treatment after 48 hours. The 6nmol/L, 8nmol/L and 10nmol/L Portimine 
treated cultures had largest percent of apoptosed dead cells. B) Apoptosis in a range of 
Portimine treated (blue) and solvent control (grey) concentrations in MDCK treated cell 
cultures. The most apoptosis occurred in the 6nmol/L and 8nmol/L Portimine treated cultures 
after 48 hours. The Portimine concentrations which had the largest percent of apoptosed dead 
cells were 8nmol/L and 6noml/L. n = 2 assays per cell line. 
 
3.1.3.3.2 Gymnodimine and Portimine treated 2.5D cyst assay 
To identify if these apoptosis inducing compounds had any effect on cystic growth, we 
tested them in MDCK 2.5D cyst growth assays using the previously optimised concentrations 
and treatment length. To determine the ability of these compounds to slow cyst growth, cultures 
were imaged both prior to, and 48 hours after treatment to calculate the average area change of 
the cysts using ImageJ software. The amount of apoptosis was also measured in these cultures 





 The MDCK 2.5D cyst growth assays were treated with either 120nmol/L Gymnodimine 
or ethanol (solvent control) for 48 hours. The Gymnodimine treated cyst assays showed a 1.8-
fold (0.002mm2) reduction in cystic area when compared to the solvent controls, however was 
not statistically significant (figure 3.1-19A). Flow cytometry detection of apoptosis found that 
the Gymnodimine treated cultures had only 5.3% more apoptotic cells in the living population 
than the solvent controls (figure 3.1-19B).  
 
Figure 3.1-19 The change in growth area and apoptosis of control and 120nmol/L 
Gymnodimine treated 2.5D MDCK cyst assays 
A) The area change of solvent control and Gymnodimine treated 2.5D MDCK cyst assay 
cultures. The Gymnodimine treated cultures  had a decrease in area change after 48 hours of 
treatment which was not statistically significant (p = 0.08) when compared to the controls, n 
= 3 assays, nine fields of view. B) Apoptosis in the living population of solvent control and 
Gymnodimine treated MDCK cyst assay cultures by Annexin V staining.  The Gymnodimine 
treated cultures had a small increase in the percent of apoptosing cells than the controls, n= 
1 example of three independent assays.  
 
Portimine 
MDCK 2.5D cyst growth assays were treated with either 6nmol/L Portimine or DMSO 
(solvent control) for 48 hours in order to induce apoptosis. A statistically significant 2.7-fold 
decrease (0.024mm2) in cystic area was identified in the Portimine treated cultures compared 
to the solvent controls (figure 3.1-20A). However, these cultures showed minimal difference 
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in apoptosis, with 2.6% of the living Portimine treated population undergoing apoptosis, 
compared to the 6.7% of apoptosis in the solvent control population (figure 3.1-20B). 
 
Figure 3.1-20 The change in growth area and apoptosis of control and 6nmol/L 
Portimine treated 2.5D MDCK cyst assays. 
A) The area change of solvent control and Portimine treated 2.5D MDCK cyst assay cultures. 
The Portimine treated cultures had a statistically significant decrease in area change after 48 
(p < 0.05) when compared to the controls, n = 3 assays, nine fields of view. B) Apoptosis in 
the living population of solvent control and Gymnodimine treated MDCK cyst assay cultures 
by Annexin V staining. The solvent control cultures had a larger percent of apoptosing cells 
than the treated, n = 1 example of three independent assays. 
 
The treatment of 2.5D MDCK cyst growth assays with Gymnodimine and Portimine 
has shown that Gymnodimine treatment caused a reduction in cyst growth, although was not 
statistically significant, while Portimine treatment was able produce a significant cyst growth 
reduction. Apoptosis assays of the treated MDCK cultures gave less distinct changes, with 
Gymnodimine inducing a small amount of apoptosis and Portimine having the inverse effect 
by causing less apoptosis than the controls. 
3.1.3.3.3 Gymnodimine and Portimine treated 3D spheroid assay 
Following Portimine and Gymnodimine treatment of 2.5D MDCK cyst assays, the 
apoptosis inducing compounds were tested in 3D spheroid forming MDCK and LLC-PK1 
cultures to identify the response of more complex structures to the potential therapeutic 
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compounds. ImageJ software was used for area measurements prior to treatment and 48 hours 
after treatment to determine the change in spheroid area, and Annexin V staining was used to 
measure the extent of apoptosis induced by this treatment. 
Gymnodimine 
The MDCK and LLC-PK1 spheroids were treated with 120nmol/L Gymnodimine for 
48 hours to investigate the effect Gymnodimine had on apoptosis in the spheroid structures and 
any change in cyst area that occurred. The MDCK spheroids treated with Gymnodimine, grew 
to half the size of the controls with a 2.1-fold (0.1mm2) reduction in spheroid area change, 
however large variability in these spheroids resulted in their inability to reach statistical 
significance (figure 3.1-21A). Flow cytometry analysis showed overlapping Annexin V 
fluorescence peaks, representing equal amounts of apoptosis in both cultures (figure 3.1-21B). 
 
Figure 3.1-21 The change in growth area and apoptosis of control and 120nmol/L 
Gymnodimine treated MDCK spheroids. 
A) The area change of solvent control and Gymnodimine treated MDCK spheroid cultures. 
He Gymnodimine treated spheroids had a reduction in area growth after 48 hours that was 
not statistically significant (p = 0.36) when compared to the controls, n = 2, 42 individual 
spheroids. At t0 the Gymnodimine treatment population area was significantly larger (p < 
0.01)(appendix C). B) Apoptosis in the living population of solvent control and 
Gymnodimine treated MDCK spheroid cultures by Annexin V staining. The treated and 
control cultures had equal percentages of apoptosing cells in the living population, n = 1 
example of two independent assays.  
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In contrast to the MDCK spheroid assay, the LLC-PK1 spheroids treated with 
Gymnodimine showed a significant 21.6-fold reduction in cyst area compared to the controls 
(p = 0.01), with an average increase in growth of 0.54mm2 in the controls, and 0.025mm2 in 
the Gymnodimine treated (figure 3.1-22A). Additionally, apoptosis assays of the 
Gymnodimine treated cultures showed a 10.9% increase in the percent of apoptotic cells, when 
compared to the solvent controls (figure 3.1-22B).  
 
Figure 3.1-22 The change in growth area and apoptosis of control and 120nmol/L 
Gymnodimine treated LLC-PK1 spheroids. 
A) The area change of solvent control and Gymnodimine treated LLC-PK1 spheroid cultures. 
The treated spheroids had a significant reduction in area growth after 48 hours (p = 0.01) 
when compared to the controls, n = 2 assays, 42 individual spheroids. At t0 the Gymnodimine 
treatment population area was significantly larger (p < 001)(appendix C). B) Apoptosis in 
the living population of solvent control and Gymnodimine treated LLC-PK1 spheroid cultures 
by Annexin V staining. The Gymnodimine treated cultures had a larger percentage of 
apoptosis in the living population  than the controls, n = 1 example of two independent assays.  
 
Portimine 
 After 48-hours of treatment the 6nmol/L Portimine exposed MDCK spheroids had an 
average 0.06mm2 increase in area, while the solvent controls had an average 0.57mm increase 
in area. Therefore, the area of growth change observed in the Portimine treated MDCK 
spheroids was significantly reduced 9.3-fold (0.51mm2) from the solvent controls (p < 0.01) 
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(figure 3.1-23A). However, 1.5% more apoptosis was observed in the solvent controls than the 
Portimine exposed cultures (figure 3.1-23B). 
 
Figure 3.1-23 The change in growth area and apoptosis of control and 6nmol/L 
Portimine treated MDCK spheroids. 
A) The area change of solvent control and Portimine treated MDCK spheroid cultures. The 
treated spheroids had a significant reduction in area growth after 48 hours (p = 0.02) when 
compared to the controls, n = 1 assay, 16 individual spheroids. B) Apoptosis in the living 
population of solvent control and Portimine treated MDCK spheroid cultures by Annexin V 
staining. The solvent control spheroids had a larger percent of apoptosis in the living 
population than the treated, n = 1 assay.  
 
The LLC-PK1 spheroids show a trend similar to the MDCK spheroids, with reduced 
cystic growth after 48-hours of Portimine treatment. The Portimine treated and solvent control 
LLC-PK1 spheroids both showed a reduction in area after the 48 hour treatment, likely due to 
the sensitivity of this cell line to DMSO (figure 3.1-24A). However, the Portimine treated 
spheroids had significantly more cystic area loss (0.5mm2) when compared to the controls 
(0.17mm2), resulting in an overall 3.9-fold (0.67mm2) reduction in area with treatment (figure 
3.1-24A). Apoptosis assays did not reflect the reduction in spheroid growth, with the solvent 




Figure 3.1-24 The change in growth area and apoptosis of control and 6nmol/L 
Portimine treated LLC-PK1 spheroids. 
A) The area change of solvent control and Portimine treated LLC-PK1 spheroid cultures. The 
treated spheroids had a significant reduction in area growth after 48 hours (p < 0.01) when 
compared to the controls, n = 1, 16 individual spheroids. At t0 the Portimine treatment 
population area was significantly larger (p < 0.01)(appendix C). B) Apoptosis in the living 
population of solvent control and Portimine treated LLC-PK1 spheroid cultures by Annexin 
V staining. The solvent control spheroids had a larger percent of apoptosis in the living 
population than the treated, n = 1 assay. 
 
In summary, Gymnodimine treatment of the MDCK and LLC-PK1 spheroids caused a 
reduction in growth area, which was statistically significant in the LLC-PK1 cultures. 
Apoptosis assays of the Gymnodimine treated cultures found equal amounts of apoptosis in the 
treated and control MDCK spheroids, and an increase in the amount of apoptosis with treatment 
in the LLC-PK1 spheroids. Portimine treatment of the MDCK and LLC-PK1 spheroids was 
able to cause a significant reduction in both cultures, although apoptosis assays found that 





3.1.4 Novel Therapeutic Compound Discussion 
The development of human ADPKD primary cells resulted in six cultures from two 
donated diseased kidneys. From the two kidneys, huADPKD-M cultures had equal amounts of 
proximal tubules, distal tubules and collecting duct derived cells, compared to the huADPKD-
W cultures which had large proportions of uncharacterised cells. Therefore, the huADPKD-M 
cell lines were used for therapeutic compound optimisation. In addition, use of the previously 
optimised 2.5D MDCK cyst assay and the development of the 3D MDCK and LLC-PK1 
spheroid assays were important for determining the effect of SAHA, EG1, Gymnodimine and 
Portimine on cyst growth in vitro. The cyst growth assays were used to measure the change in 
spheroid area growth over the treatment duration as well as the identification of cellular 
changes these compounds evoked. 
3.1.4.1.1 Culture optimisation 
This study involved two culture optimisations, the optimisation of the ADPKD human 
primary kidney cell lines, and of the MDCK and LLC-PK1 spheroid cultures. Firstly, 
characterisation of the human primary cell lines was important in the identification of 
therapeutic compound effect, and kidney specific peptide uptake in a diseased model. From the 
two donor kidneys, the huADPKD-M cell cultures gave larger proportions of tubule and 
collecting duct derived cells than the huADPKD-W after passaging at one week of growth 
(appendix A) and lectin staining after a further three days (figure 3.1-1). It is possible that the 
predominant cell types which arose in these culture is due to the location in the kidney that 
they were harvested from. During development, these cell lines had adhered at two days post 
kidney harvesting, and began to form isolated cell populations by day three which became fully 
established after one week, a similar time frame as what has been observed in renal cell 
carcinoma primary proximal tubule cultures (Valente et al., 2011; Yap et al., 2018). The growth 
rate of the huADPKD cells preceding the first passage was faster than the growth in the first 
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week, with divisions occurring every 12 hours (appendix H), imitating that of other ADPKD 
kidney derived cultures (Loghman-Adham et al., 2003). However, after undergoing 10 
passages the growth of these primary cells slowed and there was invasion of fibroblasts in some 
cultures, which were identified by their elongated and spindled morphology compared to the 
more rounded epithelial cells of the tubules and collecting duct. Additionally, 2.5D MDCK 
cultures were used to precede the development of the 3D spheroid cultures for the identification 
of potential novel compound impact and later to enable a comparison between the actions of 
these compounds in cultures of differing complexity. The development of the 3D spheroids 
produced cultures with characteristics more similar to cells in vivo, and so were an 
advancement on the use of 2D or 2.5D cell culture for drug discovery (Edmondson et al., 2014). 
The MDCK spheroids required very little 3D optimisation due to their ability to form the well 
published, cyst-like cellular structures (Hall et al., 2006; McAteer et al., 1987). However, the 
LLC-PK1 culture required the manipulation of their environment via the addition of a number 
of growth factors, and the knock down of the inositol triphosphate receptor 1 (ITPR1) to enable 
appreciable spheroid growth (Kuo et al., 2014) (figure 3.1-6). The use of spheroids has been 
widely accepted as a model for determining therapeutic potential, and can reliably identify the 
effect of compounds in vitro (Ravi et al., 2015). Other studies have found that the success of 
novel compounds trialled in spheroids translates to clinical trials more effectively than 2D 
cultures, as the microenvironment of spheroids better reflects cells in tissue (Langhans, 2018). 
The majority of these studies involved cancer drug treatments, which had the desired effects in 
2D culture, but showed resistance in spheroids and failed clinical trial (Hoarau-Véchot et al., 
2018; Zanoni et al., 2019). Therefore, spheroids were used in this study to better understand 
the action of SAHA, EG1, Gymnodimine and Portimine in cystic kidney cultures, and their 
efficacy as therapeutic compounds for ADPKD. 
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3.1.4.1.2 SAHA treatment 
The treatment of SAHA in ADPKD cyst growth models was optimised by 2.5D cyst 
growth area measurements and histone deacetylase (HDAC) activity, identifying 15μmol/L as 
the optimal concentration of SAHA, which inhibits the most HDACs after nine hours. The 
treatment of SAHA in the cyst assays was extended over three days in order to observe the 
impact this compound has on cellular growth. An anomaly that was observed during SAHA 
optimisation was the increase in HDAC activity with 40μmol/L SAHA exposure, as the 
20μmol/L and 50μmol/L concentrations both had a greater impact on HDAC inhibition (figure 
3.1-8a). However, in the identification of the lowest inhibitory concentration 40μmol/L was 
removed, and concentrations between 2.5μmol/L and 20μmol/L became the focus. From these 
concentrations HDAC activity steadily dropped from 2.5μmol/L to 15μmol/L, but had 
unexpectedly risen in the 17.5μmol/L and 20μmol/L SAHA treated HDACs (figure 3.1-8b). 
This may be due to SAHA being a competitive inhibitor, and so binding of the fluorescent 
substrate to HDACs at the active site will prevent SAHA binding regardless of the 
concentration of the compound (Berg et al., 2002). SAHA treatment of the 2.5D MDCK cyst 
assays had increased average cyst growth area over all three days of treatment compared to the 
controls, especially after the third day, when these cultures also had higher levels of HDAC 
activity (figure 3.1-10). However, over the first two days HDAC activity in the SAHA treated 
is lower than the controls even though the average area of growth is larger, possibly due to 
HDACs being extracted from the cells of both the monolayer and cyst structures causing the 
non-cystic cells to interfere with the signal of the HDACs from the cystic cells. Additionally, 
there were fewer cysts per well in the SAHA treated cultures, possibly due to SAHA stopping 
the initiation of cyst development altogether, without affecting the growth of the mature cysts. 
This inhibition of growth has been identified in in vitro uterine sarcoma cultures with SAHA 
treatment for 24, 48 and 72 hours, in which there was minimal growth after 48 hours and a loss 
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of growth after 72 hours (Hrzenjak et al., 2010). SAHA treatment in the MDCK spheroids has 
shown a potential delay in cyst growth over three days, with an average area change on day 
three less than that of the controls (figure 3.1-11A). Yet, the LLC-PK1 spheroids showed no 
change in SAHA treated area growth from the controls over the duration of treatment, while 
the control spheroids had increased on day three due to their division after 40 hours (figure 3.1-
11B and appendix H), not observed in the SAHA treated spheroids. The lack of difference in 
growth of the SAHA treated cultures may be explained by changes in cell cycle regulation with 
HDAC inhibition, as a study of SAHA in a human leukemia cell line (HL-60) found that 
concentrations greater than 2.5μmol/L caused cell cycle arrest between the second growth 
phase and the mitotic phase (Shiozawa et al., 2009). This finding could support why the loss 
of HDAC activity by day three in the spheroid cultures coincides with the cessation of growth 
in the LLC-PK1 cultures and the reduction in area change of the MDCK cultures. The HDAC 
activity assays performed on each of these cultures produced similar trends yet had 
incomparable ranges and therefore were unable to be combined in this study, therefore a 
representative graph has been shown (figure 3.1-12). Furthermore, the decrease in HDAC 
activity of LLC-PK1 spheroids led to an increase in histone acetylation on days two and three 
compared to the controls, which occurred during the extent of the division phase (figure 3.1-
11B and appendix H). Histone acetylation in the MDCK 3D culture had the highest detection 
on day one of treatment, with a loss of acetylation in the control and treated spheroids on days 
two and three (appendix F). The identification of histone acetylation by western blotting was 
performed to determine if the inhibition of HDACs by SAHA leads to evident changes in 
acetylation, specifically on lysine 23 of histone H3 tails, a location which has been identified 
as having decreased acetylation in mouse models of kidney disease (Fontecha-Barriuso et al., 
2018). 
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To conclude, this study found that SAHA was unable to cause a reduction in cyst area 
over three days of treatment in the 2.5D or 3D assays, compared to the controls. This compound 
was also limited in its ability to inhibit HDACs or cause an increase in acetylation within the 
spheroid cultures. 
3.1.4.1.3 EG1 treatment 
The optimisation of EG1 was modelled off the Grimley et al. (2017) paper, with a 
change in treatment length. The 2017 paper treated the cultured kidney model once for 48 
hours, however we found that it took three days of 25μmol/L EG1 treatment to show an obvious 
slowing of cyst growth in the 2.5D MDCK cultures, compared to the controls (figure 3.1-13). 
We also observed a reduction in the average area change of MDCK and LLC-PK1 spheroid 
cultures, over the three days of treatment (figure 3.1-15). The spheroid cultures gave more 
immediate decreases in the EG1 treated cyst growth area, with MDCK spheroids showing a 
significant change on day three, and LLC-PK1 spheroids showing a significant change on days 
two and three. The growth of both EG1 treated spheroid cultures seemed to plateau on days 
two and three, while on average the controls continued to grow in area (figure 3.1-15), which 
may indicate that the inhibition of DNA binding by its target, PAX2, modifies the regulation 
of cellular growth. The transcription factor PAX2 is important for the expression of genes 
involved in development, cellular maintenance and anti-apoptotic pathways (Lang et al., 2007), 
and has been associated with tumorigenesis and cystogenesis (Grimley & Dressler, 2018). In 
renal cell carcinoma increased PAX2 has been shown to upregulate ADAM10 which causes 
increased cell proliferation (Doberstein et al., 2011), similarly in ADPKD mouse models the 
overexpression of PAX2 has been linked to cyst expansion in the kidneys (Ostrom et al., 2000; 
Stayner et al., 2006). The identification of tissue-specific genes or proteins that are 
dysregulated in disease is useful for identifying modified cellular functions, and can make 
appropriate therapeutic targets (Grimley et al., 2017). So, in this study the inhibition of PAX2 
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by EG1 is likely to have affected cellular growth pathways and slowed proliferation in both the 
2.5D MDCK cyst assays and the MDCK and LLC-PK1 spheroids after two days of treatment, 
which was observed as a decrease in area compared to the controls. To determine the effect 
EG1 was having on PAX2, we performed western blotting for the detection of N-cadherin 
expression. The transmembrane protein, N-cadherin, was chosen on accord of previous work 
in our lab which identified, by qPCR, that PAX2 regulated the transcription of N-cadherin (Li, 
2010). This was shown by knocking down PAX2 expression in three different cell lines, and 
consequently reducing N-cadherin transcription (figure 1.3-1). In the MDCK spheroids a 
gradual loss in N-cadherin expression was identified over the three days of EG1 treatment 
(figure 3.1-16). These findings share similarities with the observed in area change, as a 
reduction in the EG1 treated spheroid area on day two and three was occurring in parallel with 
the reduction of N-cadherin expression. EG1 treatment of LLC-PK1 spheroids caused a 
depletion of N-cadherin on day two of treatment, but these spheroids then regained expression 
on day three while the controls continued to express less N-cadherin. The inconsistency of N-
cadherin expression in the LLC-PK1 spheroids may be due this cell line expressing minimal 
amounts of this protein, especially compared to the MDCK cells (appendix G). However, 
MDCK and LLC-PK1 express similar amounts of PAX2, and so it is possible that EG1 
treatment had comparable effects in these cell types (appendix G). A study of prostate cancer 
suggested that the overexpression of PAX2 caused upregulation of N-cadherin expression 
during tumour invasion by signalling epithelial to mesenchyme transition (EMT) (Ueda et al., 
2013), an event that is prominent in the kidneys of ADPKD patients (Thiery et al., 2009; Wang 
et al., 2019), and has been shown to be mediated in MDCK spheroids by N-cadherins role in 
cell-cell adhesion (Shih & Yamada, 2012). Thus, the significant reduction in spheroid growth 
may have been amplified due to the loss of PAX2 driven proliferation and N-cadherin’s role 
in cell junctions, whereas the 2.5D MDCK cultures were less affected by changes in cell 
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adhesion and showed a less obvious delay in growth (Shih & Yamada, 2012). Additionally, to 
ensure that the detection of N-cadherin in the spheroid cultures was not influenced by cell 
count, the input concentration of total protein was made equal in all lanes, and each lane, or 
sample, was normalised to β-actin, a housekeeping protein which is not regulated by PAX2 
and therefore was unaffected by EG1 treatment. 
Overall, EG1 and the inhibition of PAX2 has shown the potential to delay 2.5D and 3D 
cystic growth with the loss of N-cadherin expression, and potentially other PAX2 target genes 
which were not been identified in this study. 
3.1.4.1.4 Apoptosis inducing compound treatment 
To determine the appropriate concentrations of Gymnodimine and Portimine for use in 
the cyst growth assays, the dosages were optimised via Annexin V apoptosis and zombie 
viability staining. The importance of measuring cell viability was to guarantee that the 
concentration chosen for cyst assay treatment did not induce excessive cytotoxicity, and that 
cells were undergoing apoptosis after therapeutic compound exposure, due to its action. 
Measuring apoptosis in the living population removed cells which died prior to, or within the 
48-hour treatment. Unfortunately, these were unable to be separated which may have caused 
some cells that died during treatment to be missed. During optimisation we found that the 
120nmol/L Gymnodimine treatment, which induced the highest percentage of apoptosis in the 
huADPKD cells, was the optimal concentration for cyst assay treatment. Additionally, the 
6nmol/L Portimine treatment had more apoptosis in the huADPKD cell cultures and less cell 
death in the MDCK cell cultures compared to the controls, so was chosen as the optimal 
concentration. The treatment of Gymnodimine in the MDCK cyst growth assays caused 
reductions in area growth, with a corresponding increase in apoptosis from the solvent control 
of the 2.5D cultures, and no change in apoptosis of the spheroid cultures (figures 3.1-19, 3.1-
21 and 3.1-22). Gymnodimine treatment in the LLC-PK1 spheroids caused a significant 
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reduction in area growth as well as an increase in the percent of cells undergoing apoptosis. A 
previous study investigating seven apoptosis inducers in the LLC-PK1 and NRK-52E renal cell 
lines found that the LLC-PK1 cells had a higher sensitivity to more of the compounds, 
identified by the occurrence of DNA laddering in apoptosis (Heussner & Dietrich, 2013). The 
distinct sensitivities of the MDCK and LLC-PK1 cells could be caused by differences in cell 
polarity and their trafficking of proteins to the apical or basolateral membranes (Miranda et al., 
2001), which in spheroid culture can impact the ability of the apoptosis inducing compounds 
to reach their target. In the LLC-PK1 spheroids, Gymnodimine has shown a potential for 
delaying cyst growth, which was not seen in the  MDCK cultures. However, Portimine 
treatment of the 2.5D MDCK,  3D MDCK  and 3D LLC-PK1 assays resulted in a statistically 
significant reduction in cystic growth compared to the controls (figures 3.1-20A, 3.1-23A and 
3.1-24A). Notably, the Portimine treated MDCK and LLC-PK1 spheroids both had a 0.5mm2 
reduction in cystic growth area after 48 hours. However, Annexin V staining of the Portimine 
treated assays consistently identified less apoptosis than the control cultures (figures 3.1-20b, 
3.1-23B and 3.1-24B). This has been observed in other studies where apoptosis inducing 
compound treatment of MDCK and LLC-PK1 cell lines caused no apoptosis (Knoll et al., 
2004), or very limited apoptosis (Healy et al., 1998). A study by Knoll et al (2004) found that 
calcium oxalate was unable to promote apoptosis at 1mmol/L, 2mmol/L or 4mmol/L in MDCK 
and LLC-PK1 cell lines, likewise a study by Healy et al. (1998) found that treating LLC-PK1 
cells with cyclosporine A only had a 6% increase in apoptosis. A caspase assay was attempted 
in this study as another means of measuring apoptosis, however was not continued due to 
technical issues. Overall, Portimine treatment of 2.5D and 3D assays of MDCK and LLC-PK1 
cultures was able to slow cystic growth, but has provided no evidence of inducing apoptosis 
with Annexin V staining. The minimal shifts in the percent of apoptotic cells isolated from the 
total population when treated with Gymnodimine or Portimine may be due to inherent 
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apoptosis with cystic growth of MDCK and LLC-PK1 cultures (appendix L). An issue with 
normal apoptosis occurring in these cell lines is the correct identification of cells which were 
apoptosing due to the treatment rather than occurring spontaneously, especially with large cell 
volumes in the spheroid cultures. It is also possible that the novel compound targets are active 
through cell mechanisms other than apoptosis, and were able to cause a reduction of cystic 
growth in the MDCK and  LLC-PK1 cultures. An example is ERK, which Gymnodimine 
indirectly modifies and Portimine directly targets (Chambon et al., 2002; Kharrat et al., 2008), 
and is involved in the regulation of cellular growth via the MAPK pathway. The MAPK/ERK 
pathway relays signals from the cell surface to the nucleus by movement of phosphate groups 
for the activation of transcription factor complexes with ERK binding (Whitmarsh, 2007). 
Previous studies found that phosphorylated ERK is associated with the transcription factor 
activating protein 1 (AP-1) (Benkoussa et al., 2002), the TATA binding protein of the 
transcription factor IID (TFIID) (Biggs et al., 1998), and general transcription factors (GTFs) 
of RNA polymerase I and II (Felton-Edkins et al., 2003; Zhao et al., 2003). Interestingly, AP-
1 is overexpressed in ADPKD and has been shown to cause upregulation of the polycystin 1 
protein in cystic cells (Le et al., 2004; Le et al., 2005). The regulation of gene expression by 
transcription factor directed RNA polymerases is important in cellular growth and 
maintenance, in which the MAPK/ERK pathway is involved during development by promoting 
differentiation with stable ERK activation, and proliferation with transient ERK activation 
(Whitmarsh, 2007). It is likely that ERK activity is modified in ADPKD causing increased 
proliferation, and so potential inactivation of ERK by Gymnodimine and Portimine may result 
in a loss of cell growth and proliferation rather than an increase in apoptosis. Determining the 
activity of ERK in the novel compound treated cultures would require the identification of 
ERK phosphorylation, transcription factor binding of ERK, or the transcription of downstream 
genes. Investigation of the ERK pathway by RT-qPCR, or TUNEL staining and other caspase 
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based assays of the spheroids could confirm if the novel compounds induce apoptosis or cause 
an effect in other pathways. 
 
3.2 Kidney Specific G3-C12 Peptide Uptake 
Development of therapies capable of directly targeting the kidneys has potential to limit 
the toxicity caused by side effects in off-target organs (Cadnapaphornchai, 2017; Saigusa & 
Bell, 2015). Therefore, drug targeting using a carrier system, such as the G3-C12 peptide, may 
be important in developing polycystic kidney disease treatments, especially due to the long 
term nature of this disease, and can further assist by reducing drug dosages and increasing 
treatment efficacy at the site of cystic growth. 
Previous research in our lab has shown that G3-C12 peptide uptake was preferentially 
retained in the kidneys of a wild type mouse model injected with 10nmol/L of fluorescently 
tagged G3-C12 peptide (appendix N). At thirty minutes after injection, the kidneys were able 
to retain an intense fluorescence, which was absent in the liver, spleen, heart and lungs. 
Following on from this work, we aimed to confirm uptake of the peptide into specific structures 
of the kidney. To undertake this, fixed and embedded tissues from the kidneys of these mice 
were sectioned and lectin stained to identify the proximal tubules, distal tubules and glomeruli. 
Megalin staining was also used to locate the presumptive receptor for the G3-C12 peptide. 
 
3.2.1 In vitro peptide receptor expression and uptake 
The in vitro models used in this part of the study include the primary human ADPKD 
kidney derived cells (huADPKD-M), a proximal tubule derived cell line (ADPKD 9-7), a distal 
tubule and collecting duct derived canine kidney cell line (MDCK) (Nakazato et al., 1989), and 
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a proximal tubule derived porcine kidney cell line (LLC-PK1) (Nielsen et al., 1998). These cell 
lines were used to demonstrate peptide uptake via flow cytometry  and fluorescent imaging of 
methanol:acetone fixed cultures, after exposure to 15nmol/L of fluorescently tagged G3-C12 
peptide. Conjugation of the G3-C12 peptide to a rhodamine fluorophore was carried out by 
collaborators at the University of Auckland, and provided to us for this study (figure 3.2-1b) .  
 
Figure 3.2-1 Structure of the polypeptide linker and fluorophore conjugated G3-C12 
peptide. 
A) The polypeptide linker allows for compounds to be conjugated to the G3-C12 peptide 
while also lessening steric hindrance. The weight of the C3-C12 peptide with the polypeptide 
linker only is 2.4kDa. B) The G3-C12 peptide has been conjugated to the red fluorophore 
Rhodamine via the polypeptide linker for fluorescent detection of peptide uptake. By 
Professor Margaret Brimble, based on Geng et al. (2018).  
 
3.2.1.1.1 Peptide uptake in ADPKD derived cells 
The human ADPKD cell lines, huADPKD-M and ADPKD 9-7, were incubated for six 
hours with 15nmol/L of the rhodamine or polypeptide linker only (negative control) conjugated 
G3-C12 peptide (figure 3.2-1) for fluorescent assessment of peptide uptake in these human 
derived in vitro models of polycystic kidney disease. Megalin is the assumed receptor for the 
G3-C12 peptide due to its positioning on the cell surface and role in the initiation of glomerular 
filtrate endocytosis when bound by peptides (De et al., 2014; Geng et al., 2012). Therefore, 
these cells were fixed and stained with an anti-megalin antibody to identify the G3-C12 peptide 
receptor expression and its co-localisation with the peptide. Peptide uptake in the primary 
huADPKD-M cells by fluorescent imaging and flow cytometry showed 86% of the peptide-
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exposed cell population fluoresced positively for the peptide, 85% more than the negative 
controls (figure3.2-2D and 3.2-2E). The huADPKD cells had megalin in 93% of cultured cells 
by immunofluorescence, but only 5% of peptide co-localisation was able to be detected in the 
imaged cells (figure 3.2-2F). 
 
Figure 3.2-2 Fluorescent peptide uptake into huADPKD-M cell cultures. 
A) The negative control cultures were nuclear DAPI stained only. B and E) Peptide exposed 
cultures were imaged by fluorescent microscopy (red) D) Peptide uptake was determined by 
flow cytometry (blue). Fluorescent imaging and flow cytometry of the peptide exposed 
huADPKD-m cultures produced similar percentages of peptide uptake. C and F) In the 
megalin stained (green) culture we identified much less peptide uptake. Cellular peptide 
indicated by white arrows. Scale bar = 50μm, n = 12 fields of view. 
 
The ADPKD 9-7 cell line was also incubated with 15nmol/L of the fluorescently tagged 
G3-C12 peptide. Fluorescent imaging of the cultures indicated that 15% of the total populations 
were positive for the peptide (figure 3.2-3E). Immunofluorescent staining of megalin in these 
cultures identified 26% of cells having co-localisation of megalin and peptide (3.2-3F). 
However, flow cytometry detection of the peptide-treated cells exhibited likely uptake into 
91.6% of the population, with 89.1% more fluorescent cells than the negative controls 
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(figure3.2-3D). This result indicates some sensitivity differences in peptide uptake between 
fluorescent imaging and flow cytometry. 
 
Figure 3.2-3 Fluorescent peptide uptake into ADPKD9-7 cell cultures. 
A) The negative control cultures were nuclear DAPI stained only. B and E) Peptide exposed 
cultures were imaged by fluorescent microscopy (red). D) Peptide uptake was determined in 
the by flow cytometry (blue). Fluorescent imaging of ADPKD9-7 cultures has shown a 
smaller percentage of peptide uptake than what was detected in flow cytometry. C and F) 
Co-localisation between the peptide (red) and Megalin receptor (green) was similar to what 
was observed in the peptide exposed culture. Cellular peptide indicated by white arrows. 
Scale bar = 50μm, n = 10 fields of view   
 
To summarise, peptide uptake was observed in both human ADPKD cell cultures, 
especially in the huADPKD-M cells. These cultures also expressed the Megalin receptor, with 
co-localisation at sites of peptide uptake in the ADPKD9-7 cells. The amounts of peptide 




3.2.1.1.2 Peptide uptake in cyst forming kidney cells 
Kidney derived cyst forming cells of canine (MDCK) and porcine (LLC-PK1) origins 
were incubated with 15nmol/L of the rhodamine conjugated fluorescent G3-C12 peptide for 
six hours in order to determine their suitability as a model for cyst growth in peptide drug 
delivery assays. MDCK 2.5D cultures showed minimal cellular peptide uptake, with the 
peptide exposed population having only 6% more than the controls by fluorescent imaging, 
and 3% more than the controls by flow cytometry (figure 3.2-4D). However, fluorescent 
imaging of the peptide exposed methanol:acetone fixed cultures shows the accumulation of 
fluorescence in areas of high cell density, likely to be cyst forming regions. When the MDCK 
cells were stained for megalin expression 72% of the cultures stained positive and 18% of cells 
had peptide co-localisation (figure 3.2-4F). 
 
Figure 3.2-4 Fluorescent peptide uptake into MDCK cell cultures. 
A) The negative control cultures were nuclear DAPI stained only. B, D and E) Fluorescent 
imaging and flow cytometry of peptide exposed cultures have identified that 2.5D MDCK 
cultures undergo minimal peptide uptake. C and F) Megalin receptor staining (green) in this 
cell line co-localises with more peptide (red) than the peptide exposed cultures. Cellular 
peptide indicated by white arrows. Scale bar = 50μm, n = 6 fields of view. 
 114 
 
Observation of peptide uptake by fluorescent imaging in the LLC-PK1 identified 
peptide accumulation in 8% of cells (figure 3.2-5E). However through flow cytometry, there 
was peptide uptake in 99% of peptide-exposed cells, compared to 0.26% in the controls (figure 
3.2-5D). Additionally, 67% of these cells consistently stained intensely for megalin throughout 
the culture and showed 6% co-localisation of the peptide with megalin (figure 3.2-5F). 
 
Figure 3.2-5 Fluorescent peptide uptake into LLC-PK1 cell cultures. 
A) The negative control cultures were nuclear DAPI stained only. B and E) Fluorescent 
imaging of the LLC-PK1 cell line has shown a small percent of peptide uptake (red). D) Flow 
cytometry of peptide exposed cultures had a larger percentage of uptake (blue) than what was 
seen in fluorescent imaging. C and F) Fluorescent imaging of megalin expression (green) in 
this cell line co-localised with similar amounts of peptide (red) as the peptide exposed 
cultures. Cellular peptide indicated by white arrows. Scale bar = 1mm, n = 12 locations. 
 
In summary, there were differences in the capacity of these kidney cell cultures to take 
up the G3-C12 peptide and the measurements sometimes varied depending on the modality 
used.  Further experimentation aimed to identify if the delivery of an epigenetic modifier 
conjugated to this peptide could effect a change in cyst growth and activity of the target. 
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3.2.1.2 G3-C12-SAHA treatment of Cyst Assays 
To identify the functionality of the G3-C12 peptide as a vector for drug delivery, the 
peptide was conjugated to Suberoylanilide Hydroxamic Acid (SAHA)(figure 3.2-6) by 
collaborators in Auckland and tested in MDCK 2.5D and 3D cyst assays. The concentration of 
this peptide bound SAHA was kept the same as the free modified SAHA treatment, therefore 
these cyst assays were treated with 15μmol/L SAHA once a day for three consecutive days and 
the cells harvested nine hours after treatment.  
 
Figure 3.2-6 Structure of the G3-C12 peptide conjugated to the modified SAHA through 
a polypeptide linker. 
Collaborators at the university of Auckland conjugated a modified SAHA to the kidney 
specific G3-C12 peptide to study the potential of the peptide to be used as a drug carrier 
(Geng et al., 2012). 
3.2.1.2.1 2.5D cyst culture exposure to the G3-C12-SAHA compound 
An MDCK 2.5D cyst assay was grown for seven days pre-treatment, at which point the 
culture was imaged prior to G3-C12-SAHA treatment and then further imaged over three days, 
nine hours post treatment (figure 3.2-7). The treatment of G3-C12-SAHA was able to markedly 
delay cyst growth during the three days of treatment, causing a significant 0.3mm2 (2.4-fold) 
reduction in cyst area compared to the controls by day three (figure 3.3-8A). HDAC lysates 
were made from these cultures for the fluorometric detection of HDAC activity in the G3-C12-
SAHA exposed and solvent control cultures. HDAC activity on day one was 19% higher in the 
SAHA cells than in the controls, which then further peaked on day two, yet by day three the 
HDAC activity in the SAHA exposed cultures was 57% less than that of the solvent controls 
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(figure 3.2-8B). These HDAC activity readings matched what was observed in the growth of 
the cyst assay, where on day one and two there was minimal change in cyst area, while on day 
three a reduction in the C3-C12-SAHA treated cyst growth corresponded with a decrease in 
HDAC activity, when compared to the solvent control cultures. 
 
Figure 3.2-7 Representative images of a G3-C12-SAHA treated 2.5D MDCK cyst assay. 
The control 2.5D MDCK cyst assay consistently grew large rounded cystic structures as 
identified by the black arrow. However, when treated with the G3-C12-SAHA compound the 




Figure 3.2-8 Treatment of 2.5D MDCK cultures with 15μmol/l G3-C12-SAHA. 
A) Area change in solvent control and G3-C12-SAHA treated MDCK cyst assays. Cyst assay 
area measurements over three days identified a slowing of growth in the G3-C12-SAHA 
treated MDCK cultures, with a significant decrease in area compared to the controls on day 
three. n = 3 assays, 15 fields of view. B) An example of an HDAC activity assay of the G3-
C12-SAHA treated MDCK cultures produced a similar trend of increasing activity between 
days one and two in the treated and controls, but by day three the treated had lost activity 
while activity in the controls continued to increase. n = 1 example of two independent assays 
 
3.2.1.2.2 3D spheroid culture exposure to the G3-C12-SAHA compound 
The G3-C12-SAHA treatment was further investigated in a 3D MDCK spheroid culture 
to give an indication of how these cells would respond to treatment as a more morphologically 
complex structure. To determine the impact the G3-C12-SAHA compound had on these 
spheroids, the change in area growth was calculated by imaging the cultures pre-treatment as 
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well as on each consecutive day of treatment after nine hours of exposure. A reduction was 
observed in the area change of the SAHA treated cells compared to the controls, by 0.2mm2 
(1.3-fold) on day two of treatment, and by 2mm2 (2.7-fold) on day three of treatment (figure 
3.2-9A). Additionally, there was a significant 3.8mm2 (3.8-fold) decrease in the G3-C12-
SAHA treated spheroid growth between days one and two, as well as a 6.2mm2 (6.2-fold) 





Figure 3.2-9 Treatment of MDCK spheroids with 15μmol/L G3-C12-SAHA. 
A) Measurement of the change in cyst growth of G3-C12-SAHA treated and control MDCK 
over three consecutive days. The treated and control spheroids both decreased in area over 
this time, presumably due to toxic effects of the acetonitrile solvent. n = 1 assay, 21 
individual spheroids. At t0 the control treatment population area was significantly larger (p 
= 0.05) (appendix C). B) Western blotting of solvent control and 15μmol/l G3-C12-SAHA 
treated MDCK spheroids for the detection of acetylated histone H3 (top band) histone H2A 
(bottom band) on lysine 23. Pure histone (1ug quantified by Pierce BCA assay) was loaded 
into each well. The SAHA treated MDCK spheroids had an increase in histone acetylation 
over three days of treatment, n = 1 assay. * = p<0.05,    ** = p<0.01 
 
To determine if the G3-C12-SAHA could influence the acetylation of histones, western 
blotting of acetylated lysine 23 on histones H2A and H3 was performed. The action of SAHA 
was expected to increase histone acetylation due to the inhibition of HDACs. The MDCK 
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spheroids treated with G3-C12-SAHA had 39% (1.6-fold) less histone acetylation on day two, 
and 70% (3.2-fold) more acetylation on days three compared to the controls (figure 3.2-9B). 
This was a preliminary experiment due to limited available SAHA conjugated G3-C12 peptide 
and will require more replicates to reinforce these findings. 
 
3.2.2 In vivo Peptide Receptor expression and Uptake 
In vivo models of whole mouse kidney and dissected human ADPKD kidney have 
previously been utilised in our laboratory to identify kidney specific peptide uptake (appendix 
N)(Bates, 2016). To further characterise the efficacy of C3-C12 peptide uptake lectin staining 
was used to analyse the tubule types that co-localises with the fluorescent peptide signal in 
these tissues. Alongside the peptide-specific lectin staining, these tissues were stained for 
megalin receptor expression. Megalin plays role in endocytosis and is therefore the expected 
route of peptide uptake into the cells (Geng et al., 2012).  
3.2.2.1 Megalin and Lectin co-localisation with the G3-C12 peptide 
 The kidneys from four mice that underwent fluorescently labelled peptide or free 
fluorophore injection were fixed, embedded and sectioned for immunofluorescent staining of 
the megalin receptor, and lectin staining to determine the tubule type in which the peptide 
accumulated. 
3.2.2.1.1 Megalin staining of peptide injected mouse kidneys 
The megalin receptor is a low-density lipoprotein with a role in receptor mediated 
endocytosis in luminal cells of the proximal tubule during reabsorption of filtered material from 
the glomerulus (Tao et al., 2005). Geng et al. (2012) has suggested that this receptor is a means 
by which the G3-C12 peptide is absorbed by kidney tubular cells, and was further investigated 
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in this study via immunofluorescent detection of megalin in peptide injected mice. We found 
that 27% of megalin stained tubules co-localised with the peptide, with 98.6% of all peptide 
uptake occurring in tubules expressing megalin (figure 3.2-10C), consistent with the hypothesis 
that megalin is the predominant route of uptake for the peptide.  
 
Figure 3.2-10 Megalin receptor staining of the G3-C12-Cy3.5 peptide injected mouse 
kidney. 
A) A DAPI and megalin stained saline injected wild type mouse kidney section. B) A mouse 
kidney with fluorescently tagged G3-C12 peptide uptake (red) that was stained for the 
detection of the megalin receptor (green). C) The percent of peptide located in megalin 
stained mouse tubules. Scale bar = 50μm. 
3.2.2.1.2 Lectin staining of G3-C12 peptide injected mice kidneys 
To identify uptake of the G3-C12 peptide into specific kidney tubules, lectin staining 
of the nephron segments was performed. The proximal tubules are recognised by Lotus 
Tetragonolobus lectin (LTL), the distal tubules are recognised by Soy bean agglutinin (SBA), 
and the glomeruli are recognised by Whole germ agglutinin (WGA). WGA also differentially 
stains the proximal and distal tubules. These fluorescently labelled lectins bind specific mono- 
or oligo-saccharides expressed on the cell surface (Lis & Sharon, 1998), therefore are able to 
act as a marker of certain cell types to discriminate between nephron segments. LTL staining 
indicated that 30% of all proximal tubules co-localise with the peptide, with minimal peptide 
uptake occurring outside of these tubules (figures 3.2-11B and 3.2-13A). SBA staining of the 
distal tubule has shown only 1.3% of peptide co-localisation in these tubules and peptide 




Figure 3.2-11 Lectin staining of distal and proximal tubules in G3-C12-Cy3.5 injected 
mouse kidney sections. 
A) The negative controls with DAPI nuclear staining. Autofluorescence in the red blood cells 
(purple) was observed. B) The LTL proximal tubule staining (green) consistently co-localised 
with the peptide (red) in the mouse kidney sections (indicated by arrow). C) The SBA distal 
tubule staining (green) rarely co-localised with the peptide (red) in adjacent mouse kidney 
sections (indicated by arrows). Scale bar = 20μm 
 
The WGA lectin was used to stain the glomeruli, but also shows apical staining of 
proximal tubules, and basal staining of distal tubules (figures 3.2-12B)(Holthofer, 1983). We 
observed with WGA staining, 0.1% and 0.2% of peptide uptake into the glomeruli and distal 
tubule respectively, while the peptide resided in 45% of all apically stained proximal tubules 
(figure 3.2-13). 
 
Figure 3.2-12 WGA stained mouse kidney injected with fluorescently tagged G3-C12 
peptide. 
A) A saline injected mice stained with WGA (green) was used as the controls to identify 
background or non-specific staining. B) The glomeruli had intense staining while the 
proximal tubules had apical staining and the distal tubules had basal staining. Most peptide 




In summary, uptake of the G3-C12 peptide into mouse kidney tubules has been found 
to co-localise with Megalin receptor expression and LTL stained proximal tubular cells. The 
distal tubules and glomeruli showed minimal uptake (figure 3.2-13). 
 
Figure 3.2-13 Peptide co-localisation in lectin stained kidney tubules of mice injected 
with a fluorescently tagged G3-C12 peptide. 
A) Peptide uptake into LTL stained proximal tubules. The peptide largely co-localised with 
LTL staining of the proximal tubules. B) Peptide uptake into SBA stained distal tubules. A 
small percentage of peptide uptake occurred in the distal tubules. C) Peptide uptake into 
WGA stained glomeruli. Almost no glomeruli had undergone peptide uptake. Percentages 
calculated from the number of identified tubules or glomeruli compared to the total number 
of DAPI stained tubules or glomeruli. 
 
3.2.2.2 H&E, Megalin AND Lectin Staining of human ADPKD kidney tissue 
Donated human ADPKD kidney tissue used to develop cell lines was also fixed, 
embedded in paraffin, sectioned and stained to investigate cystic changes in the kidneys, detect 
megalin expression and determine the location of megalin within cystic kidney tubules.  
3.2.2.2.1 Haematoxylin and eosin staining of human ADPKD kidneys 
Haematoxylin and eosin (H&E) staining of serial human kidney tissue sections was 
used to examine kidney structures, specifically cysts and the cells lining cyst walls. The 
huADPKD-W sections have shown cystic growth, fibrosis and eosin-positive inclusions in the 
cystic tubules of this kidney. Interestingly, in these sections we saw enlarged blood vessels 
with thickened tunica media smooth muscle layers adjacent to cystic structures (appendix Q). 
In the huADPKD-M sections there were regions of collapsed cystic wall, alongside areas of 
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seemingly unaffected kidney tubules. The huADPKD-D tissue sections presented with cysts 
that had internal debris, and areas of tissue damage (appendix Q). 
3.2.2.2.2 Megalin expression in human ADPKD kidney sections 
The megalin receptor was identified by immunofluorescence in sections from human 
ADPKD kidneys to investigate the ability of these individuals to retain megalin expression for 
peptide recognition and uptake via endocytosis. In the kidney, megalin is often expressed 
throughout the proximal tubules, and has a role in the reuptake of material filtered from the 
blood at the glomerulus (De et al., 2014). The huADPKD-W tissue sections expressed megalin 
in 78% of the kidney tubule cells (figure 3.2-14B), whereas the huADPKD-M kidney expressed 
megalin in only 27% of the kidney tubule cells (figure 3.2-14A), and the huADPKD-D kidney 
expressed megalin in 26% of kidney tubule cells (figure 3.2-14C). In these kidneys, megalin 
was often located in tubules, identified by the ring like orientation of DAPI stained nuclei. 
Megalin expression appears to be present throughout the kidneys, particularly in cyst lining 
epithelium (figure 3.2-15). 
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Figure 3.2-14 Megalin staining of human ADPKD kidney tissue sections. 
Megalin receptor expression (green) was located in the human kidney tissue via 
immunofluorescence. A) 78% of cells in the huADPKD-W tissue expressed megalin. B) 27% 
of cells in the huADPKD-M tissue expressed megalin. C) 26% of cells in the huADPKD-D 
tissue expressed megalin. n = 10 fields of view per tissue type, scale bar = 50μm 
 
 
Figure 3.2-15 Megalin staining in cystic tissue of human ADPKD kidney tissue sections. 
The huADPKD-W, huADPKD-M and huADPKD-D kidneys expressed fluorescently stained 
megalin in cells lining the cyst boarders, identified by the pattern of DAPI staining and 
supported by the H&E stained sections (appendix Q). Scale bar = 50μm 
 
3.2.2.2.3 Megalin and lectin staining of human ADPKD kidney sections 
Dual staining of megalin and several lectins was performed to investigate the tubular 
location of megalin expression in ADPKD tissue. All three patient kidneys showed 
significantly more co-localisation between megalin and the LTL stained proximal tubules than 
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the SBA stained distal tubules (figure 3.2-16). The huADPKD-W kidney had megalin staining 
in 63% of proximal tubules, and only 9% of distal tubules (figure 3.2-16A and 3.2-16D). The 
huADPKD-M kidney had megalin staining in 32% of proximal tubules, and 12% of distal 
tubules (figure 3.2-16B and 3.2-16E), with small sites of intense auto fluorescence in both the 
negative control and stained sections, consistent with the H&E staining of this tissue (figure3.2-
16B and appendix Q). The negative control sections remained unstained to allow for the 
identification of areas of highly fluorescent tissue and used to adjust for background staining. 
The amount of background staining in the stained sections was removed by using the negative 
control fluorescence as baseline. The huADPKD-D kidney had megalin staining in 44% of 
proximal tubules, and a comparatively high 26% of staining in the distal tubules (figure 3.2-









Figure 3.2-16 Lectin and megalin staining of human ADPKD kidney tissue sections. 
A) LTL proximal tubule (green) staining co-localised with megalin (red) staining in 
huADPKD-W tissue (white arrow). B) LTL proximal tubule (green) staining co-localised 
with megalin (red) staining in huADPKD-M tissue (white arrow). C) LTL proximal tubule 
(green) staining co-localised with megalin (red) staining in huADPKD-D tissue (white 
arrow). D) SBA distal tubule (green) staining distant from megalin (red) staining in 
huADPKD-W tissue (white and yellow arrows respectively). E) SBA distal tubule (green) 
staining distant from megalin (red) staining in huADPKD-M tissue (white and yellow arrows 
respectively). F) SBA distal tubule (green) staining distant from megalin (red) staining in 
huADPKD-D tissue (white and yellow arrows respectively). G) The percent of megalin 
stained proximal and distal tubules. These sections were further quantified for the co-
localisation between megalin and lectin staining. n=12 fields of view per lectin. (Over pages 
117 and 118) 
 
 
3.2.3 Kidney Specific G3-C12 Peptide Uptake Discussion 
3.2.3.1.1 Peptide uptake, megalin expression and lectin co-localisation 
Uptake of the G3-C12 peptide has been demonstrated in this study both in vitro and in 
vivo. In addition, the co-localisation of megalin and fluorescently tagged peptide was explored. 
The reason for investigating the co-localisation of megalin receptor expression in cystic tissue 
is due to the likelihood of it being the route of peptide uptake. This theory has been proposed 
due to megalin presentation on the cell surface of kidney proximal tubule epithelia and its 
involvement in the uptake of small compounds (De et al., 2014). Therefore, megalin was 
expected to be expressed on cells of the proximal tubule, or of proximal tubular origin, so 
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fluorescent techniques were used to investigate megalin expression and co-localisation with 
lectin stained kidney tubules and glomeruli. We also expected the peptide to be localised to 
megalin expressing and proximal tubule derived cells. 
 The in vitro cultures huADPKD, ADPKD 9-7 and LLC-PK1, all showed uptake of the 
peptide, more so via flow cytometry than fluorescent imaging. The discrepancy in these 
findings may be due to flow cytometry having a greater sensitivity to small changes in 
fluorescence and the removal of human error during detection. The ability of the three cultures 
to take up the peptide is likely due to their being comprised of proximal tubular cells that 
express megalin (figures 3.2-2C and 3.2-16G), allowing them to effectively recognise the 
peptide. Peptide uptake into the huADPKD-M and the proximal tubule derived ADPKD 9-7 
cultures indicates that cells derived from individuals with ADPKD, which are likely to be 
carrying a PKD mutation and have modified signalling pathways (section 1.1.1), are capable 
of retaining the megalin receptor expression for the recognition and uptake of the G3-C12 
peptide. However, peptide uptake into the megalin stained huADPKD-M cultures by 
fluorescent imaging did not match what was shown by fluorescent imaging without megalin 
staining or flow cytometry. Additionally, the in vitro culture MDCK, has presented with limited 
amounts of peptide uptake, possibly due to its distal tubule and collecting duct origin, and so 
it should not express the megalin receptor. Yet, with megalin staining, the majority of the 
MDCK cultures fluoresced positively for this protein. As previously published, MDCK 
cultures express the apolipoprotein E receptor (LRP1), a homolog of the megalin receptor 
(LRP2) which shares many structural similarities (Marzolo et al., 2003), making it possible 
that LRP1 is detected by antibodies against megalin. Reactivity with different LRP isotopes 
has been suggested by the antibody manufacturer, abcam. 
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Three human ADPKD kidneys were sectioned and megalin stained for the 
identification of megalin retention in the diseased kidney. Megalin staining was identified in 
all three kidney tissue sections, most prominently in huADPKD-W. The megalin staining 
observed across all three ADPKD kidneys indicated that patients express the G3-C12 peptide 
receptor, and so have the potential for peptide uptake into some cysts. To further determine the 
tubule type expressing megalin, LTL and SBA lectins were used to stain the proximal and 
distal tubules, respectively. Megalin in the huADPKD-W, huADPKD-M and huADPKD-D 
sections co-localised in the majority of proximal tubules, however megalin was identified in a 
large proportion of huADPKD-D distal tubules. These findings show that megalin expression 
occurs primarily in the proximal tubules, although less co-localisation than expected was 
observed. This is possibly due to the loss of endocytosis in the tubules of ADPKD patients as 
a result of cyst formation, which has been represented in cy/+ rat models and may contribute 
to the high levels of proteinuria seen in patients (Obermüller et al., 2017; Witzgall et al., 2002). 
A mouse model injected with 10nmol/L fluorescently tagged peptide had its kidney 
harvested and sectioned for megalin and lectin staining. In doing the megalin expressing 
tubules were most commonly identified as undergoing peptide uptake in wildtype mouse 
kidney, with almost no peptide located in the unstained tubules (figure 3.2-10). Therefore, 
peptide uptake almost entirely occurred in megalin expressing tubules of the mouse kidney, 
consistent with the idea of this receptor being the means of peptide uptake into tubular cells. 
Additionally, lectin staining of the mouse kidneys also identified peptide accumulation mostly 
in the proximal tubules. Peptide co-localisation in the megalin stained and proximal LTL 
stained tubules of adjacent tissue sections provides confidence of megalin receptor expression 
on the surface of proximal tubule epithelia in the mouse tissue, as was observed in the human 
ADPKD tissue (figures 3.2-10, 3.2-11 and 3.2-16). Additionally, peptide uptake was located 
on the WGA stained apical surface of proximal tubules that were adjacent to, or in the vicinity 
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of, either blood vessels or glomeruli (figure 3.2-12), indicating that megalin receptor regulated 
endocytosis of the peptide could be happening during filtrate reuptake from the glomeruli (De 
et al., 2014). 
In summary, there was co-localisation of Megalin expression and G3-C12 peptide 
uptake in a wild type mouse model. Additionally, cell cultures of ADPKD patient kidneys and 
a proximal tubule cyst derived cell line have shown the ability to take up the peptide in vitro. 
3.2.3.1.2 G3-C12-SAHA treatment 
 The G3-C12 peptide was conjugated to the histone deacetylase (HDAC) inhibitor, 
SAHA, by collaborators at the University of Auckland, and its practicality as a delivery system 
was identified in this study using in vitro cyst assays. MDCK 2.5D and 3D cyst assays were 
exposed to 15μmol/L of G3-C12-SAHA compound for three consecutive days, to determine 
the delivery and action of SAHA in kidney derived cells. Treatment of the 2.5D cystic culture 
with G3-C12-SAHA was able to reduce cyst size by day three, in contrast to the increase in 
cystic growth observed with the free SAHA treated assay over this period (figures 3.2-8A and 
3.1-10A). The measurement of the HDAC activity in the G3-C12-SAHA treated cultures 
showed a loss of HDAC activity on the third day of SAHA treatment compared to the controls, 
whereas HDAC activity in the free SAHA cultures had increased from the controls by day three 
(figures 3.8-8B and 3.1-10B). Therefore, it is likely that the G3-C12 peptide provided an 
advantage in the delivery of SAHA into already established cysts, allowing the G3-C12-SAHA 
cultures to maintain delayed cystic growth. This accentuated delay of cystic growth was also 
observed in the 3D MDCK spheroid cultures treated with G3-C12-SAHA, when compared to 
the free SAHA treated cultures (figures 3.2-9A and 3.1-11A). The G3-C12-SAHA treated 
spheroids on day two and three were 10-fold smaller on average than the free SAHA treated 
spheroids, and detection of acetylated lysine 23 of histones H2A and H3 in the G3-C12-SAHA 
treated spheroids was greater than the controls, which was not observed in the free SAHA 
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treated spheroids. The increase of histone acetylation in the G3-C12-SAHA exposed spheroids 
over the three days, when normalised, may be due to the reduction of deacetylation with the 
inhibition of HDACs by SAHA (figure 3.2-9B). Overall, the treatment of G3-C12-SAHA in 
MDCK cyst growth cultures has provided evidence of the peptide’s ability to be successfully 
conjugated to SAHA for the delivery of the therapeutic compound to cells derived from kidney 
















C H A P T E R  4  :  F I N A L  D I S C U S S I O N  
In this study we aimed to determine the ability of four novel compounds to delay cyst 
growth in vitro, by targeting cellular mechanisms often modified in ADPKD kidney tissue, as 
well as identifying the ability of the G3-C12 peptide to deliver therapeutic compounds to the 
kidneys. 
4.1 Results Summary 
The novel therapeutic compounds, SAHA and Gymnodimine, were found to be less 
convincing than Portimine and EG1 in their ability to delay cyst growth. When treated with the 
modified SAHA the 2.5D MDCK and 3D LLC-PK1 cyst assay cultures produced larger cysts 
than the controls, while the 3D MDCK cultures had a minimal average decrease in cystic area 
and HDAC activity. In the G3-C12-SAHA treated cyst assays the delay in cystic growth was 
similar to what has been found in mouse and zebrafish models of ADPKD (Cao et al., 2009; 
Yanda et al., 2017), likely due to the activity of SAHA which caused a loss of HDAC activity 
in the 2.5D MDCK cyst assays. Treatment with the apoptosis inducer Gymnodimine in 2.5D 
and 3D MDCK cyst assays gave small reductions in cyst growth areas which were not 
statistically significant. However statistical significance was reached in growth area reduction 
of the Gymnodimine treated LLC-PK1 spheroids, likely due to these cells being of different 
origin than the MDCKs and having greater sensitivity to apoptosis inducing compounds 
(Heussner & Dietrich, 2013). Portimine treatment of MDCK and LLC-PK1 cultures had 
significantly reduced cystic growth over 48 hours, although was unable to induce apoptosis 
and therefore may cause cellular modifications through other pathways, such as MAPK/ERK 
(Chambon et al., 2002), which were not identified in this study. Treatment with EG1 in the 
2.5D and 3D cyst assay cultures consistently delayed area growth, likely due to the inhibition 
of PAX2 transcription factor activity which was identified by a reduction in N-cadherin 
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expression by day three. PAX2 is normally expressed in the nephric duct, uteric bud and 
mesenchymal cells during kidney development and lost in the adult kidney (Heuvel, 2014), but 
has been shown to be expressed in cystic tissue of ADPKD mouse models (Ostrom et al., 2000; 
Qin et al., 2012; Cherie Stayner et al., 2006). Therefore, the ability of EG1 to inhibit PAX2 
and subsequently delay cyst growth in in vitro ADPKD models expands on what has been 
shown in the literature, making EG1 a promising therapeutic compound which requires further 
testing in vivo. 
To improve the longevity of therapy in ADPKD patients, this study also focused on 
determining the potential of the G3-C12 peptide as a drug delivery system to the kidneys, 
thereby reducing toxicity in other organs (Geng et al., 2012; Lanktree & Chapman, 2017; 
Stayner et al., 2018). We found that human ADPKD kidney derived cell lines were able to take 
up the peptide more effectively than the cyst forming LLC-PK1 porcine proximal tubule 
derived cell line, and that the MDCK canine collecting duct and distal tubule derived cell line 
had the least uptake overall. It has been suggested that the megalin receptor is the route of 
peptide uptake, which is consistent with our results with fluorescent co-localisation in these 
cell lines as well as in a peptide injected wild type mouse. Megalin is normally expressed on 
the apical surface of kidney proximal tubular cells (Marzolo & Farfán, 2011), but can be lost 
during ADPKD progression (Obermüller et al., 2017; Witzgall et al., 2002). Nevertheless, this 
study observed Megalin expression in the majority of human late stage ADPKD derived cells. 
 
4.2 Study Limitations 
Throughout this study we encountered issues in relation to the actions of SAHA, 
Gymnodimine and Portimine. The inability of the modified SAHA treatment to reproduce the 
delayed cystic growth observed in the literature (Cao et al., 2009; Liu & Zhuang, 2015), or 
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when conjugated to G3-C12 by G3-C12-SAHA treatment  may be due to the inability of cells 
to recognise and cleave the small polypeptide structure attached to SAHA. The polypeptide 
was attached to SAHA by collaborators to represent a partial structure of peptide conjugation. 
If the polypeptide linker remained bound to SAHA there is a chance of its interference with 
the compound’s ability to bind within hydrophobic pockets of the histone deacetylase enzymes 
(Lauffer et al., 2013), and inhibition may be affected as seen from the HDAC activity in the 
2.5D MDCK cyst assays. The exception to this may be the HDAC8 enzyme, which has a 
flexible structure that enables inhibition by linker bound SAHA compounds (Singh et al., 
2014), and may explain the small reduction of HDAC activity in the SAHA treated spheroids. 
When bound to the G3-C12 peptide SAHA was able to cause HDAC inhibition, so may have 
undergone cleavage in this conformation within the MDCK cells. Gymnodimine had a limited 
impact on cyst growth, and may be inappropriate for use as a therapeutic compound due to it 
targeting the nicotinic acetylcholine receptor, which is involved in sympathetic and 
parasympathetic pathways such as the baroreceptor reflex (Mendelowitz, 2017). The 
baroreceptor reflex modulates blood pressure, and so interfering with normal homeostasis may 
aggravate hypertension further in PKD patients. Excessive apoptosis throughout the nephron 
with cyst development has been observed in ADPKD patient kidneys (Lee, 2016), and 
previously targeted by inhibitors as a therapy for PKD (Goilav, 2011; Zhou & Li, 2015). 
Therefore, inducing further apoptosis in cells with already high levels of apoptosis may have 
produced the inconclusive results seen in the Gymnodimine treatment. Apoptosis in cystic 
tissue may in part be why the apoptosis inducer Portimine was unable to increase the amount 
of apoptosis in the cyst assays, regardless of the significant decreases in cyst growth area 
observed in the 2.5D and 3D cyst assays. It is also possible that Annexin V is a poor indicator 
of cell death in proximal tubule cell lines, as indicated in a study by Healy et al. (1998) who 
found that treatment of LLC-PK1 cells with the apoptosis inducer cyclosporine A promoted 
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only 6% of cell apoptosis, compared to the controls. Instead a caspase assay may have provided 
more substantial apoptosis results that better reflected cyst growth (Cuddihy et al., 2016), as 
Portimine and Gymnodimine treatment has previously been found to cause indirect 
upregulation of caspase activity (Chambon et al., 2002; Resende & Adhikari, 2009). 
Developing the spheroid assays has been crucial in the discovery of novel therapeutic 
compound action throughout this study, and by treating spheroid assays at two weeks of growth 
rather than eight weeks, as suggested by Kuo et al. (2014), the confluency of the cells was 
reduced, ensuring that the spheroids remained growing during treatment. Keeping cells out of 
arrest was important for the treatment by EG1 and SAHA, which have an effect on cellular 
mechanisms that are active during cellular growth, so as the cells enter the stationary growth 
phase the impact of SAHA and EG1 will lessen. In retrospect, the LLC-PK1 spheroid assay 
would produce more reliable results when treated for nine days rather than three, allowing the 
cells to undergo an equivalent number of divisions as the MDCK cells. Therefore, we might 
expect more similarity in the LLC-PK1 and MDCK results than what was observed. A 
limitation of using LLC-PK1 and MDCK cell lines as 2.5D and 3D models of cyst growth in 
ADPKD is their being of pig and dog origin respectively. The inability to produce a human 
kidney derived spheroid negatively impacts the likelihood that the novel compounds will 
produce the same or similar outcome as a translated therapy in humans.  
The use of the G3-C12 peptide for drug delivery may encounter problems regarding its 
uptake in the kidneys being limited to the proximal tubules, and its stability during 
administration. The endocytic uptake of the peptide through the megalin receptor may cause 
an issue if the endosome fails to release the compound into the cytoplasm, resulting in its 
degradation in the lysosome (Torchilin, 2009). Yet, G3-C12-SAHA treatment of MDCK 
cultures caused a loss of HDAC activity, indicating that SAHA has reached its target, and 
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therefore further testing in vivo could aid in verifying this finding. Additionally, fluorescently 
tagged peptide accumulation in the proximal tubules of wild type mice was shown via lectin 
staining, where megalin is regularly expressed (De et al., 2014). An issue with uptake occurring 
in these tubules is that initial cystic growth has been proposed to arise in the collecting ducts 
of ADPKD patients (Grantham et al., 2010). However, a mouse model of ADPKD found early 
cystic growth in the glomeruli (Ahrabi et al., 2010), and a study of cyst growth in adult ADPKD 
patients identified that even though cysts reside primarily in the collecting ducts in utero, cyst 
development during adulthood occurs throughout the kidney (Grantham et al., 2010), 
depending on changes in gene expression and dosage (Leonhard et al., 2016). Furthermore, a 
restriction for the use of peptides in drug delivery is the reliance of proteolysis to cleave the 
therapeutic compound at the correct location, as the route by which the therapy is administered 
may induce proteolytic cleavage before the peptide reaches the kidneys. Drugs are most 
commonly given to patients orally, intravenously, or subcutaneously, and can have 
implications related to premature cleavage of the peptide. The oral route of administration is 
often ineffective for peptide delivery due to peptidase and other protease activity throughout 
the gastrointestinal system, and so delivery via this route requires further modifications to the 
peptide to ensure resistance to these enzymes (Bruno et al., 2013). Peptide modifications can 
include cyclization, PEGylation or lipidization. Cyclization is the process of producing a cyclic 
peptide structure to reduce enzyme recognition and cleavage, PEGylation is the attachment of 
the amphipathic PEG molecule (Bruno et al., 2013), yet the clearance of unmodified PEG 
through the kidneys can cause tubular necrosis so is unsuitable for the treatment of ADPKD, 
and lipidization is the binding of lipids to the polypeptide, allowing transport across 
gastrointestinal membranes. Another means by which oral peptide delivery has been improved 
is via enzyme inhibitors and absorption enhancers, which are administered simultaneously with 
the peptide conjugated drug (Cano-Cebrián et al., 2005; Ziv et al., 1987). The enzyme 
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inhibitors work at certain pH levels, so are highly specific to regions of the gastrointestinal 
tract, which differ in acidity (Piper & Fenton, 1965; Renukuntla et al., 2013), yet the use of 
enzyme inhibitors long term can result in tissue damage (Bernkop-Schnürch, 1998) so are 
inappropriate for the prolonged treatment of ADPKD. The absorption enhancers most 
commonly used are Chitosans, medium-chain fatty acids and lectins, which help to improve 
the passage of the peptide through the epithelial lining of the gastrointestinal tract (Bies et al., 
2004; Chen et al., 2013; Lindmark et al., 1998). The Chitosans and lectins are a plausible 
methods of enhancing peptide absorption into the bloodstream, however the medium-chain 
fatty acids are limited to peptides 1.2kDa or smaller, whereas the G3-C12 peptide is 2kDa in 
size so is unable to be transported via this mechanism (Bruno et al., 2013). Additionally, the 
G3-C12 peptide receptor megalin is expressed throughout the intestines (Yammani et al., 
2001), among other organs (Erranz et al., 2004; Marzolo & Farfán, 2011), and so may undergo 
cellular uptake prior to its entry into the blood system via the oral route. The intravenous and 
subcutaneous routes are other means of drug delivery for peptides (Jitendra et al., 2011). These 
methods have fewer barriers to overcome than the oral route so may provide a more direct path 
to the organ of interest and allow the drug compounds to enter the blood stream with little 
resistance. An issue which may arise with these methods is the potential that the peptide will 
encounter proteases, causing cleavage while in the blood stream (Boöttger et al., 2017), 
although our lab has observed successful delivery of the G3-C12 peptide to the kidneys of tail 
vein injected mice. However, an intravenous route into the kidneys may be unsatisfactory in 
terms of uptake into cysts which have separated from the tubular walls. The G3-C12 peptide is 
predicted to be filtered from the bloodstream into the nephron, and so a loss of association with 
the tubules may result in the inability of the peptide to reach the cysts regardless of megalin 
retention in these structures, as identified in the huADPKD tissues (figure 3.2-14). 
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4.3 Future Directions 
Findings from this study suggest that the novel therapeutic compounds, Portimine and 
EG1, have the potential to delay cystic growth in 2.5D culture and 3D spheroids. Therefore, to 
strengthen this observation these compounds will need to be tested in models of higher 
complexity, such as organoids or a PKD mouse model. To further study the ability of EG1 to 
slow cyst growth, Professor David Larsen provided us with a partial construct of EG1 for 
peptide conjugation via the attachment of an ester. The use of an ester is likely to cause less 
interference than the polypeptide linker in the binding of EG1’s carboxylic group to its PAX2 
target (Grimley et al., 2017). Treatment of 2.5D and 3D spheroid and organoid assays with the 
ester bound EG1 could then determine the likelihood of a modified EG1 compound to retain 
its ability to inhibit PAX2 and slow cystic growth. Additionally, the conjugation of EG1 and 
Portimine to the G3-C12 peptide, will enable us to determine the efficacy of a peptide delivery 
system for these compounds in the 2.5D cultures, 3D cultures and an in vivo model of ADPKD. 
This work has the potential to identify the ability of the G3-C12 peptide to reach its target 
organ, release the novel compound, and reduce drug related toxicity in non-kidney cells. 
Additionally, successful cleavage of the compounds from the peptide is expected to slow cystic 
growth, as observed with free compound treatment. In addition to this, treating in vivo wild-
type and ADPKD mouse models with the SAHA conjugated G3-C12 compound is expected to 
cause a reduction in cyst growth similar to what a study by Cao et al. (2009) showed via an 
ADPKD mouse model administered the free SAHA compound. 
Other work in our lab identified global hypomethylation in ADPKD kidney cystic tissue 
compared to healthy controls (Bowden et al., 2018), likely to modify gene expression during 
disease progression. Bowden et al. (2018) also found increased methylation at the 3’ end of the 
PKD1 gene associated with the upregulation of PKD1 mRNA expression in patients, not 
observed in healthy kidney tissue. Therefore, it is possible that the use of the DNA 
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methyltransferase inhibitor (DNMTi) in treating 2.5D and 3D cyst growth assays could provide 
a reduction in cyst growth by modifying the pattern of gene expression associated methylation 
on CpG islands. DNMTi treatment with Decitabine showed promise in the treatment of 
myelodysplastic syndromes (Kantarjlan et al., 2006; Santos et al., 2010), and leukaemia (Malik 
& Cashen, 2014), and so may also show an effect in the treatment of ADPKD cyst growth 
models. 
 
4.4 Final Conclusion 
This study hypothesised that the treatment of cyst growth assays with the therapeutic 
compounds, SAHA, EG1, Gymnodimine and Portimine, would reduce cystic growth by 
targeting mechanisms often modified in ADPKD. This study shows this using EG1 and 
Portimine compounds, with EG1 providing evidence of PAX2 inhibition resulting in a loss of 
N-cadherin expression that coincided with reduced cyst growth, while Portimine was likely to 
cause reduced cyst growth through a mechanism other than apoptosis which has not been 
identified in this study. The SAHA and Gymnodimine compound treatments also showed 
reduced cyst growth in some instances, as well as the targeting of their proposed mechanisms, 
although did not consistently give statistical significance in their effects. This study also 
showed that the G3-C12 peptide is able to successfully enter ADPKD kidney derived cell 
cultures and the proximal tubules of an in vivo mouse model, likely via the initiation of 
endocytosis following megalin receptor binding. Observations of peptide uptake in vitro and 
in vivo, as well as the ability of a SAHA conjugated G3-312 peptide to reduce cystic growth in 
2.5D and 3D MDCK assays via HDAC inhibition, provides evidence that the G3-C12 peptide 
could improve drug delivery to the kidneys of ADPKD patients to lessen off-target toxicity. 
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S U P P L E M E N T R Y  M A T E R I A L  
Appendix A: Primary Cell Line Growth 
Growth of the human ADPKD kidney derived primary cell lines after one week.  
A) The huADPKD-M1 cultures produced large uniform populations of rounded epithelial-like cells 
after one week on undisturbed growth. B) The huADPKD-M cultures produced large populations of 
seemingly mixed cell types. The cells which grew in this culture after one week had both rounded and 
elongated morphologies, which may be due to epithelial and fibroblast growth. The mix of cell types 



















Appendix B: Cystic Cell Line Growth 
Appendix B.1 
MDCK and LLC-PK1 culture growth observations.  
A) The MDCK cell line is comprised of multiple cell types (McAteer et al., 1987; Nakazato et al., 1989) 
as indicated by the white arrows. Scale bar = 250μm. B) The LLC-PK1 showed some potential of 2.5D 
cyst growth after one week plated at a density of 30,000 cells in a 24 well plate, however this growth 






LLC-PK1 spheroid growth with siRNA knockdown.  
PKH67 on the cell membranes has been fluorescently labeled to enable measurement of the cells or cell 
clusters. This figure represents the no siRNA, 15nm ip3 siRNA and 20nm siRNA IP3 treated LLC-PK1 






Appendix C: Pre-treatment Areas of Cyst Growth Assays  
Appendix C.1 
Area measurement of SAHA, EG1 and G3-C12-SAHA pre-treated 2.5D and 3D cyst assays.  
A) Average area of 2.5D MDCK control (0.4mm2, n = 58) and SAHA (0.5mm2 n=64) cysts pre-
treatment. B) Average area of 3D MDCK control (2.3mm2 n=57) and SAHA (2.2mm2 n=59) spheroids 
pre-treatment. C) Average area of 3D LLC-PK1 control (1.5mm2, n = 36) and SAHA (1.6mm2, n = 43) 
spheroids pre-treatment. D) Average area of 2.5D MDCK control (0.78mm2, n = 224) and EG1 
(0.72mm2, n = 221) cysts pre-treatment. E) Average area of 3D MDCK control (2.0mm2, n = 48) and 
EG1 (2.1mm2, n = 60) spheroids pre-treatment. F) Average area of 3D LLC-PK1 control (1.2mm2, n = 
34) and SAHA (1.3mm2, n = 47) spheroids pre-treatment. G) Average area of 2.5D MDCK control 
(1.3mm2, n = 192) and G3-C12-SAHA (1.1mm2, n = 192) cysts pre-treatment. H) Average area of 3D 












Area measurement of apoptosis inducer pre-treated 2.5D and 3D cyst assays.  
A) Average area of 2.5D MDCK control (0.25mm2, n = 37) and Gymnodimine (0.3mm2, n = 38) cysts 
pre-treatment. B) Average area of 3D MDCK control (1.7mm2, n = 42) and Gymnodimine (2mm2, n = 
42) spheroids pre-treatment. C) Average area of 3D LLC-PK1 control (2.4mm2 n=39) and 
Gymnodimine (3.2mm2, n = 41) spheroids pre-treatment. D) Average area of 2.5D MDCK control 
(0.3mm2, n = 36) and Portimine (0.3mm2, n = 40) cysts pre-treatment. E) Average area of 3D MDCK 
control (1.2mm2, n = 16) and Portimine (1mm2, n = 16) spheroids pre-treatment. F) Average area of 3D 

















Appendix D: Treatment length optimisation of SAHA Treatment 
Optimisation of SAHAs HDAC inhibitory length in huADPKD, MDCK and LLC-PK1 cell 
cultures against Trichostatin A. 
Inhibition of HDACs was measured by their enzymatic activity via the detection of fluorescent output 
during the deacetylation of the fluoroacetylated assay substrate. A) SAHA treatment of the huADPKD 
cultures caused HDAC inhibition to be greater than the Trichostatin control at all time points over 48 
hours, with the most inhibition occurring at nine hours post treatment. B) SAHA treatment of the 
MDCK cultures caused HDAC inhibition to be greater than the Trichostatin A control between six and 
24 hours, with the most inhibition occurring at nine hours post treatment. C) SAHA treatment of the 
LLC-PK1 cultures caused HDAC inhibition to be greater than the Trichostatin A control at all time 




Appendix E: SAHA Treated 2.5D MDCK Cyst Count 
Cyst count of solvent control and SAHA treated 2.5D MDCK cyst assays. 
On day one the control cultures grew 145 cysts throughout 21 locations in seven wells, on day two this 
decreased to 104 cysts, and by day three the control cultures had 113 cysts. Whereas, the SAHA treated 
MDCK cultures on day one had 110 cysts, by day two had 102 cysts and on day three had 63 cysts. To 
avoid bias, the locations in the wells where the images were taken remained consistent for culture in 


















Appendix F: SAHA Treated Spheroid Histone Acetylation 
Western blotting of solvent control and 15μmol/L SAHA treated spheroids.  
Detection of acetylated histone H3 (top band) histone H2 A (bottom band) on lysine 23, 1ug of pure 
histone lysate, quantified by pierce BCA assay, was loaded into each well. A) Western blotting of pure 
histones extracted from MDCK spheroids for the detection of histone acetylation with SAHA treatment. 
B) The fluorescent intensities of acetylated histone H3 and H2A in SAHA treated and control MDCK 
spheroids. The SAHA treated MDCK spheroids had a decrease in histone acetylation over three days 
of treatment, as did the solvent controls. C) Western blotting and Coomassie of pure histones extracted 
from LLC-PK1 spheroids for the detection of histone acetylation with SAHA treatment. D) The 
fluorescent intensities of acetylated histone H3 and H2A in SAHA treated and control LLC-PK1 
spheroids. The SAHA treated LLC-PK1 spheroids had less histone acetylation than the controls on day 
one, however on days two and three acetylation had increased in the SAHA treated when compared to 















Appendix G: MDCK and LLC-PK1 PAX2 and N-Cadherin Expression  
Expression of N-cadherin and PAX2 in untreated MDCK and LLC-PK1 2D cell cultures.  
A) A Coomassie of total cytoplasmic protein extracted from the MDCK and LLC-PK1 cultures was 
used as a loading control. B) western blotting of MDCK and LLC-PK1 total cytoplasmic protein for 
the detection of N-cadherin and PAX2 expression. C) Quantification of N-cadherin expression in 
MDCK and LLC-PK1. N-cadherin was detected at 5240RFU in MDCK, and at 158RFU in LLC-PK1. 
D) Quantification of PAX2 expression in MDCK and LLC-PK1. PAX2 was detected at 35RFU in 
















Appendix H: Division Rate of Cell Cultures 
Growth of the cell lines huADPKD-M, MDCK and LLC-PK1 over three days to determine 
division rate.  
Flow cytometry count of zombie stain negative live cells in cultured populations was used to determine 
the division rate. A) the huADPKD-M culture divides once every 12 hours, with 50,000 cells originally 
plated and cell counts of 110,000 on day one, 240,000 on day two and 1,000,000 on day three. B) the 
MDCK cell line divides once every twelve hours, with 50,000 cells originally plated and cell counts of 
120,000 on day one, 490,000 on day two and 1,000,000 on day three. C) The LLC-PK1cell line divides 
once every 40 hours, with 50,000 cells originally plated and cell counts of 30,000 on day one, 50,000 





















Appendix I: Apoptosis Inducing Compound Dosage Optimisations 
Appendix I.1 
Representation of Gymnodimine and Portimine dosage optimisation in huADPKD cultures.  
Cellular viability (zombie) versus apoptosis (Annexin V) plots were used to determine the appropriate 
concentration of the apoptosis inducing compounds by measuring the percent of live apoptotic cells, 
ensuring limited cytotoxicity for treatment. A) The 0nmol/L solvent control culture had 2.3% of 
apoptosis, the 12nmol/L Gymnodimine treated culture had 3.1% of apoptosis, the 24nmol/L 
Gymnodimine treated culture had 3.4% of apoptosis, the 120nmol/L Gymnodimine treated culture had 
3.3% of apoptosis, and the 240nmol/L Gymnodimine treated culture had 3.1% of apoptosis. B) The 
0nmol/L solvent control culture had 1.5% of apoptosis, the 2nmol/L Portimine treated culture had 3.8% 
of apoptosis, the 4nmol/L Portimine treated culture had 3.4% of apoptosis, the 6nmol/L Portimine 
treated culture had 3.2% of apoptosis, the 8nmol/L Portimine treated culture had 2.2% of apoptosis, and 























Representation of Gymnodimine and Portimine dosage optimisation in MDCK cultures.  
Cellular viability (zombie) versus apoptosis (Annexin V) plots were used to determine the appropriate 
concentration of the apoptosis inducing compounds by measuring the percent of live apoptotic cells, 
ensuring limited cytotoxicity for treatment. A) The 0nmol/L solvent control culture had 1.5% of 
apoptosis, the 12nmol/L Gymnodimine treated culture had 0.7% of apoptosis, the 24nmol/L 
Gymnodimine treated culture had 0.9% of apoptosis, the 120nmol/L Gymnodimine treated culture had 
0.6% of apoptosis, and the 240nmol/L Gymnodimine treated culture had 0.5% of apoptosis. B) The 
0nmol/L solvent control culture had 1.8% of apoptosis, the 2nmol/L Portimine treated culture had 0.7% 
of apoptosis, the 4nmol/L Portimine treated culture had 1.3% of apoptosis, the 6nmol/L Portimine 
treated culture had 2.3% of apoptosis, the 8nmol/L Portimine treated culture had 2.2% of apoptosis, and 



















Appendix J: Apoptosis Inducing Compound Treatment Length 
Optimisations 
Apoptosis assay for Portimine and Gymnodimine treatment time-point optimisation. 
 A) Exposure of the huADPKD cell culture for six hours produced minimal increases at concentrations 
of 4nmol/L (6.72%), 6nmol/L (7.05%) and 8nmol/L (6.71%) compared to the control (6.47%). B) 
Gymnodimine treatment of the huADPKD culture for 24 hours induced small amount of apoptosis at 
concentrations of 12nmol/L (4.1%), 24nmol/L (4.1%) and 240nmol/L (4.2%) compared to the control 
(4%). C) Gymnodimine treatment of the MDCK culture for 24 hours increased apoptosis at the 












Appendix K: Apoptosis Inducer Treated Cyst Assay Viability 
Representation of cell viability in apoptosis inducing compound treated 2.5D and spheroid assays.  
The percent of apoptosis induced in each assay was measured in the gated zombie unstained living 
population. A) The living population of the MDCK 2.5D assay treated with Gymnodimine (67.3%) was 
smaller than the controls (73.5%). B) The living population of the MDCK 2.5D assay treated with 
Portimine (56.4%) was also smaller than the controls (64.6%). C) The living (45.4%) and dying or dead 
(53.6%) populations in the Gymnodimine treated MDCK spheroids were both similar to the control 
(44.2% and 55.3%). D) The living population of the Gymnodimine treated LLC-PK1 cells (39.3%) was 
greater than the controls (35.5%). The treated population of dying or dead cells was 5.2% smaller than 
the controls, but had a subset with an intense zombie stain likely to be dead rather than dying cells. E) 
The living population of MDCK spheroids treated with Portimine (99.44%) was the same as the controls 
(99.6%). F) The living population of LLC-PK1 spheroids treated with Portimine (23.11%) was less 
than the controls (47.5%), and the dying or dead population of the treated spheroids (75.5%) was larger 




Appendix L: Apoptosis in Untreated Cell Cultures 
Table of the apoptosis occurring in untreated MDCK and LLC-PK1 cultures in 2D and 3D 
conformation.  
Apoptosis was measured via Annexin V staining in confluent MDCK and LLC-PK1 2D cultures, 
MDCK spheroids after seven days growth and LLC-PK1 spheroids after two weeks of growth (n = 4 
cultures). The MDCK 2D culture had an average 75.9% of apoptosis while the 3D MDCK and both 
LLC-PK1 cultures had between 43% and 47% of apoptosis. As a comparison, the normal kidney HK-
2 line had an average 14% of apoptosis in 2D culture. 
 




















Appendix M: Potential Therapeutic Compounds 
This study has identified EG1 and Portimine as potential therapeutic compounds for the delay of cyst growth in ADPKD models. 
EG1 and Portimine have shown the ability to significantly reduce cyst growth in in vitro models, likely via the targeting of mechanisms or pathways modified 
in ADPKD, specifically PAX2 and ERK. 
 
Novel compounds with the potential to delay cyst growth 
Compound Possible target Role of target Treated models with cystic area reduction (p < 0.05) Supporting literature 
EG1 PAX2 Transcription factor activity during kidney development 
MDCK spheroid 
LLC-PK1 spheroid 
Pax2 associated reduction of kidney cystic 
growth in heterozygous knockout PKD mice 
(Ostrom et al., 2000; Stayner et al., 2006) 
Portimine ERK Cellular growth and maintenance via kinase activity 
MDCK 2.5D cyst assay 
MDCK spheroid 
LLC-PK1 spheroid 
Inhibition of ERK activation with treatment 
slowed cystic growth of in vitro and in vivo 
PKD models (Omori et al., 2006; Yamaguchi 









Appendix N: G3-C12 Peptide Uptake In vivo in a Wild Type Mouse 
Fluorescent images of mouse kidneys tissue sections after tail-vein injection with Cy3.5 (1 nmol) 
or G3-C12-Cy3.5 (10 nmol). 
The kidneys were shown to retain the fluorescent peptide conjugated Cy3.5 fluorophore for longer 
than the free Cy3.5 molecule. The kidneys also had a longer lasting intense red fluorescent signal than 
















Appendix O: Megalin and Peptide Co-localisation in Cell Culture 
The huADPKD-M, ADPKD9-7, MDCK and LLC-PK1 cells exposed to a rhodamine conjugated 
peptide have been stained for the endocytic megalin receptor as the possible route of uptake. 
 
A) Nuclear DAPI, Megalin and peptide staining in a huADPKD-M culture. Scale bar = 100μm. B) The 
majority of huADPKD-M cells stained positively for megalin. C) limited amount of peptide uptake was 
observed in the megalin stained huADPKD-M cells. D) Nuclear DAPI, Megalin and peptide staining in 
an ADPKD9-7 culture. Peptide uptake co-localised with some Megalin stained cells.  Scale bar = 
100μm. E) Megalin staining was observed in the majority of cells in the ADPKD9-7 cultures. F) A large 
amount of peptide uptake was also seen in the ADPKD9-7 cells. G) Nuclear DAPI, Megalin and peptide 
staining in an MDCK culture. Co-localisation between peptide uptake and Megalin expression has 
occurred in these cultures. Scale bar = 100μm. H) The MDCK cells had unexpected megalin staining, 
which is likely to be due to the expression of an LRP homolog. I) MDCK also showed peptide uptake. 
J) Nuclear DAPI, Megalin and peptide staining in a LLC-PK1 culture. Scale bar = 100μm. LLC-PK1 
and megalin expression and peptide uptake, although in some cases the peptide resided in unstained 
megalin cells. K) Megalin expression has been observed in the LLC-PK1 culture likely due to these 





Appendix P: Donated Human ADPKD Kidneys 
Appendix P.1 
Cystic kidney tissue of ADPKD patients has been harvested for primary cell line development and 
staining in this study  
A partial huADPKD kidney (huADPKD-M), after its removal during kidney transplant. Highly cystic 
areas from this kidney, as well as the huADPKD-W and huADPKD-D kidneys, have been harvested to 
best represent pathologies of the diseased kidney. A large external cyst has been indicated by a white 















Clinical information of the human ADPKD kidneys and their use within this study. 
Human ADPKD kidney tissues used in this study 
Patient kidney 
identifier 
Sex of patient Age of patient Study use 

































Appendix Q: Haematoxylin And Eosin Staining Of Human ADPKD 
Kidneys 
H&E staining of huADPKD-W kidney sections for structural analysis.  
A) In the huADPKD-M tissue at  4x magnification we observed collapsed cyst walls adjacent to areas 
of more normal looking kidney tissue, at 40x magnification we identified intense pink staining which 
may be the invasion of leukocytes into the site. B) In the huADPKD-W tissue at 4x magnification we 
saw an enlarged blood vessel located next to a cyst (top right corner), at 40x magnification the epithelial 
boarder of the cyst and the layers of the blood vessel wall could be defined further. C) In the huADPKD-
D tissue at 4x magnification we observed areas of clustered cysts, and at 40x magnification we noticed 
cellular debris within the cystic tissue Scale bar 4x = 20μm, Scale bar 40x = 200μm. 
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